docetaxel anhydrous has been researched along with Carcinoma, Squamous Cell in 702 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (3.56) | 18.2507 |
| 2000's | 230 (32.76) | 29.6817 |
| 2010's | 402 (57.26) | 24.3611 |
| 2020's | 45 (6.41) | 2.80 |
| Authors | Studies |
|---|---|
| Hazarika, M; Kumar, G; Mallik, S; Roy, PS; Saikia, BJ; Sarangi, SS; Talukdar, A | 1 |
| Deng, H; Shen, Y; Shen, Z; Tang, M; Wei, Z; Zhou, C | 1 |
| Almotlak, H; André, T; Baba-Hamed, N; Borg, C; Bouché, O; Buecher, B; de la Fouchardiere, C; Desrame, J; El Hajbi, F; Ghiringhelli, F; Jacquin, M; Jary, M; Kaminsky, MC; Kim, S; Meurisse, A; Nguyen, T; Parzy, A; Pernot, S; Saint, A; Samalin, E; Smith, D; Stouvenot, M; Taieb, J; Vernerey, D; Vienot, A; Zoubir, M | 1 |
| Kawachi, H; Kumagai, T; Matsumoto, K; Tamiya, A; Tamiya, M; Tanizaki, S; Yanase, T | 1 |
| Cai, P; Chen, B; Gao, Y; Liao, Z; Wang, F; Wang, S; Xiao, W; Yuan, Y; Zeng, Z; Zhang, R | 1 |
| Chandrasekharan, A; Dhumal, S; Ghosh Laskar, S; Kolkur, M; Kumar Chinthala, S; Menon, N; Noronha, V; Patil, VM; Prabhash, K; Simha, V; Talreja, V; Waratkar, G | 1 |
| Lohynská, R; Pechačová, Z | 1 |
| Baker, S; Blanchard, E; Brahmer, JR; Celano, P; Duma, N; Elkins, IB; Ellis, PM; Haddad, RY; Hesketh, PJ; Jain, D; Jaiyesimi, IA; Johnson, DH; Leighl, NB; Mamdani, H; Masters, G; Moffitt, PR; Phillips, T; Riely, GJ; Robinson, AG; Rosell, R; Schiller, JH; Schneider, BJ; Singh, N; Spigel, DR; Temin, S | 1 |
| Rodriguez, E; Santos, ES | 1 |
| Cirauqui, B; Cruz-Hernández, JJ; García Girón, C; Grau, JJ; Hitt, R; Iglesias Docampo, L; Lozano, A; Martínez-Trufero, J; Mesía, R; Morillo, EDB; Rubió-Casadevall, J; Taberna, M; Vázquez Estévez, S | 1 |
| Akita, H; Fujii, Y; Hara, H; Haraguchi, N; Hasegawa, S; Kanemura, T; Matsuda, C; Mikamori, M; Miyata, H; Mukai, Y; Nishimura, J; Omori, T; Shinno, N; Sugase, T; Sugimura, K; Takeoka, T; Wada, H; Yamamoto, M; Yasui, M | 1 |
| Guo, S; Li, S; Ma, K; Wang, J; Wei, S; Xu, Y; Zhang, F | 1 |
| An, G; Chen, Y; Chen, Z; Cheng, Y; Fang, Y; Feng, J; Guo, Q; Hu, W; Hu, Y; Huang, J; Li, W; Li, X; Liu, Y; Mancao, C; Niu, H; Peng, B; Shi, J; Shi, Y; Shu, Y; Song, Y; Sun, J; Sun, L; Sun, S; Sun, T; Wang, A; Wang, C; Wang, J; Wang, L; Wang, M; Wang, Y; Wang, Z; Wu, G; Wu, L; Wu, Z; Xing, P; Ye, F; Yu, X; Yuan, Y; Zhang, S; Zhang, Y; Zhao, Y; Zhou, C; Zhou, J | 1 |
| Fukuya, A; Kagemoto, K; Kawaguchi, T; Mitsui, Y; Miyamoto, H; Noda, K; Okamoto, K; Sato, Y; Takayama, T; Yamasaki, M | 1 |
| Chang, KC; Chang, KY; Chen, YW; Fang, KM; Lee, KI; Lin, JW; Liu, JM; Liu, SH; Su, CC; Wu, CT | 1 |
| Hiraki, Y; Imano, M; Kato, H; Momose, K; Shinkai, M; Shiraishi, O; Yasuda, A; Yasuda, T | 1 |
| Agarwal, A; Alone, M; Balaji, A; Bhattacharjee, A; Budrukkar, A; Chaturvedi, P; Chaukar, D; Choudhary, J; Dey, S; Ghosh-Laskar, S; Jobanputra, K; Kapu, V; Karuvandan, N; Krishna, MR; Kumar, S; Mahajan, A; Mathrudev, V; Menon, N; Nair, S; Nawale, K; Noronha, V; Pai, PS; Pathak, S; Patil, VM; Peelay, Z; Pendse, S; Prabhash, K; Purandare, N; Puranik, A; Rai, R; Ravind, R; Reddy Yallala, M; Sahu, H; Shetty, A; Singh, A; Swain, M; Thiagarajan, S | 1 |
| Killock, D | 1 |
| Chi, Z; Shao, T; Tang, W; Zhao, M | 1 |
| Khamaikawin, W; Locharoenrat, K | 1 |
| Cao, F; Fan, Y; Fang, Q; Li, D; Liu, X; Wu, D; Xu, P; Yang, X; Zhao, Z; Zhu, Y | 1 |
| Chen, X; Hata, M; Hayashi, Y; Kioi, M; Koike, I; Koizumi, T; Mitsudo, K; Yamanaka, S | 1 |
| Araya, J; Hirano, S; Konishi, K; Nagabuchi, M; Ogino, J; Sakamoto, T | 1 |
| Fujita, T; Furukawa, T; Iritani, K; Kakigi, A; Kiyota, N; Miyawaki, D; Nibu, KI; Sasaki, R; Shinomiya, H; Tatehara, S; Teshima, M; Uehara, N; Yamada, A | 1 |
| Fietkau, R; Frey, B; Gaipl, US; Gehre, S; Gostian, AO; Grottker, F; Hecht, M; Jost, T; Reichardt, CM; Rieckmann, T; Rückert, M; Sengedorj, A | 1 |
| Hui, H; Sun, Y; Wei, B; Wu, J; Xu, L | 1 |
| Ju, WT; Li, J; Liang, SY; Ma, HL; Wang, LZ; Zhang, ZY; Zhao, TC; Zhong, LP; Zhou, G; Zhu, DW | 1 |
| Endo, M; Hasegawa, H; Kaneko, T; Kanno, C; Kano, M; Kitabatake, T; Monma, T; Sato, E; Takeishi, E; Yamazaki, M | 1 |
| Kawamoto, T; Mine, S; Sasai, K; Shikama, N; Tsurumaru, M | 1 |
| Furuya, N; Hataji, O; Hida, N; Inoue, T; Ito, K; Komase, Y; Mineshita, M; Morikawa, K; Sakaguchi, T | 1 |
| André, T; Baba-Hamed, N; Bidard, FC; Borg, C; Bouché, O; Buecher, B; Dahan, L; de la Fouchardière, C; Desramé, J; El Hajbi, F; François, É; Ghiringhelli, F; Jacquin, M; Jary, M; Kim, S; Parzy, A; Rebucci-Peixoto, M; Samalin, E; Smith, D; Spehner, L; Taieb, J; Tougeron, D; Vendrely, V; Vernerey, D | 1 |
| Hashemy, I; Masood, AI; Shah, SIH; Zaidi, SHM | 1 |
| He, Y; Lan, Z; Yang, F | 1 |
| Baba, Y; Egashira, A; Emi, Y; Fujiwara, M; Iwata, N; Jogo, T; Kamori, T; Kawazoe, T; Kimura, Y; Makiyama, A; Mori, M; Morita, M; Nakaji, Y; Nakamura, T; Nakanoko, T; Nakashima, Y; Oki, E; Saeki, H; Shibata, T; Shimokawa, M; Tanaka, Y; Tokunaga, S; Zaitsu, Y | 1 |
| Chen, Q; Dai, Y; Liu, R; Wen, J; Xu, H; Xu, Y | 1 |
| Abdeljaoued, S; Adotevi, O; Borg, C; Buecher, B; François, E; Kim, S; Meurisse, A; Spehner, L; Vernerey, D; Vienot, A | 1 |
| Bilguun, EO; Kaira, K; Kawabata-Iwakawa, R; Nishiyama, M; Oyama, T; Rokudai, S; Shimizu, K; Shirabe, K; Yokobori, T | 1 |
| Alesina, P; Bartsch, D; Függer, R; Furrer, M; Gérard, MA; Gloor, B; Grieder, F; Hawle, H; Hayoz, S; Kettelhack, C; Knoefel, WT; Köigsrainer, A; Marti, WR; Piessen, G; Ruhstaller, T; Schäfer, M; Schmidt, S; Schnider, A; Steffen, T; von Holzen, U; Walz, MK | 1 |
| Igai, H; Iwashita, H; Kamiyoshihara, M; Matsuura, N; Ohsawa, F; Yazawa, T | 1 |
| Gao, Y; Jiang, C; Wang, T; Wei, B; Wu, J; Zhou, Y | 1 |
| Damghani, MA; Larizadeh, MH; Mohammadi, F; Shabani, M | 1 |
| Aladelusi, TO; Ju, W; Sun, W; Zhang, Z; Zhao, T; Zhong, L; Zhu, D | 1 |
| Murodumi, H; Ohta, K; Ono, S; Sakuma, M; Shigeishi, H; Takechi, M; Tobiume, K; Yokoyama, S | 1 |
| Hirai, S; Kojima, T; Niki, T; Sakuma, Y; Sumi, T; Tada, M; Yamaguchi, M | 1 |
| Chen, W; Gu, D; Lu, J; Tao, H; Yao, C; Zhou, Y | 1 |
| Chang, PM; Chen, MH; Chu, PY; Lu, HJ; Tai, SK; Wang, LW; Yang, MH | 1 |
| Chung, IJ; Joo, YE; Kim, SA; Lee, DH; Lee, JK; Lee, KH; Lim, SC; Park, YL; Yoon, TM | 2 |
| Fu, JH; Li, Y; Liu, MZ; Liu, SL; Xi, M; Yang, YD; Zhang, L; Zhang, P | 1 |
| Altavilla, G; Bulotta, A; Gonzalez-Cao, M; Gregorc, V; Karachaliou, N; Lazzari, C; Rosell, R; Santarpia, M; Verlicchi, A | 1 |
| Dietz, A; Görner, M; Grosse-Thie, C; Guntinas-Lichius, O; Inhestern, J; Jungehülsing, M; Kuhnt, T; Maschmeyer, G; Rotter, N; Schmalenberg, H; Sudhoff, H; Wittekindt, C | 1 |
| Akita, H; Fujiwara, Y; Kobayashi, S; Miyata, H; Miyoshi, N; Motoori, M; Ohue, M; Omori, T; Sugimura, K; Takahashi, H; Tomokuni, A; Yanagimoto, Y; Yano, M; Yasui, M | 1 |
| Hoshino, A; Kawada, K; Kawano, T; Nakajima, Y; Okada, T; Tokairin, Y | 1 |
| Albers, AE; Fichtner, I; Hoffmann, J; Keilholz, U; Klinghammer, K; Leser, U; Otto, R; Raguse, JD; Tinhofer, I | 1 |
| Avgeris, M; Awada, A; Degardin, M; Fortpied, C; Germà-Lluch, JR; Giurgea, L; Goutas, N; Herman, L; Kienzer, HR; Koutsodontis, G; Kroupis, C; Langendijk, JA; Licitra, L; Menis, J; Pateras, IS; Psyrri, A; Remenár, É; van Herpen, CML; Vermorken, JB | 1 |
| Abdelghani, MB; André, T; Aparicio, T; Baba-Hamed, N; Bachet, JB; Bennouna, J; Bidard, FC; Bonnetain, F; Borg, C; Bouché, O; Buecher, B; De La Fouchardière, C; Desrame, J; Dumont, S; El Hajbi, F; François, E; Gornet, JM; Jacquin, M; Jary, M; Kim, S; Louvet, C; Nguyen, T; Parzy, A; Peiffert, D; Pernot, S; Samalin, E; Smith, D; Vendrely, V; Zoubir, M | 1 |
| Arita, T; Asai, J; Katoh, N; Miyashita, A; Takenaka, H; Taura, M; Wada, M | 1 |
| Alcaraz, J; Gabasa, M; Hilberg, F; Ikemori, R; Reguart, N | 1 |
| Amoura, Z; Barbaud, A; Francès, C; Mathian, A; Monfort, JB; Senet, P | 1 |
| Chang, J; Cheng, Y; Goto, K; Ichinose, Y; Lim, WT; Lu, S; Maemondo, M; Mok, TSK; Morita, S; Nakagawa, K; Nishio, M; Nokihara, H; Shi, YK; Soo, RA; Sugawara, S; Takahashi, T; Tamura, T; Yamamoto, N; Yang, JC; Zhang, L | 1 |
| Dastani, H; DeRosa, M; Gralla, RJ; Morrissey, L; Orsini, L; Penrod, JR; Reck, M; Taylor, F | 1 |
| Bunger, D; Gupta, S; Pawar, SS | 1 |
| Ando, H; Fujimura, A; Hayasaka, JI; Jinbu, Y; Kusama, M; Mori, Y; Noguchi, T; Okada, N; Tsuchiya, Y; Ushijima, K | 1 |
| Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Wada, N; Yamasaki, M | 1 |
| Boito, R; Bova, F; Colombo, AF; Greco, S; Lucà, R; Rizzuto, G; Sellaro, A | 1 |
| Bernstein, JM; Bonington, SC; Carrington, BM; Homer, JJ; Kershaw, LE; Lowe, NM; Mais, K; Slevin, NJ; West, CM; Withey, SB | 1 |
| Bedenne, L; Bitzer, M; Brauchli, P; Budach, W; Eisterer, W; Girschikofsky, M; Hawle, H; Hayoz, S; Hess, V; Knorrenschild, JR; Mariette, C; Mingrone, W; Montemurro, M; Plasswilm, L; Ruhstaller, T; Schacher, S; Schmidt, SC; Schnider, A; Stahl, M; Thuss-Patience, P | 1 |
| Huang, H; Huang, X; Li, X; Liu, Y; Wang, H; Yu, M; Zhang, J; Zhang, Y | 1 |
| Brauer, M; Hertel, N; Jansen, J; Lees, M; Penrod, JR; Shafrin, J; Skornicki, M; Villeneuve, J | 1 |
| Hayata, K; Katsuda, M; Maruoka, S; Nakamori, M; Nakamura, M; Ojima, T; Shimokawa, T; Yamaue, H | 1 |
| Akiyama, Y; Amano, S; Baba, S; Chiba, T; Endo, F; Iwaya, T; Kimura, T; Kimura, Y; Koeda, K; Mizuno, M; Nikai, H; Nitta, H; Otsuka, K; Sasaki, A; Takahara, T; Umemura, A | 1 |
| Akiba, J; Azuma, K; Hoshino, T; Ishii, H; Masuda, K; Matsuo, N; Naito, Y; Sakazaki, Y; Tokito, T; Tsuneyoshi, S; Yamada, K; Zaizen, Y | 1 |
| Sclafani, F | 1 |
| Ding, XZ; Gao, SG; He, Y; Hu, XC; Kong, DJ; Li, XC; Li, Y; Lin, TY; Wang, XS; Yang, JQ; Zhang, L; Zhao, MQ | 1 |
| Baatar, S; Gombodorj, N; Kumakura, Y; Kuriyama, K; Kuwano, H; Miyazaki, T; Nishiyama, M; Sakai, M; Shirabe, K; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T; Yoshida, T | 1 |
| Bahl, C; Behera, D; Sharma, S; Singh, N | 1 |
| Harari, PM; Rosenthal, DI; Wu, Q; Zhang, QE | 1 |
| Ballinger, M; Bordoni, R; Cobo, M; Conkling, P; Fehrenbacher, L; Gandara, DR; Gandhi, M; Han, JY; Hida, T; Kowanetz, M; Matheny, C; Moro-Sibilot, D; Park, K; Patel, H; Rittmeyer, A; Sandler, A; Satouchi, M; von Pawel, J; Yu, W | 1 |
| Fukuda, Y; Harada, T; Koga, S; Mukae, H; Ogawara, D; Okuno, D; Soda, H; Taniguchi, H; Tomono, H; Umemura, A; Yamaguchi, H; Yoshida, M | 1 |
| Ahn, MJ; Baas, P; de Castro, G; Dubos Arvis, C; Emancipator, K; Felip, E; Fidler, MJ; Garon, EB; Garrido, M; Han, JY; Herbst, RS; Jensen, EH; Kim, DW; Kim, JH; Lubiniecki, GM; Majem, M; Molina, JR; Perez-Gracia, JL; Samkari, A; Shentu, Y; Surmont, V | 1 |
| Chikugo, T; Hiraki, Y; Imamoto, H; Imano, M; Iwama, M; Kato, H; Kawakami, H; Kimura, Y; Nakagawa, K; Okuno, T; Shinkai, M; Shiraishi, O; Ueda, H; Yasuda, A; Yasuda, T | 1 |
| Chen, L; Huang, JQ; Li, J; Sun, W; Wen, WP; Wen, YH; Zhu, XL | 1 |
| Aizawa, T; Furusaka, T; Hirai, R; Homma, T; Ikeda, A; Ishibashi, N; Maebayashi, T; Sakaguchi, M | 1 |
| Hata, M; Hayashi, Y; Hirota, M; Iida, M; Iwai, T; Kioi, M; Koike, I; Koizumi, T; Mitsudo, K; Nozato, T; Oguri, S; Tohnai, I | 1 |
| Chen, Q; Wang, X; Wei, KJ; Yu, YC | 1 |
| Bacay, A; Bakst, RL; Catalano, PJ; Chau, NG; Gupta, V; Haddad, RI; Hanna, GJ; Mahmood, U; Margalit, DN; McHugh, P; Misiukiewicz, KJ; Posner, M; Rabinowits, G; Rath, L; Rawal, B; Schoenfeld, JD; Tishler, RB | 1 |
| Doki, Y; Kobayashi, T; Makino, T; Mori, M; Tanaka, K; Yamasaki, M | 1 |
| Chintakuntlawar, AV; Foote, RL; Foster, NR; Garces, YI; Garcia, JJ; Ginos, B; Graner, DE; Hinni, ML; Janus, JR; Kasperbauer, JL; Ma, DJ; Miller, R; Moore, EJ; Neben-Wittich, M; Olsen, KD; Patel, SH; Price, DL; Price, KA; Shiraishi, S; Van Abel, KM; Waddle, M | 1 |
| Kazuno, A; Koyanagi, K; Ninomiya, Y; Oguma, J; Ozawa, S; Yamamoto, M; Yatabe, K | 1 |
| Arpa, D; Burgio, MA; Gavelli, G; Genestreti, G; Ghigi, G; Monti, M; Parisi, E; Polico, R; Romeo, A; Rossi, A; Sarnelli, A; Scarpi, E; Tesei, A | 1 |
| Cai, QL; Li, G; Niu, YJ; Wang, Z; Xu, J; Yang, X; Zhang, HT; Zhu, SM | 1 |
| Burke, MS; Ford, D; Kim, J; Loree, JT; Loree, TR; Popat, SR; Szymanowski, AR | 1 |
| Fukushima, H; Mitani, H; Nakano, K; Sasaki, T; Seto, A; Shimbashi, W; Takahashi, S; Yonekawa, H | 1 |
| Behera, M; Chen, Z; Fu, H; Gal, AA; Govindan, R; Harvey, RD; Khuri, FR; Klass, CM; Kono, SA; Owonikoko, TK; Ramalingam, SS; Saba, NF; Shin, DM; Sica, G; Subramanian, J; Sun, SY | 1 |
| Akutsu, Y; Hoshino, I; Kono, T; Matsubara, H; Miyazawa, Y; Shiratori, T; Shuto, K; Takeshita, N; Uesato, M | 1 |
| Argenone, A; Caponigro, F; Daponte, A; Fulciniti, F; Ionna, F; Longo, F; Muto, P; Perri, F; Sandomenico, F | 1 |
| Arnold, D; Dietz, A; Eberhardt, W; Gauler, TC; Gruenwald, V; Hennemann, B; Hofele, C; Jordan, WO; Keilholz, U; Knoedler, M; Matzdorff, A; Schroeder, M; Weissinger, F | 1 |
| Hansen, AR; Siu, LL | 1 |
| Argiris, A; Burtness, B; Forastiere, AA; Ghebremichael, M; Gilbert, J; Kolesar, JM; Lee, JW; Sachidanandam, K | 1 |
| Fleitas, T; Gómez-Codina, J; Martín, M; Martínez-Sales, V; Mesado, D; Montalar, J; Reganon, E; Reynés, G; Vila, V | 1 |
| Cao, X; Feng, Y; Huang, H; Huang, X; Huang, Y; Lan, C; Liu, J | 1 |
| Bae, WK; Cho, IS; Cho, SH; Chung, IJ; Chung, WK; Han, HS; Hwang, JE; Lee, JK; Lee, KH; Lim, SC; Shim, HJ; Song, EK; Yun, HJ | 1 |
| Lee, JJ; Li, J; Liu, Y; Ma, J; Myers, JN; Wang, LZ; William, WN; Yang, CZ; Yang, X; Zhang, CP; Zhang, ZY; Zhong, LP; Zhu, DW | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Armstrong, JL; Birch-Machin, MA; Ellis, R; Lovat, PE; McKee, C; Wright, TJ | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Wang, B; Wang, XD; Yue, K; Zhang, S | 1 |
| Aderhold, C; Birk, R; Erben, P; Faber, A; Hofheinz, RD; Hörmann, K; Sauter, A; Schultz, JD; Sommer, JU; Stern-Straeter, J; Umbreit, C | 1 |
| Kang, JH; Kim, HK; Park, JC; Park, SY; Yang, YJ | 1 |
| Baykara, M; Benekli, M; Bora, H; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Kaplan, MA; Ozturk, B; Unsal, DK | 1 |
| Adkins, D; Clark, J; Haddad, R; Jaffa, Z; Limaye, S; O'Neill, A; Posner, M; Riley, S; Zhao, S | 1 |
| Dietz, A; Dimitrova, K; Mozet, C; Stoehr, M; Wichmann, G | 1 |
| Aderhold, C; Faber, A; Hoermann, K; Hofheinz, RD; Sauter, A; Schultz, JD; Sommer, JU; Stern-Sträter, J; Umbreit, C | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Mori, M; Nakajima, K; Sugimura, K; Takahashi, T; Takiguchi, S; Tanaka, K; Yamasaki, M | 1 |
| Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; Eggers, C; Grist, WJ; Khuri, FR; Kim, S; Magliocca, KR; Marcus, AI; Muller, S; Owonikoko, TK; Phelan, V; Ramalingam, SS; Saba, NF; Sarlis, NJ; Shin, DM | 1 |
| Eroglu, C; Kaplan, B; Kurtul, N; Oguz, A; Tasdemir, A; Unal, D | 1 |
| Caudell, JJ; Elci, O; Ganeshan, B; Graham, CM; Griswold, ME; Hamilton, RD; Khan, MA; Pitman, K; Smith, AD; Zhang, H; Zhang, X | 1 |
| Coyle, C; Dyker, KE; Karakaya, E; Prestwich, RJ; Sen, M; Teo, M; Young, CA | 1 |
| Bian, D; Du, W; Feng, X; Fu, C; Wang, X; Zhao, Y | 1 |
| Hirai, Y; Ito, S; Kawashima, H; Kurosaki, Y; Uekusa, T | 1 |
| Daiko, H; Hamamoto, Y; Hara, H; Hosoya, Y; Igaki, H; Kadowaki, S; Kato, K; Matsushita, H; Nagase, M; Tahara, M; Tanaka, Y | 1 |
| Stinchcombe, TE | 1 |
| Chen, WW; Cheng, AL; Hsu, CH; Huang, TC; Lin, CC; Yeh, KH | 1 |
| Daiko, H; Ebihara, M; Fujii, S; Hayashi, R; Miyazaki, M; Sakuraba, M; Shinozaki, T; Suzuki, K; Tahara, M; Zenda, S | 1 |
| Montero, M; Stack, BC; Ye, J | 1 |
| Denaro, N; Merlano, MC; Russi, EG | 1 |
| Ozdemir, O; Ozdemir, P; Ozhan, MH; Uluer, H; Veral, A | 1 |
| Li, X; Lin, S; Lin, W; Lin, Y; Wang, H | 1 |
| Fajdiga, I; Gale, N; Grašič Kuhar, C; Jančar, B; Kadivec, M; Karner, K; Kocjan, BJ; Poljak, M; Strojan, P; Zakotnik, B; Žumer, B | 1 |
| Bahl, A; Barber, J; Burnett, S; Carrington, B; Chester, JD; Cruickshank, C; Elliott, T; Hall, E; Harland, SJ; Nicholson, S; Pickering, L; Thomson, A; Waters, R | 1 |
| Berrocal, A; Brandariz Castelo, JA; Cruz-Hernández, JJ; García-Girón, C; Grau, JJ; Hitt, R; Irigoyen, A; López-Pousa, A; Martínez-Trufero, J; Sastre, J; Verger, E | 1 |
| Bechmann, I; Dietz, A; Gerlach, MM; Kubick, C; Lordick, F; Merz, F; Wichmann, G; Wittekind, C | 1 |
| Hata, M; Inoue, T; Kioi, M; Koike, I; Koizumi, T; Mitsudo, K; Mukai, Y; Oguri, S; Omura, M; Tohnai, I | 1 |
| Comans, EF; Lammertsma, AA; Smit, EF; van der Veldt, AA | 1 |
| Ando, T; Fujinami, H; Hosokawa, A; Kajiura, S; Mihara, H; Minemura, M; Nishikawa, J; Ogawa, K; Sugiyama, T; Ueda, A; Ueda, Y; Yoshita, H | 1 |
| Horibe, K; Maeda, N; Moritani, S; Sekimizu, M; Ueki, H; Yamashita, Y | 1 |
| Guo, W; Li, C; Lyu, J; Ren, G; Wang, R; Wu, Y | 1 |
| Bakan, S; Demiryas, S; Kantarci, F; Korkmazer, B; Olgun, DC; Samanci, C; Tutar, O | 1 |
| Ebisui, C; Makino, S; Miyamoto, T; Miyazaki, M; Murata, K; Tamai, M; Tsuji, F; Wada, Y; Yokouchi, H | 1 |
| Balermpas, P; Bauer, C; Fokas, E; Fraunholz, I; Ottinger, A; Rödel, C; Seitz, O; Stöver, T; Wagenblast, J; Weiss, C | 1 |
| Fusi, A; Keilholz, U; Klinghammer, K; Knödler, M; Nonnenmacher, A; Pfisterer, K | 1 |
| Battafarano, RJ; Burrows, WM; Edelman, MJ; Hanlon, AL; Horiba, MN; Kim, GJ; Koshy, M; Suntharalingam, M | 1 |
| Ban, X; Cai, Z; Cao, TT; Chen, J; Fu, L; Guan, XY; Huang, P; Li, JB; Li, Y; Qian, C; Qin, Y; Xie, D; Zeng, TT; Zeng, ZL; Zhou, J | 1 |
| Aigner, A; Boehm, A; Dietz, A; Mozet, C; Stoehr, M; Wichmann, G | 1 |
| Cai, L; Li, CH; Li, DD; Liu, MY; Liu, W | 1 |
| Li, J; Liu, Y; Ma, J; Montgomery, B; Wang, LZ; Yang, CZ; Zhang, CP; Zhang, ZY; Zhong, LP; Zhu, DW | 1 |
| Arai, Y; Isitoya, J; Komatsu, M; Nishimura, G; Oridate, N; Sakuma, N; Sakuma, Y; Sano, D; Shiono, O; Taguchi, T; Takahashi, M; Yabuki, K | 1 |
| Baba, H; Baba, Y; Ishimoto, T; Iwagami, S; Iwatsuki, M; Nagai, Y; Watanabe, M; Yoshida, N | 1 |
| Cheng, Y; Cun, Y; Li, M; Li, Z; Peng, Y; Qian, C; Ren, T; Wang, D; Xia, L; Xiong, Y; Zhang, S | 1 |
| Hata, M; Hirota, M; Iida, M; Iwai, T; Kioi, M; Koike, I; Koizumi, T; Mitsudo, K; Nakashima, H; Oguri, S; Tohnai, I | 1 |
| Chikamatsu, K; Ishioka, NS; Kaira, K; Kanai, Y; Nagamori, S; Ohshima, Y; Oriuchi, N; Oyama, T; Sakakura, K; Shino, M; Takahashi, K; Takayasu, Y; Tominaga, H; Toyoda, M | 1 |
| Baba, H; Baba, Y; Ida, S; Imamura, Y; Ishimoto, T; Iwagami, S; Karashima, R; Miyamoto, Y; Sakamoto, Y; Watanabe, M; Yoshida, N | 1 |
| Belot, A; Céruse, P; Cosmidis, A; Favrel, V; Fayette, J; Fuchsmann, C; Pommier, P; Poupart, M; Rabilloud, M; Ramade, A; Tartas, S; Zrounba, P | 1 |
| Azuma, M; Hayakawa, K; Higuchi, K; Ishido, K; Ishiyama, H; Katada, C; Katada, N; Koizumi, W; Komori, S; Sasaki, T; Tanabe, S | 1 |
| Han, H; Kim, H; Kim, K; Kwon, IC; Lee, M; Oh, KS; Seo, DW; Seo, JH; Yoon, BD; Yuk, SH | 1 |
| Jin, J; Li, RX; Liu, SH; Wang, LP; Wang, Y; Ye, MC; Zhou, Y; Zhu, WZ; Zuo, Y | 1 |
| Argiris, A; Fu, P; Galanopoulos, N; Gibson, M; Lavertu, P; Machtay, M; Rezaee, R; Savvides, P; Wasman, J; Yao, M; Zender, C | 1 |
| Feng, Q; Gao, S; He, J; Huang, J; Jiang, Y; Liu, Y; Lyu, X; Mao, Y; Shao, K; Wang, J | 1 |
| Haruma, K; Higashida, M; Hirai, T; Hiratsuka, J; Kubota, H; Matsumoto, H; Nakamura, M; Yoden, E | 1 |
| Chen, CH; Lin, SF; Liu, YC; Sun, Y; Tang, JY; Wu, CF; Yang, WC | 1 |
| Akita, H; Fukuda, S; Hatakeyama, H; Homma, A; Kakizaki, T; Kano, S; Kinoshita, I; Mizumachi, T; Onimaru, R; Sakashita, T; Shimizu, Y; Shirato, H; Taguchi, J; Tsuchiya, K; Yasuda, K | 1 |
| Ang, K; Foote, RL; Gillison, ML; Harari, PM; Harris, J; Jordan, RC; Khuntia, D; Kies, MS; Machtay, M; Myers, JN; Rotman, M; Straube, W; Zhang, Q | 1 |
| Ades, S; Alcindor, T; Aloraini, A; Asselah, J; Brisson, S; David, M; Ferri, L; Frechette, D; Sudarshan, M; Thirlwell, M; van Huyse, M | 1 |
| Al-Massarani, G; Alali, A; Alammar, M; Almalla, N; Altahan, M; Bachour, M; Najjar, F | 1 |
| Chin, K; Doki, Y; Fujitani, K; Hironaka, S; Kato, K; Kii, T; Kitagawa, Y; Kojima, T; Kusaba, H; Matsushita, H; Mizusawa, J; Nakamura, T; Okuno, T; Seki, S; Taira, K; Taniki, T; Tomori, A; Tsubosa, Y; Tsushima, T; Ura, T | 1 |
| Agulnik, MB; Braegas, B; Brockstein, BE; Cohen, EE; Egan, R; Haraf, DJ; Huang, CH; Karrison, TG; Kocherginsky, M; Kumar, P; Marchand, P; Mehra, R; Mittal, BB; Mueller, J; Ondrey, F; Raez, LE; Samant, S; Seiwert, TY; Villaflor, VM; Vokes, EE; Yunus, F | 1 |
| Dang, J; Li, G; Yao, L; Zang, S; Zhang, S | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Hoshikawa, H; Indo, K; Kamitori, K; Mori, N; Mori, T; Tokuda, M; Yamaguchi, F | 1 |
| Huang, ZJ; Lin, JQ; Xu, TW; Yang, N | 1 |
| Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C | 1 |
| Doki, Y; Kurokawa, Y; Miyata, H; Miyazaki, Y; Mori, M; Nakajima, K; Takahashi, T; Takiguchi, S; Yamasaki, M | 1 |
| Antonia, S; Chiappori, A; Dilling, TJ; Extermann, M; Gray, J; Haura, E; Kim, J; Kim, S; Pinder-Schenck, M; Stevens, CW; Tanvetyanon, T; Thompson, LM; Williams, C; Yue, B | 1 |
| Georgoulias, V; Giagkas, G; Ioannidis, G; Koutsopoulos, A; Lagoudaki, E; Mavroudis, D; Papadaki, C; Sfakianaki, M; Souglakos, J; Trypaki, M; Tsakalaki, E; Voutsina, A | 1 |
| Boku, N; Fuke, T; Hamauchi, S; Haraguchi, Y; Hikosaka, T; Iida, Y; Izawa, N; Kamijo, T; Machida, N; Nakagawa, M; Nishimura, T; Ogawa, H; Onitsuka, T; Onozawa, Y; Todaka, A; Tsushima, T; Yasui, H; Yokota, T | 1 |
| Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishikawa, A; Okita, N; Sasaki, Y; Sawada, R; Shimada, Y; Shirakawa, T; Shoji, H; Takahashi, N; Takashima, A; Yamada, Y | 1 |
| Chung, CH; Fertig, EJ; Gillison, ML; Harari, PM; Harris, J; Jordan, RC; Kong, CS; Le, QT; Raben, D; Redmond, KP; Shenouda, G; Trotti, A; Wang, D; Zhang, Q | 1 |
| Di, ZL; Ke, Y; Ma, HB; Ren, J; Sun, X; Wen, J | 1 |
| Carlson, SG; Chen, Z; Eytan, DF; Schiltz, S; Snow, GE; Van Waes, C | 1 |
| Agüero, A; Farré, N; García, J; León, X; López, M; López-Pousa, A; Quer, M | 1 |
| Hanai, N; Hasegawa, Y; Hirakawa, H; Nakashima, T; Nishikawa, D; Ozawa, T; Suzuki, H | 1 |
| Adkins, D; Bauman, JE; Beauregard, P; Bowles, DW; Hausman, D; Jimeno, A; Levy, B; Rudin, CM; Schnadig, I; Seetharamu, N; Shirai, K; Spira, A; Walker, L; Weissman, C | 1 |
| Adkins, DR; Diaz, J; Gay, H; Lewis, J; Ley, J; Michel, L; Nussenbaum, B; Paniello, RC; Rich, J; Schell, A; Thorstad, W; Trinkaus, K; Wildes, TM; Wu, N | 1 |
| Autret, D; Capitain, O; Cellier, P; El Alouani, C; Gustin, P; Jadaud, É; Laccourreye, L; Peyraga, G; Pointreau, Y; Septans, AL; Tuchais, C; Vinchon-Petit, S; Yossi, S | 1 |
| Albert, S; Antoine, M; Banal, A; Baril, P; Belloc, JB; Benetkiewicz, M; Bonnetain, F; Céruse, P; Chabolle, F; Chibaudel, B; de Gramont, A; Gatineau, M; Housset, M; Lacau St Guily, J; Lacave, R; Lefevre, M; Moukoko, R; Périé, S; Soussan, P | 1 |
| Liu, D; Qian, J; Su, B; Xu, W; Zhang, J; Zhang, ZW; Zheng, H | 1 |
| Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Saito, K; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T | 1 |
| Cho, H; Hanamoto, A; Inohara, H; Nakahara, S; Nishiike, S; Takenaka, Y; Yamamoto, Y; Yasui, T | 1 |
| Fukuda, S; Furusawa, J; Hatakeyama, H; Homma, A; Kano, S; Mizumachi, T; Nakamaru, Y; Onimaru, R; Sakashita, T; Shirato, H; Terasaka, S; Tsuchiya, K; Yasuda, K; Yoshida, D | 1 |
| Fodor, J; Gödény, M; Hitre, E; Kásler, M; Major, T; Oberna, F; Polgár, C; Remenár, É; Takácsi-Nagy, Z | 1 |
| Ageshio, F; Kagawa, H; Kimura, H; Matsui, H; Mori, M; Niinaka, M; Satomi, A; Uenami, T; Yamaguchi, T; Yano, Y; Yokota, S; Yoneda, T | 1 |
| Inohara, H; Isohashi, F; Nakahara, S; Ogawa, K; Seo, Y; Sumida, I; Suzuki, O; Takenaka, Y; Tomiyama, Y; Yamamoto, Y; Yoshii, T; Yoshioka, Y | 1 |
| Choi, HG; Choi, JY; Kim, JH; Kim, JO; Nukolova, N; Poudel, BK; Pradhan, R; Ramasamy, T; Tak, JW; Yong, CS | 1 |
| Ahn, HK; Ahn, MJ; Hwang, IG; Jung, HA; Jung, KS; Kim, HS; Kim, M; Kim, SM; Lee, J; Lee, JY; Lee, MY; Lee, SC; Lee, SI; Lim, DH; Lim, SH; Park, KW; Park, SH; Sun, JM; Yi, SY | 1 |
| Bacchus, ID; Mittal, BB; Refaat, T; Sachdev, S; Sathiaseelan, V | 1 |
| Fukuda, M; Gemma, A; Inoue, A; Isobe, H; Katakami, N; Kobayashi, K; Kubota, K; Kudoh, S; Kunitoh, H; Michimae, H; Minato, K; Nakamura, Y; Nishio, M; Ohmatsu, H; Okamoto, H; Sakai, H; Sugawara, S; Takeuchi, M; Takiguchi, Y; Yokoyama, A | 1 |
| Chen, CH; Chien, CY; Chiu, TJ; Chuang, HC; Fang, FM; Hsu, CM; Huang, TL; Huang, WT; Lai, CC; Li, SH; Lin, WC; Luo, SD; Su, YY | 1 |
| Chen, X; Gao, Y; Han, Q; Jin, Y; Qian, Z; Wan, L; Wei, B; Wu, J; Xu, L; Zhang, X; Zhou, J; Zhu, J | 1 |
| Das, D; Govindan, SV; Hicks, W; Kulsum, S; Kuriakose, MA; Pandian, RS; Seshadri, M; Suresh, A | 1 |
| Ding, X; Geng, M; Huang, M; Li, H; Sun, W; Wu, H; Xie, Z; Zhang, X | 1 |
| Kulkarni, AB; Liu, B; Sun, ZJ; Wang, YF; Zhang, L; Zhang, W; Zhang, WF; Zhao, YF | 1 |
| Aerts, JG; Antonia, S; Arén Frontera, O; Baas, P; Baudelet, C; Brahmer, J; Crinò, L; Domine, M; Eberhardt, WE; Gainor, J; Garassino, MC; Harbison, CT; Havel, L; Holgado, E; Lestini, B; Paz-Ares, L; Pluzanski, A; Poddubskaya, E; Ready, N; Reck, M; Reckamp, KL; Spigel, DR; Steins, M; Vokes, EE; Waterhouse, D | 1 |
| Deng, J; Deng, JH; Niu, PG; Ouyang, XN; Shi, DH | 1 |
| Carp, L; Corthouts, B; Specenier, P; Szturz, P; Van Den Weyngaert, D; Van Laer, C; Van Marck, E; Vanderveken, O; Vermorken, JB | 1 |
| Yaqub, F | 1 |
| Aghili, M; Garajei, A; Harirchi, I; Kazemian, A; Keyhani, A; Motiee Langroudi, M; Nikparto, N; Sadighi, S; Zendehdel, K | 1 |
| Choi, SH; Kim, JH; Kim, SC; Ryoo, I; Sohn, CH | 1 |
| Bourhis, J; Bozec Le Moal, L; Dillies, AF; Fayette, J; Guigay, J; Henry, S; Kerger, JN; Machiels, JP; Pointreau, Y; Schilf, A; Sire, C; Tennevet, I; Zanetta, S | 1 |
| Cai, YL; Guo, W; He, Y; Hong, CS; Hu, YJ; Ji, T; Lee, JJ; Li, J; Myers, JN; Ren, GX; Sun, J; Tu, WY; Wang, LZ; Wang, YA; Wang, ZH; William, WN; Xu, LQ; Yang, WJ; Ye, WM; Yin, QM; Zhang, CP; Zhang, ZY; Zhong, LP; Zhu, HG; Zhuang, Z | 1 |
| Dou, S; Guan, X; Li, F; Liu, Y; Xu, T; Zhu, G | 1 |
| Han, S; Liang, H; Liu, W; Wen, H; Yang, H; Yao, J; Yu, L | 1 |
| Guo, Z; Jiang, C; Li, J; Pei, SY; Si, TB; Wang, Q; Zhao, J | 1 |
| Feifan, Z; Kun, M; Lin, M; Xinxin, Z | 1 |
| Bettini, A; Broggini, M; Copreni, E; Farina, G; Ganzinelli, M; Garassino, MC; Labianca, R; Lauricella, C; Longo, F; Marabese, M; Marsoni, S; Martelli, O; Moscetti, L; Rulli, E; Torri, V; Veronese, S | 1 |
| Liu, MZ; Liu, SL; Luo, LL; Wu, YJ; Xi, M; Yang, H; Yang, YD; Zhang, P; Zhao, L | 1 |
| Berg, S; Boessert, P; Fruth, K; Haxel, BR; Mann, WJ | 1 |
| Bencivenga, M; Carbone, C; De Manzoni, G; Frizziero, M; Giacopuzzi, S; Melisi, D; Merz, V; Mina, MM; Piro, G; Santoro, R; Tortora, G; Verlato, G; Zanoni, A; Zanotto, M | 1 |
| Ye, D; Zhang, S; Zhu, Y | 1 |
| Ban, X; Guan, XY; Li, L; Li, XD; Li, Y; Xie, D; Yang, H; Yun, J; Zeng, TT; Zhang, BZ; Zhou, Y | 1 |
| Nakashima, T; Sakurai, K; Sasabe, H; Sato, A; Sato, M; Shibamori, M; Uematsu, N; Umehara, K; Yamamura, Y | 1 |
| Hanamoto, A; Honma, K; Inohara, H; Kitamura, K; Morii, E; Nakahara, S; Takenaka, Y; Yamamoto, Y; Yasui, T | 1 |
| Benezery, K; Bozec, A; Chamorey, E; Chand, ME; Dassonville, O; Demard, F; Ettaiche, M; Falewee, MN; Hannoun-Lévi, JM; Haudebourg, J; Hebert, C; Leysalle, A; Peyrade, F; Poissonnet, G; Riss, JC; Saada, E; Santini, J; Sudaka, A; Vandersteen, C | 1 |
| Aboshady, H; Barrueco, J; Bennouna, J; Bondarenko, I; Cheng, Y; Douillard, JY; Gottfried, M; Hocke, J; Kaiser, R; Luft, A; Mellemgaard, A; Reck, M; von Pawel, J; Zarogoulidis, K | 1 |
| Blumenthal, G; Kazandjian, D; Keegan, P; Khozin, S; Kluetz, P; Libeg, M; Pazdur, R; Sridhara, R; Tang, S; Zhang, L | 1 |
| Airoldi, M; Di Muzio, J; Fasolis, M; Franco, P; Garzaro, M; Garzino Demo, P; Melano, M; Moretto, F; Pecorari, G; Potenza, I; Ragona, R; Rampino, M; Ricardi, U; Riva, G; Schena, M | 1 |
| Spicer, J; Wu, Y | 1 |
| Daga, H; Goto, K; Hattori, Y; Iwamoto, Y; Kaneda, H; Kawaguchi, T; Nagase, S; Nakagawa, K; Nakanishi, Y; Nishimura, T; Oguri, T; Saka, H; Seto, T; Shukuya, T; Sugawara, S; Takahashi, T; Yamamoto, N; Yamanaka, T; Yokota, S | 1 |
| Bu, LL; Huang, CF; Liu, B; Liu, JF; Ma, SR; Sun, ZJ; Zhang, WF; Zhao, ZL | 1 |
| Bölke, E; Budach, W; Gerber, PA; Gripp, S; Kammers, K; Matuschek, C; Orth, K | 1 |
| Ferdous, T; Harada, K; Harada, T; Ueyama, Y | 1 |
| Chan, KK; Furness, S; Glenny, AM; Wakeford, H; Weldon, JC; Worthington, HV | 1 |
| Baba, H; Baba, Y; Harada, K; Higashi, T; Ida, S; Imamura, Y; Ishimoto, T; Iwagami, S; Izumi, D; Kosumi, K; Miyamoto, Y; Miyata, T; Sakamoto, Y; Shiraishi, S; Taki, K; Tokunaga, R; Watanabe, M; Yamashita, Y; Yoshida, N | 1 |
| Carles, J; Cruz, JJ; del Barco, E; Escobar, Y; García, C; García-Paredes, B; García-Sáenz, JA; Grau, JJ; Irigoyen, A; Lozano, A; Mañós, M; Mesía, R; Taberna, M; Vázquez, S | 1 |
| Fushida, S; Harada, S; Hayashi, H; Kinoshita, J; Makino, I; Miyanaga, S; Miyashita, T; Nakagawara, H; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Tajima, H; Takamura, H; Tsukada, T | 1 |
| Alfonsi, M; Calais, G; Chapet, S; Garaud, P; Jadaud, E; Janoray, G; Pointreau, Y; Sire, C | 1 |
| Hayata, K; Iwahashi, M; Katsuda, M; Matsumura, S; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H | 1 |
| Hayata, K; Iwahashi, M; Kato, T; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Tabata, H; Takeuchi, A; Yamaue, H | 1 |
| Benepal, T; Cadranel, J; Christoph, DC; Das, M; Fennell, DA; Ferry, D; Lal, R; Maxwell, F; Summers, Y; Visseren-Grul, C | 1 |
| Cooray, P; Ferraro, DA; Ganju, V; Gebski, V; Hall, M; Pavlakis, N; Price, TJ; Shannon, JA; Sjoquist, KM; Strickland, A; Tebbutt, NC; Underhill, C; Varma, SC; Veillard, AS; Wong, N; Young, R | 1 |
| Hoshi, K; Hosoda, K; Katada, C; Katada, N; Koizumi, W; Mieno, H; Moriya, H; Watanabe, M; Yamashita, K | 1 |
| Audigier-Valette, C; Auliac, JB; Baize, N; Bérard, H; Bota, S; Chouaïd, C; Corre, R; Dansin, E; Daurès, JP; Decroisette, C; Descourt, R; Dujon, C; Falchero, L; Greillier, L; Lamy, R; Le Caër, H; Léna, H; Marcq, M; Massuti, B; Monnet, I; Pérol, M; Plassot, C; Vergnenègre, A | 1 |
| Cho, BC; Choi, EC; Kim, HR; Kim, JH; Koh, YW; Lee, CG | 1 |
| Matsuhashi, N; Miyazaki, T; Okumura, N; Tanahashi, T; Tanaka, Y; Yamada, A; Yamaguchi, K; Yoshida, K | 1 |
| Fukuchi, M; Inose, T; Kato, H; Kuwano, H; Masuda, N; Miyazaki, T; Nakajima, M; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N | 1 |
| Hara, K; Honjo, H; Kuwano, H; Miyazaki, T; Ozawa, D; Sakai, M; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T | 1 |
| Fu, P; Gibson, M; Lavertu, P; Machtay, M; Rezaee, R; Savvides, P; Sharma, N; Wasman, J; Woods, C; Yao, M; Zender, C | 1 |
| Qin, RQ; Wang, WP; Wen, YS; Xi, KX; Yu, XY; Zhang, LJ | 1 |
| Cheng, Y; Guan, S; Huang, X; Jia, Y; Ma, Y; Song, Q; Sun, Y; Tan, B; Wang, C; Wang, J; Yao, B | 1 |
| Akerley, W; Bazhenova, LA; Borghaei, H; Camidge, DR; Cheney, RT; Chirieac, LR; D'Amico, TA; Dilling, TJ; Dobelbower, MC; Ettinger, DS; Govindan, R; Gregory, K; Hennon, M; Horn, L; Hughes, M; Jahan, TM; Komaki, R; Lackner, RP; Lanuti, M; Lilenbaum, R; Lin, J; Loo, BW; Martins, R; Otterson, GA; Patel, JD; Pisters, KM; Reckamp, K; Riely, GJ; Schild, SE; Shapiro, TA; Sharma, N; Stevenson, J; Swanson, SJ; Tauer, K; Wood, DE; Yang, SC | 1 |
| Hah, JH; Han, DH; Heo, DS; Keam, B; Kim, DW; Kim, DY; Kim, TM; Kwon, TK; Lee, SH; Ock, CY; Rhee, CS; Sung, MW; Won, TB; Wu, HG | 1 |
| Kawada, K; Kawano, T; Miyawaki, Y; Nakajima, Y; Okada, T; Tokairin, Y | 1 |
| Chen, YH; Chien, CY; Chiu, TJ; Fang, FM; Hsu, CM; Huang, TL; Lai, CC; Li, SH; Lin, WC; Luo, SD; Su, YY | 1 |
| Azami, Y; Fuwa, N; Hareyama, M; Hatayama, Y; Hayashi, Y; Kikuchi, Y; Mitsudo, K; Nakamura, T; Ono, T; Suzuki, M; Takayama, K; Tohnai, I; Tsukiyama, I; Yamaguchi, H | 1 |
| Chikamatsu, S; Imai, H; Ishioka, C; Kasahara, Y; Kobayashi, A; Komine, K; Oishi, T; Okada, Y; Okita, A; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Bai, L; Cheng, Z; Dai, G; Han, Z; Liang, P; Liu, F; Tan, S; Yu, J; Yu, X; Zhou, F | 1 |
| Matsuhashi, N; Okumura, N; Tanahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K | 1 |
| Agena, S; Azama, K; Heianna, J; Iraha, Y; Kinoshita, R; Maeda, H; Murayama, S; Suzuki, M; Toita, T; Toyama, M; Yamashiro, K; Yamashiro, T | 1 |
| Daiko, H; Doi, T; Fujii, S; Fujita, T; Hatogai, K; Kadota, T; Kojima, T; Ohtsu, A; Takiguchi, Y; Yoshino, T | 1 |
| Bu, LL; Gutkind, JS; Huang, CF; Kulkarni, AB; Liu, B; Liu, JF; Ma, SR; Sun, ZJ; Yu, GT; Zhang, L; Zhang, WF; Zhao, ZL | 1 |
| Ambrun, A; Céruse, P; Daveau, C; Diallo, A; Fayette, J; Fontaine-Delaruelle, C; Neidhardt, EM; Péron, J; Poupart, M; Ramade, A; Zrounba, P | 1 |
| Hayata, K; Katsuda, M; Nakamori, M; Nakamura, M; Nakamura, Y; Ojima, T; Yamaue, H | 1 |
| Qiu, L; Yu, Y | 1 |
| Arai, Y; Hata, M; Komatsu, M; Nishimura, G; Oridate, N; Sano, D; Shiono, O; Taguchi, T; Takahashi, H; Takahashi, M; Yabuki, K | 1 |
| Guo, X; Hu, YH; Li, QQ; Liu, H; Liu, MZ; Liu, Q; Liu, SL; Luo, LL; Xi, M; Zhang, P; Zhao, L | 1 |
| Bando, H; Chin, K; Hamauchi, S; Hara, H; Honma, Y; Iwasa, S; Kato, K; Kii, T; Kiyota, N; Kojima, T; Mochizuki, S; Ohtsu, A; Satake, H; Tahara, M; Tsushima, T; Yamazaki, T; Yokota, T; Zenda, S | 1 |
| Bellile, E; Bradford, C; Carey, TE; Chepeha, DB; Eisbruch, A; Jackson, TL; Malloy, K; McKean, E; McLean, S; Moyer, J; Nör, JE; Pearson, AT; Prince, M; Sacco, AG; Shuman, A; Spector, ME; Sukari, A; Swiecicki, PL; Taylor, JM; Wang, S; Wolf, GT; Worden, FP | 1 |
| Chikamatsu, K; Ida, S; Mito, I; Sakakura, K; Takahashi, H | 1 |
| Kajiwara, M; Moriyama, H; Yonehara, S | 1 |
| Chang, YC; Chi, KH; Chi, MS; Hsu, PS; Jiang, JS; Kao, SJ; Ko, HL; Lin, CC; Wang, HE; Yang, KL; Yeh, DY | 1 |
| Gill, HS; Mody, MD; Saba, NF | 1 |
| Ahn, PH; Anne, PR; Axelrod, RS; Cognetti, D; Dicker, AP; Keane, WM; Machtay, M; Wuthrick, E | 1 |
| Deák, P; Fábián, G; Kahán, Z; Kovács, L; Mózes, P; Nagy, O; Pál, M; Reisz, Z; Rovó, L; Rusz, O; Szilágyi, É; Tiszlavicz, L; Tomisa, B; Varga, Z | 1 |
| Arya, S; Goswami, C; Goud, S; Joshi, A; Juvekar, S; Murthy, V; Noronha, V; Patil, S; Patil, VM; Prabhash, K | 1 |
| Gao, X; Huang, G; Li, G; Li, X; Qin, S; Ren, H; Sun, X; Wang, H; Xiao, G; Yang, C; Zhang, B | 1 |
| Chen, L; Chen, NX; Ma, L; Wang, JL; Yan, F; Zhang, XX | 1 |
| Ambrosi, E; Casella, F; de Manzoni, G; Di Leo, A; Giacopuzzi, S; Motton, M; Ricci, F; Rice, TW; Vassiliadis, A; Verlato, G; Weindelmayer, J; Zanoni, A | 1 |
| Chen, J; Liu, JY; Liu, ZQ; Qian, CY; Wang, Y; Yin, JY; Zheng, Y; Zhou, HH | 1 |
| Aretin, MB; Fuchs, H; Fuereder, T; Grah, A; Kornek, G; Pammer, J; Posch, D | 1 |
| Dermitzaki, EK; Georgoulias, V; Hatzidaki, D; Karavassilis, V; Katsaounis, P; Kentepozidis, N; Koinis, F; Kotsakis, A; Matikas, A; Mavroudis, D; Samantas, E; Varthalitis, II | 1 |
| Baba, H; Baba, Y; Hiyoshi, Y; Kurashige, J; Sakamoto, Y; Watanabe, M; Yoshida, N | 1 |
| Doki, Y; Fujitani, K; Hirao, M; Kimura, Y; Kobayashi, K; Makino, T; Miyata, H; Mori, M; Motoori, M; Satoh, T; Shiraishi, O; Tamura, S; Yamasaki, M; Yano, M; Yasuda, T | 1 |
| Adkins, D; Axelrod, R; Dakhil, S; Debruyne, PR; Dong, J; Kornek, G; Murugappan, S; O'Brien, P; Oliner, KS; Pant, S; Wirth, LJ | 1 |
| Dumollard, JM; Forest, F; Fournel, P; Froudarakis, M; Gavid, M; Giroult, JB; Karpathiou, G; Monaya, A; Peoc'h, M; Prades, JM | 1 |
| Alfieri, S; Bergamini, C; Bossi, P; Cavallo, A; Cova, A; Granata, R; Huber, V; Iacovelli, NA; Imbimbo, M; Licitra, L; Locati, L; Mariani, L; Miceli, R; Orlandi, E; Resteghini, C; Rivoltini, L | 1 |
| Cho, H; Hayashi, T; Ikeda, K; Kano, K; Maezawa, Y; Masuda, M; Nakajima, T; Ogata, T; Ohshima, T; Rino, Y; Sato, T; Segami, K; Yamada, T; Yamamoto, N; Yoshikawa, T; Yukawa, N | 1 |
| Blanco, R; Camps, C; de Aguirre, I; Garrido, P; Gonzalez-Larriba, JL; Insa, A; Isla, D; Moran, T; Pérez Cano, M; Provencio, M; Queralt, C; Ramirez, JL; Rosell, R; Santarpia, M | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Berghmans, T; Biesma, B; Chittazhathu Kurian Kuruvilla, Y; Ciardiello, F; Coate, L; Cobo Dols, M; Collado Martin, R; Cuffe, S; Curioni-Fontecedro, A; Dafni, U; de Hosson, S; Garde Noguera, J; Gasca-Ruchti, A; Gautschi, O; Gregorc, V; Groen, HJM; Horgan, A; Insa, A; Juan Vidal, Ó; Kassapian, M; Láng, I; López Martín, A; Mark, MT; Massutí, B; Meldgaard, P; Novello, S; Palmero Sanchez, R; Peralta, S; Peters, S; Pieterman, R; Ponce Aix, S; Rauch, D; Smit, EF; Stahel, RA; Summers, Y; Torri, V; Tsourti, Z; van den Berg, PM; van Heemst, R; van Henten, AMJ; Villa Guzmán, JC; Zielinski, CC | 1 |
| Bhandari, M; Jones, RG; Kang, SY; Seim, NB; Teknos, TN | 1 |
| Adkins, D; Daly, K; Ley, J; Oppelt, P; Wildes, TM | 1 |
| Hosoda, K; Katada, C; Katada, N; Komori, S; Mieno, H; Moriya, H; Sugawara, M; Watanabe, M; Yamashita, K | 1 |
| Fujisaki, S; Sakurai, K; Takashina, M; Takayama, T; Tomita, R | 1 |
| Feng, X; Gao, C; Liu, L; Qu, D; Shi, F; Su, X; Wang, C | 1 |
| Aizawa, M; Bamba, T; Homma, K; Katsumi, C; Matsuki, A; Nakagawa, S; Yabusaki, H | 1 |
| Atagi, S; Fujita, S; Hida, T; Kato, T; Masuda, N; Nakanishi, Y; Namba, Y; Sakai, H; Satouchi, M; Takahashi, M; Takeda, K; Tamura, T; Tanaka, H | 1 |
| Cai, R; Dai, M; Diao, D; Ding, Y; Dong, X; Han, Z; Jia, C; Li, J; Shan, L; Su, Y; Wang, L; Xiong, G; Xu, W; Zheng, H; Zhou, L | 1 |
| Breen, L; Clynes, M; Keenan, J; Murphy, L | 1 |
| Baghi, M; Gstoettner, W; Hambek, M; Knecht, R; Moertel, S; Strebhardt, K; Wagenblast, J | 1 |
| Bernier, J; Vrieling, C | 1 |
| Onizawa, K; Otsuka, Y; Yamagata, K; Yoshida, H | 1 |
| Ensley, JF; Kim, H; Kucuk, O; Lin, HS; Lonardo, F; Piechocki, MP; Stevens, T; Subramanian, G; Tulunay, OE; Won, J; Yoo, GH | 1 |
| Ishizaka, A; Matsuzaki, T; Morishita, T; Naitou, A; Ogawa, R; Terashima, T | 1 |
| Enomoto, T; Fukutsuji, K; Ikeda, H; Kitano, H; Morizane, R; Nakahara, K; Nosaka, A; Sakoda, T; Shibano, A; Yamanishi, M | 1 |
| Asamura, H; Ichinose, Y; Kato, H; Koike, T; Kunitoh, H; Mitsudomi, T; Nagai, K; Nakagawa, K; Okada, M; Saijo, N; Shibata, T; Tada, H; Tsuboi, M | 1 |
| Castro, J; Friesland, S; Ghaderi, M; Laytragoon-Lewin, N; Lewin, F; Lundgren, J; Turesson, I; Ustun, H | 1 |
| Bu, Q; Cai, QQ; Guan, ZZ; Hu, XH; Huang, HQ; Li, YH; Lin, XB; Pan, ZH; Shuang, YR; Wang, AL | 1 |
| Bradshaw-Pierce, EL; Gustafson, DL; Raben, D; Steinhauer, CA | 1 |
| Han, JX; Huang, HN; Pan, JH; Sheng, LJ; Wu, JM; Yu, QZ | 1 |
| Belani, CP; Butler, EH; Guidice, RA; Marsland, TA; Ramalingam, SS; Schreeder, MT; Steis, RG | 1 |
| Bolger, M; Dunphy, F; Edelman, MJ; Green, MR; Gu, L; Hoffman, P; Khatri, J; Miller, AA; Vokes, EE; Wang, XF | 1 |
| Fujita, Y; Hiramatsu, M; Kawai, M; Nishimura, H; Sumiyoshi, K; Tanigawa, N | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Sumitsawan, Y; Tharavichitkul, E | 1 |
| Fujii, Y; Harata, K; Ishiguro, H; Katada, T; Kimura, M; Kuwabara, Y; Mitsui, A; Mori, R; Mori, Y; Ogawa, R; Tomoda, K | 1 |
| Adkins, DR; Blajman, CR; Cohen, RB; Cullen, KJ; Frenette, GP; Freue, JM; Gorbunova, VA; Haddad, RI; Mickiewicz, EA; Norris, CM; Plinar, LF; Posner, MR; Raez, LE; Roessner, MR; Shin, DM; Steinbrenner, LM; Tishler, RB; Tjulandin, SA; Winquist, EW; Wirth, LJ | 1 |
| Ball, D; Campeau, MP; Drummond, E; Herschtal, A; Hogg, A; Mac Manus, M; Michael, M; Wheeler, G; Wirth, A | 1 |
| Alvarez, EA; Crisp, MP; Lambrou, NC; Lucci, JA; Mendez, LE; Pearson, JM; Wolfson, AH | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Kuzur, M; Lunin, S; Markus, TM; Shipley, D; Spigel, DR | 1 |
| Chang, JW; Chen, CH; Lin, CM; Tsao, TC | 1 |
| Alfonsi, M; Calais, G; Chapet, S; Faivre, S; Garaud, P; Guerrif, S; Pointreau, Y; Sire, C; Tortochaux, J; Tuchais, C | 1 |
| Athanassiou, E; Bamias, A; Bobos, M; Fountzilas, G; Kalogera-Fountzila, A; Kalogeras, KT; Karayannopoulou, G; Kosmidis, P; Misailidou, D; Papakostas, P; Tolis, C; Tsekeris, P; Vamvouka, C; Zamboglou, N; Zaramboukas, T | 1 |
| Shinden, S; Shiotani, A; Watabe, T; Yamashita, T | 1 |
| Bilici, A; Eren, M; Gumus, M; Karabulut, SG; Kocak, M; Mayadagli, A; Oruc, F; Oven Ustaalioglu, BB; Ozkan, A; Parlak, C; Seker, M | 1 |
| Cho, BC; Choi, EC; Choi, HJ; Keum, KC; Kim, JH; Kim, SH; Lee, YJ; Shin, SJ | 1 |
| Choy, H; Dobbs, T; Dowlati, A; Hughes, RS; Jain, AK; Muldowney, NJ; Sandler, AB; Schlabach, L; Schwartzberg, LS; Wu, J | 1 |
| Fujii, M; Fukada, J; Kawaguchi, O; Kubo, A; Kunieda, E; Ohashi, T; Shigematsu, N; Shiotani, A; Takeda, A; Tomita, T | 1 |
| Choudhury, A; Clark, JI; Eisner, RM; Emami, B; Hofmeister, C; Lathers, D; Lau, A; Norton, J; Petruzzelli, G; Thomas, S; Young, MR | 1 |
| Boehm, A; Dietz, A; Dollner, R; Horn, IS; Mozet, C; Tschop, K; Wichmann, G | 2 |
| Burtness, B; Egleston, B; Forastiere, AA; Gibson, M; Lacy, J; Mehra, R; Murren, JR; Quintanilla, M; Sipples, R; Thomas, L; Watkins, S | 1 |
| Hah, JH; Heo, DS; Jeon, YK; Kim, CW; Kim, DW; Kim, KH; Kim, TM; Koh, Y; Kwon, TK; Lee, SH; Rhee, CS; Sung, MW; Wu, HG | 1 |
| Cao, Z; Jin, J; Li, X; Liu, J; Lu, W; Tucker, SJ; Wang, D; Wang, F; Xu, X; Yan, G; Zhong, B | 1 |
| Adelstein, DJ; Giri, PG; Hanna, E; Mills, GM; Moon, J; Urba, SG; Wolf, GT | 1 |
| Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Sasajima, K; Suzuki, S; Tajiri, T; Yanagi, K; Yokoyama, T | 1 |
| Furuta, I; Kurashina, K; Kurita, H; Miyata, M; Nozaki, S; Wada, S; Yamamoto, E | 1 |
| Agatsuma, T; Fujimoto, K; Hanaoka, M; Koizumi, T; Kubo, K; Urushihata, K; Yamamoto, H; Yasuo, M | 1 |
| Corry, P; Moros, EG; Peñagarícano, JA; Ratanatharathorn, V; Yan, Y | 1 |
| Argiris, A; Axelrod, R; Brockstein, B; Buchanan, A; Forastiere, A; Ghebremichael, M; Hahn, K; Kolesar, J; Pins, M | 1 |
| Caponigro, F; Ionna, F; Longo, F; Perri, F | 1 |
| Fossella, FV; Glisson, BS; Herbst, RS; Khuri, FR; Kim, ES; Lee, JJ; Lippman, SM; William, WN; Zinner, RG | 1 |
| Hanai, N; Hasegawa, Y; Hirakawa, H; Ozawa, T; Terada, A; Yokoi, H | 1 |
| Andreozzi, B; Annino, D; Balboni, TA; Costello, R; Goguen, L; Haddad, RI; Lorch, J; Norris, C; Posner, MR; Tishler, RB; Wirth, L | 1 |
| Fukuda, S; Hatakeyama, S; Kano, S; Maeda, H; Miyajima, N; Okumura, F; Tsukiyama, T | 1 |
| Beltran, P; Brammer, C; Jansen, JP; Parthan, A; Posner, MR | 1 |
| He, ZY; Hu, YH; Li, QQ; Lin, HX; Liu, H; Liu, MZ | 1 |
| Ehara, S; Nakamura, R; Nakasato, T; Nishimura, K; Oikawa, H; Sato, H | 1 |
| Buiret, G; Céruse, P; Combe, C; Ecochard, R; Favrel, V; Fayette, J; Martin, L; Pommier, P; Ramade, A; Tartas, S | 1 |
| Ando, M; Katsumata, N; Mukai, H; Watanabe, T | 1 |
| Aulino, J; Baumann, J; Burkey, B; Chung, CH; Cmelak, AJ; Gilbert, J; Hatakeyama, H; Muldowney, NJ; Murphy, BA; Netterville, J; Parker, J; Shyr, Y; Sinard, R; Slebos, RJ; Yarbrough, WG | 1 |
| Ju, JH; Kang, JH; Kang, MH; Kim, HG; Kim, JP; Lee, GW; Park, JJ | 1 |
| Beckett, LA; Burich, RA; Davies, AM; Gandara, DR; Holland, WS; Lara, PN; Li, Y; Mack, PC; Sangha, R; Solis, LJ | 1 |
| Dalphin, JC; Depierre, A; Elleuch, R; Gainet, M; Girard, N; Jacoulet, P; Pernet, D; Westeel, V | 1 |
| Arimura, Y; Hokari, K; Hosokawa, M; Kodaira, J; Okahara, S; Shinomura, Y; Takahashi, H; Tanuma, T; Tsukagoshi, H; Yamashita, K | 1 |
| Cullen, KJ; Goloubeva, O; Haddad, RI; Nikitakis, N; Posner, MR; Sarlis, NJ; Schumaker, L; Tan, M | 1 |
| Budach, V; Keilholz, U; Klinghammer, K; Knödler, M; Schmittel, A; Tinhofer, I | 1 |
| Ardizzoia, A; Bonetti, A; Buffoli, A; Campostrini, F; Cavallo, R; Dondi, D; Gardani, G; Gava, A; Ghi, MG; Guaraldi, M; Koussis, H; Loreggian, L; Mione, CA; Paccagnella, A; Tomio, L | 1 |
| Chen, LM; Dai, CL; Fu, LW; Liang, YJ; Su, XD; Tao, LY; Wang, FP; Yan, YY; Zhang, X | 1 |
| Altintas, S; Dyck, J; Huizing, MT; Schrijvers, D; Specenier, PM; Van Den Brande, J; Van Den Weyngaert, D; Van Laer, C; Vermorken, JB | 1 |
| Bae, WK; Cho, SB; Cho, SH; Chung, IJ; Hwang, JE; Joo, YE; Lee, WS; Na, KJ; Shim, HJ; Song, SY | 1 |
| Arnoldner, C; Bisdas, S; Gstöttner, W; Hambek, M; May, A; Mörtel, S; Wagenblast, J | 1 |
| Asaka, S; Ide, H; Isohata, N; Katsube, T; Konno, S; Murayama, M; Naritaka, Y; Ogawa, K; Shimakawa, T; Yamaguchi, K | 1 |
| Kaiho, T; Miyazaki, M; Nishimura, M; Nobumoto, D; Nomura, S; Okamoto, R; Shinmura, K; Togawa, A; Tsuchiya, S; Yanagisawa, S | 1 |
| Guo, JF; Nie, XY; Peng, J; Wang, B; Wu, F; Xing, H; Zhang, B; Zhu, GY | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Cooper, J; Eaby, B; Evans, T; Kaiser, L; Kucharczuk, J; Langer, C; Rengan, R; Shrager, J; Stevenson, J; Weiss, J | 1 |
| Bauerfeind, P; Bertschinger, P; Binek, J; Brauchli, P; Frossard, JL; Jost, C; Knuchel, J; Metzger, U; Meyenberger, C; Ruhstaller, T; Schuller, JC; Werth, B | 1 |
| Burris, HA; Clark, BL; Farley, C; Gray, JR; Greco, FA; Hainsworth, JD; Lane, CM; Meluch, AA; Spigel, DR | 1 |
| Feigenberg, S; Huang, CH; Jotte, RM; Langer, CJ; Monberg, MJ; Movsas, B; Obasaju, CK; Ross, HJ; Wang, L; Xu, F | 1 |
| Bastos, BR; Gomez, J; Hatoum, GF; Lopes, G; Raez, LE; Santos, ES; Takita, C; Tolba, K; Walker, GR | 1 |
| Ellerton, JA; Gettinger, SN; Hicks, W; Murren, JR; Otterson, GA; Pan, X; Villalona-Calero, MA | 1 |
| Adachi, M; Furuse, S; Ijichi, K; Mitsudo, K; Miura, S; Nakazawa, M; Ohta, S; Tohnai, I; Torigoe, S | 1 |
| Bamberg, M; Belka, C; Berger, B; Budach, W; Hehr, T; Weinmann, M | 1 |
| Bruzzone, A; Dellepiane, M; Figliomeni, M; Ghio, R; Grillo-Ruggieri, F; Grimaldi, A; Mencoboni, M; Moratti, G; Rebella, L; Salami, A; Scasso, F; Spigno, F | 1 |
| Agrawal, A; Aimiumu, J; Chan, KK; Chen, P; Cheng, H; Dancey, J; Grever, MR; Kraut, EH; Lang, J; Rhoades, C; Young, DC; Zhang, Y | 1 |
| Piérard, GE; Quatresooz, P | 1 |
| Ensley, JF; Folbe, AJ; Kafri, Z; Kim, H; Lin, HS; Lonardo, F; Stevens, T; Won, J; Yoo, GH | 1 |
| Egashira, H; Fujiwara, J; Honda, M; Izumi, Y; Kato, T; Miura, A; Monma, K; Nemoto, T; Ryotokuji, T | 1 |
| Chitapanarux, I; Lorvidhaya, V; Mayurasakorn, S; Pattarasakulchai, T; Sittitrai, P; Srivanitchapoom, C; Tananuwat, R; Tharavichitkul, E | 1 |
| Fujimoto, Y; Furue, H; Fuwa, N; Itoh, Y; Mitsudo, K; Nishiguchi, H; Shigetomi, T; Tohnai, I; Ueda, M; Yamamoto, N | 1 |
| Aoe, K; Hayashi, H; Hotta, K; Kawai, H; Kiura, K; Maeda, T; Matsuo, K; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yoshioka, H | 1 |
| Ansari, RH; Choong, NW; Ferguson, MK; Fishkin, PA; Haraf, DC; Hoffman, PC; Kesler, KA; Kocherginsky, M; Krauss, SA; Mauer, AM; Posner, MC; Sandler, AB; Sciortino, DF; Szeto, L; Vokes, EE; Wade, J | 1 |
| Bernier, J; Betka, J; Bottomley, A; Coens, C; Degardin, M; Jelic, S; Mauer, ME; Mesia, R; Preiss, JH; Remenar, E; Stewart, JS; van den Weyngaert, D; van Herpen, CM; Vermorken, JB | 1 |
| Anders, C; Bran, G; Faber, A; Hörmann, K; Sadick, H; Sauter, A; Schultz, JD | 1 |
| Osada, S; Sanada, Y; Takahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K | 1 |
| Dyck, J; Huizing, MT; Rasschaert, M; Schrijvers, D; Specenier, P; Van den Brande, J; Vermorken, JB; Vroman, P | 1 |
| Vokes, EE | 1 |
| Budach, V | 1 |
| D'Amanzo, P; Ghi, MG; Mastromauro, C; Paccagnella, A | 1 |
| Calais, G | 2 |
| Kakehata, S; Kimura, H; Kobayashi, W; Nagahata, M; Sakaki, H; Sato, H; Teh, BG | 1 |
| de Vries, A; Gastl, G; Lukas, P; Mühlmann, G; Öfner, D; Pluschnig, U; Spizzo, G; Steger, G; Widder, J; Zabernigg, A; Zacherl, J | 1 |
| Belani, CP; Brodowicz, T; Fossella, F; Manegold, C; Scagliotti, G; Shepherd, FA; Simms, L; Sugarman, K; Vansteenkiste, J; Zielinski, C | 1 |
| Alieva, SB; Romanov, IS; Tiuliandin, SA; Tkachev, SI; Zaderenko, IA | 1 |
| Berard, H; Bota, S; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Paillotin, D; Robinet, G; Thomas, P; Vergnenegre, A | 1 |
| Gu, XW; Pan, YK; Xu, X; Zhang, TR; Zhao, T | 1 |
| Barlesi, F; Berard, H; Chavaillon, JM; Chouabe, S; Descourt, R; Falchero, L; Fournel, P; Geriniere, L; Hureaux, J; Le Caer, H; Lena, H; Monnet, I; Robinet, G; Vergnenegre, A | 1 |
| Allen, A; Hsueh, CT; Huang, CH; Kelly, K; Mayo, M; Smith, H; Tawfik, O; Uypeckcuat, AM; Van Veldhuizen, PJ; Wick, J; Williamson, SK | 1 |
| Brauchli, P; Dietrich, D; Gautschi, O; Hess, V; Inauen, R; Kranzbuehler, H; Mingrone, W; Montemurro, M; Moosmann, P; Pless, M; Rauch, D; Ruhstaller, T; Schneider, PM; von Moos, R; Widmer, L | 1 |
| Chang, SY; Chang, YC; Chu, PY; Hsieh, SL; Li, WY; Tai, SK; Tsai, TL; Wang, YF; Yang, MH | 1 |
| Fujiwara, H; Furutani, A; Ichikawa, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Okamura, H; Okamura, S; Otsuji, E; Shiozaki, A; Sonoyama, T; Todo, M; Umehara, S; Yoneda, M | 1 |
| Kanemura, T; Kobayashi, M; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Ono, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Uchiyama, C; Yanai, A; Yoshioka, Y | 1 |
| Cullen, K; Fasciano, J; Goloubeva, O; Haddad, RI; Lorch, JH; Posner, MR; Sammartino, DE; Sarlis, N; Tan, M; Tishler, R | 1 |
| Fietkau, R; Iro, H; Klautke, G; Kuwert, T; Lell, M; Linke, R; Semrau, S; Uder, M; Waldfahrer, F | 1 |
| Holmlund, JT; Karaseva, NA; Leopold, L; Luft, AV; Orlov, SV; Popovych, O; Ready, N; Wood, BA | 1 |
| Chilimoniuk, M; Maksimowicz, T; Olszewska, E | 1 |
| Devlin, PM; Haddad, RI; Holupka, EJ; Posner, MR; Sarlis, NJ; Sher, DJ; Tishler, RB | 1 |
| Goto, K; Kubota, K; Naito, Y; Niho, S; Ohe, Y; Ohmatsu, H; Yoh, K | 1 |
| Aoki, T; Hoshino, S; Ogata, T; Osaka, Y; Shinohara, M; Takagi, Y; Tsuchida, A | 1 |
| Belzer, K; Burger, AM; Chen, W; Gadgeel, SM; Hackstock, D; Konski, A; Marquette, L; Patel, BB; Ruckdeschel, JC; Turrisi, A; Valdivieso, M; Wozniak, A | 1 |
| Arango, BA; Burgos-Tiburcio, A; Raez, LE; Santos, ES | 1 |
| Chang, PM; Chang, SY; Chang, YF; Chen, MH; Hwang, WS; Su, WC; Tsao, CJ; Tzeng, CH; Yang, MH | 1 |
| Devisetty, K; Mell, LK; Wong, SJ | 1 |
| Atean, I; Calais, G; Pointreau, Y | 1 |
| Ando, M; Fujiwara, Y; Hirata, T; Katsumata, N; Ono, M; Shimizu, C; Tamura, K; Yamamoto, H; Yonemori, K | 1 |
| Dai, Y; Fan, CY; Neis, JP; Spring, PM; Vural, E; Xie, CH | 1 |
| Fujisawa, K; Iwamoto, S; Miyamoto, Y; Nagai, H; Ohe, G; Takamaru, N; Tamatani, T; Uchida, D | 1 |
| Altun, M; Aslan, I; Basaran, M; Bavbek, SE; Ekenel, M; Keskin, S; Meral, R; Ozdemir, C | 1 |
| Cui, N; Hao, Y; Hu, Y; Liu, H; Liu, M; Lu, L; Mo, Y; Rong, T; Zhu, Q | 1 |
| Coyle, C; Dyker, K; Öksüz, DÇ; Prestwich, RJ; Şen, M | 1 |
| Huang, XE; Jin, GF; Li, Y; Shen, HB; Xu, L | 1 |
| Catanzaro, M; Colecchia, M; Necchi, A; Nicolai, N; Piva, L; Salvioni, R; Torelli, T | 1 |
| Budach, V; Gauler, T; Keilholz, U; Klinghammer, K; Knödler, M; Stenzinger, A; Tinhofer, I; Weichert, W | 1 |
| Li, X; Lv, M; Ren, S; Wu, F; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Hashimoto, S; Hirai, Y; Kawago, M; Naito, K; Nakamura, R; Nishiguchi, H; Ohta, F; Okamura, Y; Oura, S; Yoshimasu, T | 1 |
| Brugarolas, A; Pérez, T; Pérez-Ruixo, JJ; Rebollo, J; Valenzuela, B | 1 |
| Berrocal, A; Blasco, A; Blasco, S; Bremnes, RM; Caballero, C; Camps, C; Del Pozo, N; Iranzo, V; Jantus-Lewintre, E; Rosell, R; Sirera, R; Tarón, M | 1 |
| Fan, X; Guo, B; Guo, W; Jiang, Y; Li, K; Liang, S; Qin, S; Wang, L; Wang, R; Zhao, Y | 1 |
| Chen, SZ; Chen, XM; Ding, Y; Mo, KL; Wang, XC; Zhang, F | 1 |
| Lin, XD; Shi, XY; Zhang, WJ; Zhou, TC | 1 |
| Aizawa, T; Fujiwara, S; Harada, K; Kubo, N; Noguchi, T | 1 |
| Doki, Y; Miyata, H; Mori, M; Motoori, M; Peng, YF; Shiozaki, H; Shiraishi, O; Tanaka, K; Yamasaki, M; Yano, M; Yasuda, T | 1 |
| Bolotina, LV; Kornietskaia, AL | 1 |
| Bernier, J | 1 |
| Benlloch, S; Chen, H; Costa, C; Ding, Y; Gimenez-Capitan, A; Liu, B; Meng, F; Moran, T; Qian, X; Rosell, R; Sanchez, JJ; Taron, M; Wei, J; Yu, L; Zou, Z | 1 |
| Benezery, K; Dassonville, O; Hebert, C; Peyrade, F; Saâda, E | 1 |
| Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Blumenschein, GR; Charnsangavej, C; Fossella, FV; Fujimoto, J; Hong, WK; Kies, MS; Lee, JJ; Liu, S; Marom, EM; Papadimitrakopoulou, V; Stewart, DJ; Tran, HT; Tsao, AS; Wistuba, II | 1 |
| Bal, A; Singh, N | 1 |
| Bergmann, ZP; Debus, J; Freier, K; Jensen, AD; Krauss, J; Münter, MW; Weichert, W | 1 |
| Bando, Y; Furukita, Y; Kajiura, K; Minato, T; Seike, J; Takechi, H; Tangoku, A; Yamai, H; Yamamoto, Y; Yoshida, T | 1 |
| Chan, CH; Chen, CC; Chen, PT; Chen, WC; Huang, CE; Kuan, FC; Lee, KD; Lu, CH; Wang, WH; Wu, JY | 1 |
| Correa, PD; Grose, D; Paterson, C; Rizwanullah, M; Robertson, AG | 1 |
| Bessho, A; Hotta, K; Kamei, H; Kanazawa, S; Katsui, K; Kiura, K; Kozuki, T; Tada, A; Takigawa, N; Tanimoto, M; Tokuda, Y | 1 |
| Cai, JF; Chen, B; Lu, HY; Ma, SL; Su, D; Sun, WY; Wang, Z; Zhang, YP; Zheng, YQ | 1 |
| Gorlia, T; Liberato, NL; Licitra, L; Marchetti, M; Quaglini, S; Rognoni, C; Rubrichi, S; Vermorken, JB | 1 |
| Stravodimou, A; Voutsadakis, IA | 1 |
| Dong, Z; Imai, A; Krishnamurthy, S; Light, E; Nör, JE; Visioli, F; Wang, S; Worden, F; Zeitlin, BD; Zhang, Z | 1 |
| Demidov, LV; Kanagavel, D; Orlova, KV; Petenko, NN; Samoĭlenko, IV; Subramanian, S | 1 |
| Osada, S; Takahashi, T; Tanaka, Y; Yamaguchi, K; Yoshida, K | 1 |
| Inoue, Y; Komaki, C; Niwa, T; Tatsuoka, H | 1 |
| Akanuma, N; Akutsu, Y; Hoshino, I; Isozaki, Y; Kono, T; Matsubara, H; Miyazawa, Y; Shiratori, T; Shuto, K; Uesato, M | 1 |
| Annino, DJ; Balboni, TA; Goguen, LA; Haddad, RI; Lorch, J; Norris, CM; Posner, MR; Sher, DJ; Thotakura, V; Tishler, RB | 1 |
| Fujita, S; Hata, A; Imai, Y; Kaji, R; Katakami, N; Kida, Y; Tanaka, K | 1 |
| Baudin, F; Bedock, B; Blanc, PL; Guillot, P | 1 |
| Chen, H; Zhang, T; Zhao, T | 1 |
| Buonerba, C; D'Aniello, C; Damiano, V; De Placido, S; Di Lorenzo, G; Di Trolio, R; Federico, P; Mainolfi, C; Matano, E; Palmieri, G; Raimondo, L; Rescigno, P | 1 |
| Hayakawa, T; Hirakata, A; Hosone, M; Katayama, H; Maruyama, H; Matsushita, A; Matsutani, T; Sasajima, K; Takao, Y; Uchida, E; Umakoshi, M; Yokoyama, T; Yoshida, H | 1 |
| Du, W; Huang, M; Ke, QH; Lei, Y; Luo, F; Yang, JY; Zhou, SQ | 1 |
| Hirota, M; Iida, M; Itoh, Y; Iwai, T; Kioi, M; Koizumi, T; Mitsudo, K; Oguri, S; Tohnai, I; Yamamoto, N | 1 |
| Abbruzzese, A; Caraglia, M; Giordano, A; Giuberti, G; Grimaldi, A; Lombardi, A; Misso, G; Ricciardiello, F; Tagliaferri, P | 1 |
| Cai, L; Guo, K; Hao, CL; Li, Z; Lin, P; Rong, TH; Wang, WP; Zhang, LJ; Zhang, Y; Zhu, JF | 1 |
| Fukuoka, M; Katakami, N; Kudoh, S; Kurata, T; Matsui, K; Mitsudomi, T; Nishimura, Y; Saka, H; Senba, H; Tada, H | 1 |
| Fujiwara, H; Ichikawa, D; Iitaka, D; Ikoma, H; Kokuba, Y; Komatsu, S; Kuriu, Y; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A; Sonoyama, T | 1 |
| Alexis, M; Awonuga, AO; Belotte, J; Bolinjkar, R; Deppe, G; Tabassum, F | 1 |
| Bando, Y; Furukita, Y; Goto, M; Minato, T; Seike, J; Takechi, H; Tangoku, A; Yamai, H; Yamamoto, Y; Yoshida, T; Yuasa, Y | 1 |
| Asano, A; Hirasawa, N; Horikawa, Y; Ishihara, S; Itoh, Y; Koyama, K; Murao, T; Naganawa, S; Nomoto, Y; Obata, Y; Sasaoka, M; Suzuki, K | 1 |
| Coyle, C; Dyker, KE; Karakaya, E; Oksuz, DC; Prestwich, RJ; Sen, M; Yetmen, O | 1 |
| Abgral, R; Gouders, D; Keromnes, N; Le Roux, PY; Leleu, C; Mollon, D; Nowak, E; Querellou, S; Rousset, J; Salaün, PY; Valette, G | 1 |
| Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Urakci, Z | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, DE; Na, KJ; Nam, TK; Shim, HJ | 1 |
| Akahane, A; Ehara, S; Izumisawa, M; Kikuchi, K; Kogi, S; Mizuki, H; Nakasato, T; Shoji, S; Sugiyama, Y | 1 |
| Baba, H; Baba, Y; Ishimoto, T; Iwatsuki, M; Kinoshita, K; Kurashige, J; Mimori, K; Nagai, Y; Saito, S; Watanabe, M | 1 |
| Anderhuber, W; Bachtiary, B; Berghold, A; Burian, M; De Vries, A; Elsäßer, W; Greil, R; Kainz, H; Kapp, KS; Kasparek, AK; Keil, F; Kopp, M; Kornek, G; Reinisch, S; Riedl, R; Selzer, E; Tinchon, C | 1 |
| Agarwal, A; Cooley, TP; Logeswaran, P; Mehta, A; Subramaniam, RM | 1 |
| Furuya, T; Hirowatari, H; Ito, K; Ito, S; Izawa, H; Karasawa, K; Matsumoto, F; Oba, S; Sasai, K | 1 |
| Asakawa, T; Furusaka, T; Ikeda, M; Matsuda, H; Tanaka, A | 1 |
| Date, S; Hirayama, K; Mukaisho, K; Nagashima, T; Niiro, M; Okihara, K | 1 |
| Ding, X; Fan, M; Huang, W; Li, B; Sun, H; Yi, Y; Zhang, J; Zhou, T | 1 |
| Dietz, A; Guntinas-Lichius, O; Kuhnt, T; Maschmeyer, G; Oertel, K; Schmalenberg, H; Spiegel, K; Sudhoff, H; Wendt, TG | 1 |
| Larizadeh, MH; Shabani, M | 1 |
| Furusaka, T; Ikeda, M; Katsura, Y; Matsuda, A; Saito, T | 1 |
| Cai, YL; Fan, XD; Guo, W; He, Y; Hu, YJ; Ji, T; Kies, MS; Lee, JJ; Li, J; Myers, JN; Ren, GX; Sun, J; Tu, WY; Wang, BS; Wang, LZ; Wang, YA; Wang, ZH; William, WN; Xu, LQ; Yang, WJ; Ye, WM; Zhang, CP; Zhang, ZY; Zhong, LP; Zhu, HG | 1 |
| Baek, SK; Jung, KY; Kim, CY; Kim, DS; Kim, IS; Kim, JS; Kim, YH; Kwon, SY; Lee, NJ; Park, KH; Park, Y; Shin, SW | 1 |
| Furusaka, T; Ikeda, M; Matsuda, A; Matsuda, H; Tanaka, A | 2 |
| Bi, LW; Zhang, LZ; Zhao, HF | 1 |
| Casella, F; de Manzoni, G; Giacopuzzi, S; Pasini, F; Verlato, G; Weindelmayer, J; Zanoni, A; Zhao, E | 1 |
| Chen, MY; Chen, Z; Luo, JC; Wei, L; Wu, S | 1 |
| Chen, JH; Chen, KY; Ho, CC; Liao, WY; Shih, JY; Wu, M; Yang, JC; Yu, CJ | 1 |
| Fujita, T; Hori, S; Indo, S; Maeba, T; Mori, S; Takeuchi, H | 1 |
| Chen, X; Gao, Y; Hu, Z; Jiang, S; Liu, B; Liu, Y; Wu, Q; Zhang, X; Zhu, J | 1 |
| Ding, JX; Han, JH; Ji, FZ; Ji, YL; Li, T; Pu, J; Qin, SS; Sun, JX; Tao, GZ; Yu, CH; Zhang, Y; Zhou, XL; Zhu, WG | 1 |
| Corry, J; Kleid, S; Peters, L; Rischin, D | 1 |
| Durdux, C; Huguet, F; Lang, P; Monnier, L; St Guily, JL; Touboul, E | 1 |
| Bubis, JA; Dragnev, KH; Gordon, SR; Gui, J; Lisovsky, M; Rigas, JR; Sutton, JE; Wood, MD; Zaki, BI | 1 |
| Hong, WK | 1 |
| Baur, M; DeSantis, M; Dittrich, C; Gerber, E; Hudec, M; Kienzer, HR; Pont, J; Schratter-Sehn, AU; Schweiger, J; Wicke, W | 1 |
| Ikeda, H; Koshiba, R; Ohsawa, H; Tanaka, A | 1 |
| Abad, A; Barnadas, A; Font, A; Guillot, M; Manzano, JL; Margeli, M; Martinez, E; Rosell, R; Sanchez, JM; Taron, M | 1 |
| Bourhis, J; Faivre, S; Monnerat, C; Raymond, E; Temam, S | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Matsuo, K; Tsuda, H; Watanabe, T | 1 |
| Busse, PM; Case, M; Colevas, AD; Costello, R; Frankenthaler, R; Karp, D; Lake-Willcutt, B; Lamb, CC; Nixon, A; Norris, CM; Posner, MR; Tishler, RB | 1 |
| Burian, M; Cartellieri, M; Fiebiger, W; Formanek, M; Gedlicka, C; Kornek, GV; Kornfehl, J; Marks, B; Selzer, E | 1 |
| Kawabori, S; Taniguchi, M; Watanabe, A | 2 |
| Ensley, JF; Kewson, D; Lonardo, F; Meng, H; Nguyen, T; Oliver, J; Piechocki, MP; Shibuya, TY; Tainsky, MA; Yoo, GH | 1 |
| Goto, H; Miki, T; Ogawa, H; Shiraga, M; Sone, S; Yamamoto, A; Yano, S; Zhang, H | 1 |
| Busse, P; Case, MA; Colevas, AD; Costello, R; Goguen, L; Haddad, R; Lake-Willcutt, B; Norris, CM; Posner, M; Sullivan, C; Tishler, R | 1 |
| Lefebvre, JL; Posner, MR | 1 |
| Odagiri, K; Okami, K; Onuki, J; Sakai, A; Takahashi, M | 1 |
| Chen, MC; Chen, YM; Lee, CS; Lin, WC; Perng, RP; Shih, JF; Tsai, CM | 1 |
| Busse, P; Case, MA; Costello, R; Goguen, LA; Haddad, R; Mahadevan, A; Norris, CM; Posner, MR; Sullivan, CA; Tishler, RB; Wirth, L | 1 |
| Araki, T; Ishihara, H; Komiyama, T; Kuriyama, K; Nishikawa, K; Onishi, H; Tanaka, S; Yamaguchi, M | 1 |
| Airoldi, M; Bumma, C; Cortesina, G; Gabriele, P; Giordano, C; Pedani, F | 1 |
| Kanamori, S; Masunaga, S; Nakamatsu, K; Nishimura, Y; Suzuki, M | 1 |
| Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V | 1 |
| Airoldi, M; Beatrice, F; Bumma, C; Cattel, L; Marchionatti, S; Maria Gabriele, A; Pedani, F; Recalenda, V; Succo, G; Tagini, V | 1 |
| Bernhard, H; Bredenkamp, R; Hennig, M; Lordick, F; Peschel, C; von Schilling, C | 1 |
| Miyahara, H; Naito, K; Yane, K | 1 |
| Bologna, F; Boughen, JM; Cubero, A; Focaccia, G; Lacava, JA; Leone, BA; Machiavelli, MR; Ortiz, EH; Pérez, JE; Romero, AO; Scenna, M; Suttora, G; Vallejo, CT; Vicente, H | 1 |
| Gooding, WE; Grandis, JR; Li, M; Lui, VW; Niwa, H; Wentzel, AL | 1 |
| Sasaki, S; Taniguchi, M; Watanabe, A | 1 |
| Alfonsi, M; Auvray, H; Bardet, E; Bourhis, J; Calais, G; Garaud, P; Man, YT; Rhein, B; Sire, C; Tortochaux, J | 1 |
| Senan, S | 1 |
| Hamakawa, H; Hino, S; Nakashiro, KI; Shintani, S; Terakado, N | 1 |
| Chihara, Y; Fujishiro, Y; Fukaya, T; Kawanabe, W; Maeda, Y | 1 |
| Taniguchi, M; Watanabe, A | 2 |
| Hashizume, T | 1 |
| Bayouth, J; Culp, LR; Jones, DV; Pou, AM; Sanguineti, G | 1 |
| Fukuchi, Y; Hirama, M; Ohhashi, R; Sato, K; Seyama, K; Suzuki, K; Takagi, Y; Takahashi, K; Uekusa, T | 1 |
| Ahmed, MM; Arnold, SM; Brown, B; Dey, S; Jones, R; Lele, SM; Mohiuddin, M; Shajahan, S; Spring, PM; Valentino, J | 1 |
| Doroshow, JH; Gandara, DR; Gandour-Edwards, R; Gumerlock, PH; Laptalo, L; Lara, PN; Lau, DH; Longmate, J | 1 |
| Blohmer, JU; du Bois, A; Hilpert, F; Pfisterer, J; Quaas, J; Wagner, U; Wallwiener, D | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Cortesina, G; Danova, M; Gabriele, AM; Giordano, C; Pedani, F; Porta, C; Recalenda, V; Tagini, V | 1 |
| Fujii, M; Inuyama, Y; Kida, A; Kohno, N; Kubota, A; Okami, K; Satake, B; Tsukuda, M | 1 |
| Biason, R; Carnuccio, R; D'Amanzo, P; Fasan, S; Fila, G; Gatti, C; Ghi, MG; Mastromauro, C; Medici, M; Mione, CA; Nascimben, O; Oniga, F; Paccagnella, A; Pallini, A; Paro, S; Rossi, F; Turcato, G | 1 |
| Boku, N; Chin, K; Fujita, H; Hamaguchi, T; Hyodo, I; Muro, K; Ohtsu, A; Ohtsu, T; Takiyama, W | 1 |
| Aikoh, K; Horiuchi, C; Ikeda, Y; Katori, H; Mikami, Y; Ono, M; Sakuma, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T | 1 |
| Dempsey, DT; Furukawa, S; Gupta, D; McClurken, JB; Piacentino, V; Ross, K; Stepnowski, D | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Blay, JY; Bleuze, JP; Bompas, E; Chaigneau, L; Cupissol, D; Guardiola, E; Madroszyk, A; Peyrade, F; Pivot, X; Ronchin, P; Schneider, M; Tchiknavorian, X | 1 |
| Komori, T; Shibuya, Y; Tanimoto, H; Umeda, M; Yokoo, S | 1 |
| Ajani, JA; Bresalier, R; Correa, AM; Erasmus, JJ; Komaki, R; Macapinlac, H; Maish, M; Munden, RF; Putnam, JB; Rice, D; Roth, JA; Smythe, WR; Swisher, SG; Vaporciyan, AA; Walsh, GL; Wu, TT | 1 |
| Furuta, I; Kurashina, K; Kurita, H; Nozaki, S; Wada, S; Yamamoto, E | 1 |
| Ensley, JF; Kim, H; Lin, HS; Lonardo, F; Oliver, J; Piechocki, MP; Shehadeh, N; Shibuya, TY; Yoo, GH; Zumstein, L | 1 |
| Bendahmane, B; Bontemps, P; Bourgeois, H; Calais, G; Cupissol, D; Dutin, JP; Genet, D; Mallard-Carre, M; Philippi, MH; Tubiana-Mathieu, N | 1 |
| Achiwa, H; Kato, D; Maeda, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 1 |
| Bitter, K; Böttcher, HD; Kovács, AF; Mose, S | 1 |
| Ishihara, S; Iwasaki, Y; Kaira, K; Minato, K; Mori, M; Saito, R; Sato, K; Takei, Y; Takise, A; Tsuchiya, S | 1 |
| Echigo, S; Rikiishi, H; Sato, T; Shinohara, F; Takahashi, M; Taniguchi, T | 1 |
| Hirose, S; Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Kimura, M; Matsuda, H; Mikami, Y; Sakuma, Y; Sato, N; Taguchi, T; Takahashi, M; Tanigaki, Y; Tsukuda, M; Yamamoto, K; Yoshida, T | 1 |
| Bamberg, M; Belka, C; Budach, W; Classen, J; Hehr, T; Koitschev, A; Schäfer, J; Welz, S | 1 |
| Schrijvers, D; Vermorken, JB | 2 |
| Anderson, L; Anzai, Y; Boyd, C; Buelna, R; Canby, R; Donahue, M; Hutson, J; Keegan, K; Montgomery, RB; Schwartz, DL; Yueh, B | 1 |
| Alper, M; Annakkaya, AN; Aydogan, I; Erbas, M; Kavak, A; Parlak, AH | 1 |
| Boinpally, RR; Ensley, JF; Ezzat, W; Iskander, A; Lin, HS; Oliver, J; Parchment, RE; Piechocki, MP; Polin, L; Shehadeh, N; Shibuya, TY; Subramanian, G; Yoo, GH | 1 |
| Berrocal, A; Cruz, JJ; Fonseca, E; García-Gómez, JM; Grau, JJ; Lara, MA; Navalón, M; Pastor, M; Rueda, A; Sastre, J; Tisaire, JL | 1 |
| Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T | 1 |
| Bredenkamp, R; Duyster, J; Hennig, M; Lersch, C; Lordick, F; Lorenzen, S; Peschel, C; von Delius, S | 1 |
| Argiris, A; Jayaram, P; Pichardo, D | 1 |
| Ando, A; Hasegawa, Y; Hyodo, I; Ogawa, T; Ozawa, T; Suzuki, Y; Terada, A | 1 |
| Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY | 1 |
| Busse, PM; Goguen, L; Guadagnolo, BA; Haddad, RI; Norris, CM; Posner, MR; Sullivan, CA; Tishler, R; Weeks, L; Wirth, LJ | 1 |
| Komatsubara, H; Komori, T; Minamikawa, T; Ojima, Y; Shibuya, Y; Shigeta, T; Umeda, M; Yokoo, S | 1 |
| Lathers, DM; Young, MR | 1 |
| Fukuda, M; Hatakeyama, S; Kashiwagi, R; Miyamoto, Y; Miyoshi, K; Murayama, D; Musashi, T; Nagai, H; Nanjo, H; Ohnuki, T; Yamaoka, K | 1 |
| Aoki, D; Eguchi, F; Fujiwara, K; Jobo, T; Katsumata, N; Kitagawa, R; Kohno, I; Kuramoto, H; Nishimura, R; Noda, K; Nozawa, S; Sohda, Y; Susumu, N; Ueki, K; Ueki, M; Yamaguchi, S | 1 |
| Ebuchi, M; Hasegawa, K; Koide, A; Maruyama, M; Maruyama, S; Miyawaki, Y; Nagahama, T; Ohbu, M; Takashima, I; Tamura, N; Tanami, H | 1 |
| Ensley, JF; Iskander, AJ; Kewson, D; Kim, H; Kim, HR; Lin, HS; Lonardo, F; Oliver, J; Piechocki, MP; Tainsky, MA; Yoo, GH | 1 |
| Amador, ML; Cortes-Funes, H; del Val, O; Hernando, S; Hitt, R; Jimeno, A; Quintela-Fandino, M | 1 |
| Tohnai, I | 1 |
| Fujii, M | 1 |
| Kohno, N | 1 |
| Akimoto, T; Chikamatsu, K; Furuya, N; Hayakawa, K; Ishikawa, H; Kitamoto, Y; Mitsuhashi, N; Nakano, T; Ninomiya, H; Nonaka, T | 1 |
| Bouchet, LG; Bova, FJ; Buatti, JM; Haller, J; Meeks, SL; Pennington, EC; Ryken, TC; Traynelis, V | 1 |
| Annable, T; Greenberger, LM; Hari, M; Loganzo, F; Morilla, DB; Musto, S; Nettles, JH; Snyder, JP; Tan, X | 1 |
| Ando, K; Kamata, T; Kitabayashi, H; Ochiai, T; Shimada, H; Tsujii, H; Yamada, S; Yasuda, S | 1 |
| Fujita, F; Fujita, M; Shakuto, S | 1 |
| Eberlein, K; Kovács, AF; Rohde, S; Smolarz, A; Weidauer, S | 1 |
| Douzinas, EE; Giannakouras, G; Ioannidou, G; Katsilieris, I; Kritselis, G; Liossi, P; Rapidis, AD; Roupakia, A; Stavrinidis, E; Trichas, M | 1 |
| Hashimoto, Y; Hayashidani, Y; Morifuji, M; Murakami, Y; Sudo, A; Sueda, T; Sugiyama, Y; Uemura, K | 1 |
| Goguen, L; Haddad, R; Li, Y; Norris, CM; O'Donnell, L; Posner, M; Sullivan, C; Tishler, R; Wirth, L | 1 |
| Bernardini, I; Chella, A; Falcone, A; Malventi, M; Russo, F; Tibaldi, C; Vasile, E | 1 |
| Kitakata, H; Omote, K; Takahashi, Y; Yamashita, K; Yasumoto, K | 1 |
| Ang, KK; Clayman, GL; Feng, L; Garden, AS; Glisson, BS; Khuri, F; Kies, MS; Lee, JJ; Lewin, J; Morrison, W; Myers, J; Papadimitrakopoulou, V; Tsao, AS; Zinner, R | 1 |
| Furusaka, T | 1 |
| Hiroi, S; Masumoto, K; Nozawa, H; Ono, T; Sato, M; Sato, Y; Tadakuma, T | 1 |
| Bidault, F; Casiraghi, O; De Baere, T; Faivre, S; Janot, F; Kuoch, V; Luboinski, B; Petrow, P; Roche, A; Sigal, R; Temam, S | 1 |
| Chun, JH; Han, JY; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Lee, SY; Yoon, SM | 1 |
| Aoki, T; Hoshino, S; Osaka, Y; Tachibana, S; Takagi, Y; Tsuchida, A | 1 |
| Alcalde García, J; Alés Díaz, I; Benavides Orgaz, M; Bretón García, JJ; Carabantes Ocón, F; Cobo Dols, M; Gil Calle, S; Gutiérrez Calderón, V; Montesa Pino, A; Villar Chamorro, E | 1 |
| Baghi, M; Bisdas, S; Gstoettner, W; Hambek, M; Knecht, R; Mack, MG; Muerthel, R; Vogl, T; Wagenblast, J | 1 |
| Adachi, Y; Bandobashi, K; Ikezoe, T; Kobayashi, M; Koeffler, HP; Nishioka, C; Taguchi, H; Takeuchi, S; Takeuchi, T; Yang, Y | 1 |
| Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Miyazaki, S; Nemoto, K; Ohtsuka, K; Sakata, Y; Sakayori, M; Shibata, H; Shimodaira, H; Yoshioka, T | 1 |
| Furutani, M; Kokubo, M; Nagano, M; Ohnishi, M; Takenobu, T; Tanaka, Y; Taniike, N | 1 |
| An, CH; Cho, EK; Choi, SJ; Hoon Lee, J; Jeong, SH; Kyung, SY; Lee, SP; Park, JW; Park, SH; Shin, DB | 1 |
| Iwabuchi, H; Nakayama, S; Uchiyama, K | 1 |
| Aoyama, N; Minamide, J; Oota, Y; Takada, K | 1 |
| Caterino, M; Cecere, FL; Ceribelli, A; Cognetti, F; Facciolo, F; Gelibter, AJ; Milella, M; Mirri, A; Pino, MS | 1 |
| Ancona, E; Boso, C; Chiarion-Sileni, V; Corti, L; Del Bianco, P; Innocente, R; Mazzarotto, R; Pigozzo, J; Ruol, A; Tomassi, O | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Mori, M; Saito, R; Sunaga, N; Tsuchiya, S; Watanabe, S; Yanagitani, N | 1 |
| Hashimoto, Y; Higashiyama, M; Inazawa, J; Ito, T; Kondo, K; Ortiz, C; Sakai, Y; Shimada, Y; Tanaka, E; Tsunoda, S | 1 |
| Bernini, M; Cordiano, C; de Manzoni, G; Giacopuzzi, S; Grandinetti, A; Minicozzi, AM; Pasini, F; Pedrazzani, C | 1 |
| Abad, A; Arellano, A; Boix, J; Cardenal, J; Casas, D; Fernández-Llamazares, J; Font, A; Manzano, JL; Margelí, M; Rosell, R | 1 |
| Fujii, M; Fujii, R; Ogawa, K; Ozawa, H; Sakamoto, K; Shinden, S; Tomita, T; Yamashita, T | 1 |
| Biete Solà, A; Calvo Manuel, FA; de Las Heras González, M; Grau de Castro, JJ; Marruecos Querol, J; Palacios Eito, A; Ramos Aguerri, A; Rovirosa Casino, A; Solano López, MV; Veiras Candal, C; Verger Fransoy, E | 1 |
| Higashida, M; Hirabayashi, Y; Hirai, T; Kawabe, Y; Matsumoto, H; Murakami, H; Tsunoda, T; Urakami, A; Yamashita, K | 1 |
| Chen, Z; Choe, MS; Klass, CM; Shin, DM; Zhang, X | 1 |
| Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Werner, C | 1 |
| Borel, C; Calais, G; Cupissol, D; Eymard, JC; Germann, N; Kohser, F; Labourey, JL; Tourani, JM; Tubiana-Mathieu, N | 1 |
| Atago, Y; Fukuda, S; Furuta, Y; Higuchi, E; Homma, A; Nagahashi, T; Oridate, N; Suzuki, F | 1 |
| Fumoto, S; Kawahara, K; Noguchi, T; Shibata, T; Takahashi, Y; Takeno, S; Watanabe, S | 1 |
| Johnston, CM; McMeekin, DS; Pearl, ML | 1 |
| Ibaragi, S; Mese, H; Nakayama, S; Sasaki, A; Yoshihama, Y | 1 |
| Hu, WH; Li, JS; Peng, M; Qi, SN; Xie, FY; Zou, GR | 1 |
| Ackermann, H; Baghi, M; Gstöttner, W; Hambek, M; Knecht, R; Strebhardt, K; Wagenblast, J | 1 |
| Boku, N; Ebihara, M; Iida, Y; Onitsuka, T; Onozawa, Y; Zenda, S | 1 |
| Glisson, BS; Karp, DD; Oh, YW; Phan, SC; Stewart, DJ; William, WN; Zinner, RG | 1 |
| Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H | 1 |
| Blessing, JA; Garcia, AA; Roman, LD; Vaccarello, L | 1 |
| Abe, M; Dehari, H; Hiratsuka, H; Kido, Y; Kobayashi, J; Miyazaki, A; Nagai, I; Nakamori, K; Takemura, K; Tomihara, K; Yamamoto, T | 1 |
| Blair, EA; Cohen, EE; Dekker, A; Haraf, DJ; Mauer, A; Seiwert, TY; Stenson, K; Vokes, EE | 1 |
| Albert, D; Bunn, PA; Kelly, K; Magree, L; Rusk, J; Vokes, EE; Weiss, GJ | 1 |
| Cho, GJ; Choi, YJ; Chung, JS; Kim, DW; Lee, BJ; Shin, HJ; Wang, SG | 1 |
| Aguilo, R; Artal, A; Astudillo, J; Barcelo, JR; Cardenal, F; Domine, M; Garrido, P; González-Larriba, JL; Hernando-Trancho, F; Insa, A; Isla, D; Massuti, B; Muguruza, I; Provencio, M; Rosell, R; Sanchez, JM; Sanchez-Ronco, M; Tarrazona, V; Torres, A; Varela, A | 1 |
| Kies, MS | 1 |
| Awada, A; Bernier, J; Betka, J; Cupissol, D; Degardin, M; Desaunois, I; Gorlia, T; Jelic, S; Kienzer, HR; Lefebvre, JL; Mesia, R; Preiss, JH; Remenar, E; Rey, A; Stewart, JS; van den Weyngaert, D; van Herpen, C; Vermorken, JB | 1 |
| Agarwala, S; Blajman, CR; Cmelak, A; Cohen, RB; Colevas, AD; Cullen, K; Dugan, M; Ervin, TJ; Gorbounova, V; Haddad, RI; Harter, KW; Hershock, DM; Markoe, AM; Mickiewicz, E; Murphy, BA; Norris, CM; Posner, MR; Raez, LE; Read, PW; Romanov, I; Roth, B; Shin, DM; Spaulding, M; Steinbrenner, L; Tishler, RB; Tjulandin, S; Venkatesan, V; Viroglio, Rdel C; Winquist, E | 1 |
| Cho, EK; Kim, DY; Kim, ST; Lee, JH; Lee, KC; Lee, SH; Lee, Y; Park, J; Park, SH; Shin, DB | 1 |
| Freilino, ML; Gooding, WE; Grandis, JR; Ogagan, MJ; Strychor, S; Thomas, SM; Walsh, DR; Zamboni, WC | 1 |
| Fukuda, M; Ito, H; Iwanami, Y; Miyamoto, Y; Nagai, H; Nakata, A; Nanjo, H; Takano, H | 1 |
| Alberola, V; Esteban, E; Juan, O; Sotillo, J | 1 |
| Argiris, A; Axelrod, R; Burtness, BA; Forastiere, AA; Manola, J | 1 |
| Kutner, A; Milczarek, M; Wietrzyk, J | 1 |
| Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Jett, J; Kelly, K; Lau, DH; Ung, YC | 1 |
| Goto, Y; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Tamura, T; Yamada, K; Yamamoto, N | 1 |
| Aitini, E; Amoroso, V; Ardizzoia, A; Bajetta, E; Bandera, M; Bidoli, P; Cortinovis, D; Cullurà, D; Fusi, A; Lorusso, V; Radula, D; Zilembo, N | 1 |
| Bisegna, R; Bratta, M; Candeloro, G; Di Staso, M; Necozione, S; Rea, S; Recchia, F; Tombolini, V | 1 |
| Hayakawa, K; Higuchi, K; Ishiyama, H; Katada, C; Koizumi, W; Sasaki, T; Tanabe, S | 1 |
| Glisson, BS; Johnson, FM; Saigal, B | 1 |
| Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Inui, T; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Fukuda, S; Furusawa, J; Furuta, Y; Hatakeyama, H; Higuchi, E; Homma, A; Mizumachi, T; Oridate, N; Suzuki, F; Taki, S | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Papakotoulas, P; Vardakis, N | 1 |
| Clynes, M; Henry, M; Keenan, J; Meleady, P; Murphy, L | 1 |
| Abe, S; Fujii, M; Furuse, K; Inoue, Y; Kurita, Y; Oizumi, K; Onoshi, T; Sato, K; Sugiura, T; Watanabe, K | 1 |
| Braakhuis, BJ; Kegel, A; Welters, MJ | 1 |
| Catimel, G; Clavel, M; Franklin, H; Hanauske, A; Kaye, SB; Le Bail, N; Mattijssen, V; Piccart, M; Verweij, J; Wanders, J | 1 |
| Hirabayashi, K; Kono, I; Noda, K; Ogita, Y; Taguchi, T; Terajima, Y; Yakushiji, M | 1 |
| Busse, PM; Clark, JR; Costello, R; Dreyfuss, AI; Lucarini, JW; Norris, CM; Posner, MR; Poulin, MD; Rossi, RM; Thornhill, L | 1 |
| Cardenal, F; Llort, G; Mesía, R; Montes, A; Seguí, J | 1 |
| Edwards, CL; Ende, K; Fishman, A; Freedman, RS; Kaplan, A; Kavanagh, JJ; Kieback, DG; Kudelka, AP; Levy, T; Mante, R; Steger, M; Verschraegen, CF | 1 |
| Fukuda, S; Inuyama, Y; Satoh, N | 1 |
| Adak, S; Barton, JJ; Busse, PM; Colevas, AD; Costello, R; Dreyfuss, A; Fabian, RL; Fitzgerald, TJ; Fried, M; Norris, CM; Peters, ES; Posner, MR; Poulin, M; Tishler, RB | 1 |
| Colevas, AD; Posner, MR | 1 |
| Androulakis, N; Chalkiadakis, G; Georgoulias, V; Kakolyris, S; Kourousis, C; Maltezakis, G; Metaxaris, G; Samonis, G; Souglakos, J; Vlachonikolis, J | 1 |
| Kokawa, Y; Oura, S; Sakurai, T; Tamaki, T; Umemura, T; Yoshimura, G | 1 |
| Baba, S; Ebihara, S; Horiuchi, M; Ichikawa, G; Inuyama, Y; Kamata, S; Kanzaki, J; Kataura, A; Kida, A; Konno, A; Kono, N; Kubota, A; Matsunaga, T; Matsuura, H; Miyake, H; Moriyama, H; Saijo, S; Saito, H; Sakai, M; Sasaki, Y; Satake, B; Taguchi, T; Takeoda, S; Togawa, K; Tsukuda, M | 1 |
| Catimel, G; Droz, JP; Gras, L; Hanauske, AR; Planting, AS; Schöffski, P; Schrijvers, A; Schrijvers, D; Verweij, J; Wanders, J | 1 |
| Kuroda, M; Mizuno, A; Noguchi, S; Ohishi, A; Sakuma, F; Takagi, T; Terashima, K | 1 |
| Hunter, NR; Mason, KA; Milas, L; Schimming, R | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Armand, JP; Bordessoule, S; Chouaki, N; Couteau, C; De Forni, M; Domenge, C; Groult, V; Janot, F; Lebecq, A; Leyvraz, S; Oulid-Aissa, D | 1 |
| Eckardt, A; Fokas, K; Haindl, J; Hüttmann, C | 1 |
| Colpaert, C; Schrijvers, D; Van den Brande, J; Vermorken, JB | 1 |
| Akimoto, T; Buchmiller, L; Hunter, N; Kishi, K; Komaki, R; Mason, KA; Milas, L | 1 |
| Furukawa, T; Irie, K; Iwanaga, K; Katoh, O; Kuroki, S | 1 |
| De Mulder, PH | 1 |
| Forastiere, AA | 1 |
| Fukunaga, K; Inoue, T; Kameyama, K; Kawada, I; Oyamada, Y; Takeshita, K; Yamaguchi, K; Yamazaki, K | 1 |
| Tsukuda, M | 1 |
| Bessa, EH; Lena, H; Paillotin, D; Pérol, M; Robinet, G; Schuller-Lebeau, MP; Taytard, A; Thomas, P; Vergnenègre, A | 1 |
| Boukis, H; Janinis, J; Lefantzis, D; Panagos, G; Papadakou, M; Poulis, A; Xidakis, E | 1 |
| Brockstein, B | 1 |
| Androulakis, N; Dimopoulos, MA; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kouroussis, C; Samonis, G; Souglakos, J; Voloudaki, A | 1 |
| Adak, S; Amrein, PC; Barton, JJ; Colevas, AD; Costello, R; Posner, MR | 1 |
| Hashimoto, T; Ito, Y; Kawakami, M; Morita, T; Nakao, K; Otsuki, Y; Sasaki, S; Tachibana, S; Tokitsu, H; Tokuhara, T | 1 |
| Colevas, AD; Posner, MR; Tishler, RB | 1 |
| Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM | 1 |
| Hansen, HS; Larsen, SK; Specht, L | 1 |
| Al-Sarraf, M; Colevas, AD; Frenette, G; Garay, CA; Glisson, B; Norris, CM; Olivares, R; Posner, MR; Seroskie, JD; Shin, DM | 1 |
| Chen, YM; Chou, KC; Lee, YC; Perng, RP; Shih, JF; Tsai, CM | 1 |
| Endo, M; Kadou, T; Kotani, Y; Ohbayashi, K; Satouchi, M; Takada, Y | 1 |
| Wang, H | 1 |
| Boghun, O; Hess, CF; Lehmann, J; Lücke, E; Pradier, O; Rave-Fränk, M; Schmidberger, H | 1 |
| Avallone, A; Biglietto, M; Caponigro, F; Comella, G; Comella, P; De Lucia, L; Mantovani, G; Manzione, L; Massa, E; Rosati, G; Sganga, P; Sguotti, C | 1 |
| Posner, MR | 1 |
| Bittner, C; Feyerabend, T; Peters, SO; Raap, M; Remmert, S; Robins, IH; Sieg, P; Sommer, K; Wiedemann, GJ | 1 |
| Akashi-Tanaka, S; Fukutomi, T; Hasegawa, T; Katsumata, N; Miyakawa, K; Takahashi, T; Tsuda, H; Watanabe, T | 1 |
| Airoldi, M; Bumma, C; Cattel, L; Delprino, L; Recalenda, V; Rocco, F; Tagini, V | 1 |
| Fujita, S; Hasegawa, T; Ikeda, A; Kaneshiro, E; Katakami, N; Nishimura, T; Nishio, C; Okazaki, M; Umeda, B | 1 |
| Yokoyama, J | 1 |
| Aihara, T; Akisada, T; Fukuda, K; Gyoten, M; Harada, T; Hiratsuka, J; Imai, S; Imajo, Y; Kajihara, Y; Morita, N; Takemoto, T | 1 |
| Araki, S; Hongo, A; Kawanishi, K; Kodama, J; Kudo, T; Miyagi, Y; Yamamoto, J; Yoshinouchi, M | 1 |
| Merlano, M; Numico, G | 1 |
| Forastiere, AA; Frenette, G; Glisson, BS; Khuri, FR; Murphy, BA | 1 |
| Adak, S; Colevas, AD; Costello, R; Fried, MP; Goguen, LA; Gopal, HV; Lamb, CC; Norris, CM; Posner, MR; Read, R; Tishler, RB | 1 |
| Guillet, G; Karam, A; Labat, JP; Leroy, JP; Metges, JP | 1 |
| Fujita, A; Hoshino, H; Ohkubo, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Kovács, AF; Schiemann, M; Turowski, B | 1 |
41 review(s) available for docetaxel anhydrous and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung; Lung Neoplasms; Platinum | 2022 |
Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cost-Effectiveness Analysis; Docetaxel; Humans; Lung Neoplasms; Nivolumab | 2023 |
Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.
Topics: Afatinib; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Ramucirumab; Retreatment; Taxoids | 2017 |
Effectiveness of chemoradiotherapy for radiation-induced bilateral external auditory canal cancer: A case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; Ear Neoplasms; Ear, External; Fluorouracil; Humans; Male; Maxillary Neoplasms; Neoplasms, Radiation-Induced | 2019 |
Unresectable Recurrent Squamous Cell Carcinoma of the Temporal Bone Treated by Induction Chemotherapy Followed by Concurrent Chemo-Reirradiation: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Re-Irradiation; Skull Neoplasms; Squamous Cell Carcinoma of Head and Neck; Taxoids; Temporal Bone | 2015 |
[A Case of Nasopharyngeal Cancer with Febrile Neutropenia Followed by Death during Adjuvant Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Colitis; Docetaxel; Fatal Outcome; Febrile Neutropenia; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Nasopharyngeal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Staphylococcal Infections; Taxoids | 2015 |
Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Randomized Controlled Trials as Topic; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2016 |
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; ErbB Receptors; Gefitinib; Humans; Immunotherapy; Lapatinib; Molecular Targeted Therapy; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2015 |
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Discovery; Gemcitabine; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2016 |
The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemoradiotherapy; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Immunotherapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2016 |
Docetaxel in the management of patients with head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Taxoids | 2008 |
Docetaxel in the management of head and neck cancer.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Head and Neck Neoplasms; Humans; Taxoids | 2009 |
Induction chemotherapy for head and neck cancer: recent data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Radiation-Sensitizing Agents; Taxoids; Time Factors | 2010 |
TPF sequential therapy: when and for whom?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Taxoids | 2010 |
TPF: a rational choice for larynx preservation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngectomy; Taxoids | 2010 |
Development of targeted therapy for squamous cell carcinomas of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Insulin-Like Growth Factor I; Neoplasm Metastasis; NF-kappa B; Proteasome Inhibitors; Recurrence; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
[Induction chemotherapy for head and neck epidermoid carcinomas].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Feasibility Studies; Fluorouracil; Head and Neck Neoplasms; Humans; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
[Use of docetaxel in treatment of squamous-cell carcinoma of head and neck].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Taxoids; Treatment Outcome | 2011 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
End points for new agents in induction chemotherapy for locally advanced head and neck cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Neoplasm Staging; Paclitaxel; Remission Induction; Taxoids | 2003 |
Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Taxoids | 2003 |
[A case of primary squamous cell carcinoma of the lung with a metastatic thyroid tumor improved following chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Thyroid Neoplasms | 2004 |
[Docetaxel and squamous cell carcinoma of the head and neck].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Remission Induction; Taxoids | 2004 |
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Irinotecan; Life Tables; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Preoperative Care; Prognosis; Proportional Hazards Models; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Taxanes in the treatment of head and neck cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Head and Neck Neoplasms; Humans; Medical Oncology; Paclitaxel; Taxoids | 2005 |
Revisiting induction chemotherapy for head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Taxoids | 2005 |
[The role of taxanes for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Neutropenia; Taxoids | 2005 |
[Planned neck dissection after weekly docetaxel and concurrent radiotherapy for advanced oropharyngeal cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Elective Surgical Procedures; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Oropharyngeal Neoplasms; Prognosis; Radiotherapy, Adjuvant; Taxoids | 2007 |
Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Remission Induction; Taxoids | 2007 |
[Head and neck cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Paclitaxel; Taxoids | 1997 |
Update on the taxoids and other new agents in head and neck cancer therapy.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; DNA Replication; DNA, Neoplasm; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Head and Neck Neoplasms; Humans; Interferon-alpha; Microtubules; Neoplasm Proteins; Organoplatinum Compounds; Paclitaxel; Radiation-Sensitizing Agents; Remission Induction; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome; Tubulin Modulators | 1998 |
Docetaxel in head and neck cancer: a review.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 1998 |
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Life Tables; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Tomography, X-Ray Computed | 1999 |
The chemotherapy of head and neck cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids | 1999 |
Taxoids in head and neck cancer: the American approach.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; United States | 1999 |
[Recent regimen of chemotherapy for advanced head and neck carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Neoadjuvant Therapy; Paclitaxel; Prognosis; Taxoids | 2000 |
The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Decision Making; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Taxoids | 2000 |
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Docetaxel in squamous cell cancer of the head and neck.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Taxoids | 2001 |
[Present role and future prospect of superselective intra-arterial infusion chemotherapy for head and neck cancer].
Topics: Adult; Aged; Antidotes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Paclitaxel; Prospective Studies; Taxoids; Thiosulfates | 2002 |
267 trial(s) available for docetaxel anhydrous and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Quality of Life; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2022 |
Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung Neoplasms; Taxoids; Transcription Factors | 2022 |
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2023 |
Stathmin guides personalized therapy in oral squamous cell carcinoma.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Male; Mice; Middle Aged; Mouth Neoplasms; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Precision Medicine; Signal Transduction; Stathmin; Taxoids; TOR Serine-Threonine Kinases | 2020 |
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Prognosis; Survival Rate | 2020 |
Anti-Telomerase CD4
Topics: Adaptive Immunity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; CD4-Positive T-Lymphocytes; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Papillomavirus Infections; Prognosis; Prospective Studies; Telomerase; Th1 Cells | 2020 |
Surgical Outcomes After Neoadjuvant Chemoradiation Followed by Curative Surgery in Patients With Esophageal Cancer: An Intergroup Phase III Trial of the Swiss Group for Clinical Cancer Research (SAKK 75/08).
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Humans; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Treatment Outcome | 2022 |
Phase II Trial of Intensity-Modulated Radiotherapy Concurrent With Chemotherapy for Postoperative Node-Positive Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Postoperative Period; Radiotherapy, Intensity-Modulated; Survival Analysis; Taxoids | 2017 |
Effectiveness of incorporating cetuximab into docetaxel/cisplatin/fluorouracil induction chemotherapy and chemoradiotherapy for inoperable squamous cell carcinoma of the oral cavity: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patien
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deglutition; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Mouth Neoplasms; Oropharyngeal Neoplasms; Postoperative Care; Quality of Life; Survival Analysis; Taxoids | 2017 |
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; DNA, Viral; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; In Situ Hybridization; Male; Papillomaviridae; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids | 2017 |
Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; France; Humans; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Research Design; Taxoids; Young Adult | 2017 |
Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Tegafur; Young Adult | 2017 |
Impact of Nivolumab versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients with Advanced Squamous Non-Small Cell Lung Cancer: Results from the CheckMate 017 Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Quality of Life | 2018 |
Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Survival Rate | 2018 |
Rescue of iCIKs transfer from PD-1/PD-L1 immune inhibition in patients with resectable tongue squamous cell carcinoma (TSCC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Transplantation; Cells, Cultured; Cisplatin; Cytokines; Docetaxel; Female; Fluorouracil; Humans; Killer Cells, Natural; Male; Middle Aged; Programmed Cell Death 1 Receptor; Taxoids; Tongue Neoplasms | 2018 |
Phase I/II Trial of Chemotherapy with Docetaxel, Cisplatin, and S-1 for Unresectable Advanced Squamous Cell Carcinoma of the Esophagus.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Humans; Maximum Tolerated Dose; Oxonic Acid; Prospective Studies; Taxoids; Tegafur | 2018 |
Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Clinical Decision Rules; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Endpoint Determination; Head and Neck Neoplasms; Humans; Progression-Free Survival; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Statistics as Topic | 2019 |
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate; Survivors | 2019 |
Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Nivolumab; Oxonic Acid; Paclitaxel; Prognosis; Ramucirumab; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur | 2019 |
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Paraffin Embedding; Prognosis; Specimen Handling; Survival Rate; Young Adult | 2019 |
A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Diarrhea; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Hypokalemia; Male; Maximum Tolerated Dose; Middle Aged; Mouth Neoplasms; Mucositis; Postoperative Period; Prospective Studies; Radiotherapy Dosage | 2019 |
Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p16; Deglutition; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oropharyngeal Neoplasms; Papillomaviridae; Papillomavirus Infections; Postoperative Period; Prospective Studies; Quality of Life; Radiation Dosage; Self Report; Smoking; Treatment Outcome | 2019 |
Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: final results of a prospective phase-II trial with a long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Radiation Dose Hypofractionation; Survival Rate | 2019 |
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Everolimus; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Sirolimus; Survival Rate; Taxoids; TOR Serine-Threonine Kinases | 2013 |
Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2013 |
Phase II study of cetuximab in combination with docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck after platinum-containing therapy: a multicenter study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Time Factors; Treatment Outcome | 2013 |
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Gefitinib; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2013 |
Multicenter phase II study of weekly docetaxel, cisplatin, and S-1 (TPS) induction chemotherapy for locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Oxonic Acid; Quality of Life; Survival Analysis; Taxoids; Tegafur | 2013 |
A trial of autologous ex vivo-expanded NK cell-enriched lymphocytes with docetaxel in patients with advanced non-small cell lung cancer as second- or third-line treatment: phase IIa study.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Killer Cells, Natural; Lung Neoplasms; Lymphocytes; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids; Transplantation, Autologous | 2013 |
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Piperidines; Quinazolines; Taxoids | 2013 |
Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Thoracotomy; Treatment Outcome | 2013 |
Phase II trial of second-line chemotherapy with docetaxel and capecitabine in advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Taxoids | 2013 |
Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Penile Neoplasms; Survival Analysis; Taxoids; United Kingdom | 2013 |
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Taxoids | 2014 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Organoplatinum Compounds; Taxoids; Treatment Failure; Vomiting | 2016 |
Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2014 |
GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Growth Differentiation Factor 15; Humans; Immunohistochemistry; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Mouth Neoplasms; Taxoids | 2014 |
Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Feasibility Studies; Febrile Neutropenia; Female; Fluorouracil; Humans; Leukopenia; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiotherapy Dosage; Taxoids | 2014 |
[Grade IV myelosuppression after induction chemotherapy of TPF on oral cancer: clinical analysis of 29 cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Mouth Mucosa; Mouth Neoplasms; Retrospective Studies; Taxoids | 2014 |
Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Docetaxel/ TS-1 with radiation for unresectable squamous cell carcinoma of the esophagus--a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2014 |
Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Postoperative Care; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2014 |
Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Induction Chemotherapy; Male; Middle Aged; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Taxoids | 2014 |
Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Protocols; Consolidation Chemotherapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Middle Aged; Movement; Pneumonia; Prognosis; Prospective Studies; Quality of Life; Respiration; Taxoids | 2014 |
p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; Neoplasm Proteins; Papillomaviridae; Papillomavirus Infections; Prognosis; Smoking; Taxoids; Treatment Outcome | 2014 |
Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Taxoids; Treatment Outcome | 2015 |
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Gonanes; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Phosphoinositide-3 Kinase Inhibitors; Recurrence; Taxoids | 2015 |
Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2015 |
Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Oropharyngeal Neoplasms; Taxoids; Treatment Outcome | 2015 |
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Otorhinolaryngologic Neoplasms; Taxoids | 2015 |
Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; DNA, Viral; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Laryngeal Neoplasms; Male; Middle Aged; Organ Sparing Treatments; Oropharyngeal Neoplasms; Papillomaviridae; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Stomatitis; Survival Rate; Taxoids | 2015 |
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Republic of Korea; Taxoids; Time Factors; Treatment Outcome | 2015 |
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Quality of Life; Survival Rate; Taxoids; Tegafur | 2015 |
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Immunoglobulin G; Lung Neoplasms; Male; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Survival Analysis; Taxoids | 2015 |
Nivolumab for squamous-cell non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Baltimore; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Invasiveness; Nivolumab; Prognosis; Proportional Hazards Models; Survival Analysis; Taxoids | 2015 |
Neoadjuvant Chemotherapy for Locally Advanced Squamous Carcinoma of Oral Cavity: a Pilot Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Pilot Projects; Taxoids; Young Adult | 2015 |
Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2015 |
Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prospective Studies; Radiotherapy; Surgical Procedures, Operative; Taxoids; Treatment Outcome; Young Adult | 2015 |
Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma: Results of a randomized phase II study.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Quality of Life; Radiotherapy, Intensity-Modulated; Stomatitis; Taxoids; Treatment Outcome; Young Adult | 2015 |
[Clinical evaluations of neoadjuvant chemotherapy with DN and FP regimens for patients with middle or lower thoracic locally advanced esophageal squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Survival Rate; Taxoids | 2015 |
Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Proto-Oncogene Proteins p21(ras); Survival Rate; Taxoids | 2015 |
Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; China; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Penile Neoplasms; Proportional Hazards Models; Taxoids; Time Factors; Treatment Outcome | 2015 |
Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Approval; Female; Humans; Lung Neoplasms; Nivolumab; Organoplatinum Compounds; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2016 |
Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Female; Humans; Intention to Treat Analysis; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Proportional Hazards Models; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Taxoids | 2016 |
Long-term Results of a Multicenter Randomized Phase III Trial of Induction Chemotherapy With Cisplatin, 5-fluorouracil, ± Docetaxel for Larynx Preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Induction Chemotherapy; Kaplan-Meier Estimate; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Neoplasm Staging; Organ Sparing Treatments; Squamous Cell Carcinoma of Head and Neck; Taxoids; Time Factors; Treatment Outcome | 2016 |
Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagus; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Research Design; Taxoids; Treatment Outcome | 2017 |
Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Feasibility Studies; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatigue; Female; Fluorouracil; Humans; Infections; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Panitumumab; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2016 |
Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Docetaxel; Epidemiologic Methods; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Taxoids; Treatment Outcome | 2016 |
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quality of Life; Survival Rate; Taxoids | 2016 |
Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Taxoids | 2016 |
Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiotherapy, Intensity-Modulated; Taxoids | 2016 |
The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Postoperative Period; Propensity Score; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxonic Acid; Taxoids; Tegafur; Treatment Outcome | 2016 |
Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Head and Neck Neoplasms; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Radiation Dosage; Severity of Illness Index; Taxoids | 2016 |
A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2016 |
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gossypol; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2016 |
Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2016 |
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate | 2018 |
Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Therapy, Combination; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Pilot Projects; Survival Analysis; Taxoids | 2016 |
Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2016 |
A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Substitution; Dyspnea; Fatigue; Female; Gastrointestinal Diseases; Greece; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2016 |
Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Doxorubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2017 |
PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Panitumumab; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2016 |
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic On
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Prognosis; Survival Rate; Taxoids | 2017 |
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Female; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Risk Factors; Smoking; Taxoids; Tomography, X-Ray Computed; Tubulin Modulators | 2017 |
[Docetaxel (TXT) and irinotecan (CPT-11) as a second-line chemotherapy for platinum-pretreated squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Platinum; Taxoids | 2008 |
A randomised phase II trial of preoperative chemotherapy of cisplatin-docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Survival Rate; Taxoids; Treatment Outcome | 2008 |
[Preliminary result of multi-center clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Nasopharyngeal Neoplasms; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Taxoids; Young Adult | 2008 |
Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Remission Induction; Survival Rate; Taxoids | 2008 |
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Darbepoetin alfa; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Erythropoietin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Mesna; Middle Aged; Neoplasm Staging; Neutropenia; Polyethylene Glycols; Prognosis; Recombinant Proteins; Survival Rate; Taxoids | 2008 |
Taxotere, cisplatin, fluorouracil, and leucovorin (TPFL)as induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Tomography, X-Ray Computed | 2008 |
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Kaplan-Meier Estimate; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Assessment; Taxoids; Time Factors; Treatment Outcome | 2009 |
A phase I study of docetaxel as a radio-sensitizer for locally advanced squamous cell cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Radiation-Sensitizing Agents; Taxoids; Uterine Cervical Neoplasms | 2009 |
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Remission Induction; Taxoids; Treatment Outcome | 2009 |
Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Epirubicin; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure | 2009 |
Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Karnofsky Performance Status; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Remission Induction; Taxoids; Treatment Outcome; Young Adult | 2009 |
Outpatient chemotherapy with S-1 for recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Taxoids; Tegafur | 2009 |
Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Rate; Taxoids | 2009 |
A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Phase I adjuvant radiation with docetaxel in high-risk head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Prospective Studies; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Single tissue samples from head and neck squamous cell carcinomas are representative regarding the entire tumor's chemosensitivity to cisplatin and docetaxel.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Reproducibility of Results; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2009 |
Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Taxoids | 2010 |
Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Neutropenia; Organoplatinum Compounds; Prospective Studies; Taxoids; Treatment Outcome; Young Adult | 2010 |
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cyclooxygenase 2; Docetaxel; Drug Administration Schedule; Female; Glucuronosyltransferase; Head and Neck Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Vascular Endothelial Growth Factor A | 2009 |
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
[A Phase II study of docetaxel and cisplatin in patients with recurrent or unresectable squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2009 |
Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids | 2009 |
Cost utility of docetaxel as induction chemotherapy followed by chemoradiation in locally advanced squamous cell carcinoma of the head and neck.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cost of Illness; Cost-Benefit Analysis; Disease Progression; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Markov Chains; Neoadjuvant Therapy; Quality of Life; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Taxoids; United Kingdom | 2009 |
Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Taxoids; Treatment Outcome | 2010 |
Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Prognosis; Prospective Studies; Survival Rate; Taxoids; Young Adult | 2010 |
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Pyrazines; Recurrence; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2009 |
Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2010 |
beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Prognosis; Taxoids; Treatment Outcome; Tubulin | 2009 |
Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Docetaxel, ifosfamide and cisplatin (DIP) in squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2009 |
Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Risk Assessment; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia | 2010 |
Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase ll study by the Swiss Group for Clinical Cancer Research
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Drug Therapy, Combination; Endosonography; Esophageal Neoplasms; Esophagus; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Predictive Value of Tests; Prospective Studies; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Taxoids; Time Factors; Treatment Outcome; United States | 2010 |
Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase I/II study of inhaled doxorubicin combined with platinum-based therapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Administration, Inhalation; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Doxorubicin; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Induction chemotherapy in head and neck cancer patients followed by concomitant docetaxel-based radiochemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasms, Squamous Cell; Remission Induction; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2011 |
Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Chromatography, Liquid; Docetaxel; Dose-Response Relationship, Drug; Enzyme Induction; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Tandem Mass Spectrometry; Taxoids | 2011 |
Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Interactions; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Taxoids; Treatment Outcome | 2011 |
A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Salvage Therapy; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2010 |
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2011 |
Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Health Status; Humans; Quality of Life; Taxoids; Time Factors; Treatment Outcome | 2010 |
Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2010 |
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Squamous Cell; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Taxoids; United States | 2010 |
Preoperative chemotherapy with cisplatin and docetaxel followed by surgery and clip-oriented postoperative chemoradiation in patients with localized gastric or gastroesophageal junction adenocarcinoma: results from a phase II feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Care; Preoperative Care; Radiotherapy Dosage; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prospective Studies; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Cystic Fibrosis; Docetaxel; Dose Fractionation, Radiation; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids; Young Adult | 2010 |
Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06).
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Digestive System Surgical Procedures; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Taxoids | 2011 |
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids | 2011 |
Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Double-Blind Method; Female; Follow-Up Studies; Gossypol; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Taxoids | 2011 |
Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Radiotherapy Dosage; Severity of Illness Index; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Time Factors | 2011 |
Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Survival Rate; Taxoids | 2011 |
Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Taxoids | 2011 |
Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Survival Rate; Taxoids; Thymidylate Synthase; Treatment Outcome | 2011 |
Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2011 |
Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Docetaxel; EGF Family of Proteins; ErbB Receptors; Glycoproteins; Head and Neck Neoplasms; Humans; Intercellular Signaling Peptides and Proteins; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2011 |
[Intensity-modulated or 3-D conformal radiotherapy combined with chemotherapy with docetaxel and cisplatin for locally advanced esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Radiotherapy, Conformal; Taxoids | 2011 |
Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Recurrence; Taxoids; Treatment Outcome | 2011 |
[Induction therapy of locally-advanced nasophayngeal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nose Neoplasms; Pharyngeal Neoplasms; Radiotherapy, Adjuvant; Remission Induction; Taxoids; Treatment Outcome | 2011 |
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Early Termination of Clinical Trials; Female; Gene Dosage; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperazines; Proportional Hazards Models; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Taxoids | 2011 |
Long-term follow-up of phase II trial of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Time Factors | 2012 |
Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Taxoids; Time Factors; Treatment Outcome | 2012 |
Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Taxoids | 2012 |
Early efficacy of taxotere and cisplatin chemo-radiotherapy for advanced cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Prognosis; Remission Induction; Taxoids; Uterine Cervical Neoplasms | 2012 |
A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Taxoids | 2012 |
Early prediction of survival following induction chemotherapy with DCF (docetaxel, cisplatin, 5-fluorouracil) using FDG PET/CT imaging in patients with locally advanced head and neck squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorodeoxyglucose F18; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron-Emission Tomography; Radiopharmaceuticals; Squamous Cell Carcinoma of Head and Neck; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
A phase II study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin in advanced oesophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2013 |
Hyperfractionated radiotherapy with concurrent docetaxel for advanced head and neck cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Radiation-Sensitizing Agents; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2012 |
Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Neoplasms; Neoplasm Grading; Neoplasm Staging; Oropharyngeal Neoplasms; Taxoids; Treatment Outcome | 2012 |
Survival following non surgical treatments for oral cancer: a single institutional result.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Turkey | 2012 |
Concurrent chemoradiation therapy with docetaxel (DOC) for laryngeal preservation in T2N0M0 glottic squamous cell carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Glottis; Humans; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Mouth Neoplasms; Mucositis; Nausea; Prospective Studies; Radiotherapy; Taxoids; Treatment Outcome | 2013 |
RASSF1A and ERCC1 expression levels might be predictive of prognosis in advanced, recurrent, and metastatic squamous cell carcinoma of the head and neck treated with docetaxel and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Head and Neck Neoplasms; Humans; Incidence; Male; Neoplasm Recurrence, Local; Prognosis; Republic of Korea; Risk Factors; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
[Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Radiotherapy, High-Energy; Remission Induction; Taxoids; Vomiting | 2012 |
A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Hysterectomy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Intensity-Modulated; Survival Rate; Taxoids; Uterine Cervical Neoplasms; Young Adult | 2013 |
Superselective intra-arterial chemoradiation therapy for functional laryngeal preservation in advanced squamous cell carcinoma of the glottic larynx.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Glottis; Humans; Infusions, Intra-Arterial; Japan; Kaplan-Meier Estimate; Laryngeal Neoplasms; Laryngectomy; Male; Middle Aged; Taxoids | 2013 |
Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Paclitaxel; Taxoids | 2002 |
Phase II study with docetaxel and cisplatin in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Head and Neck Neoplasms; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Palliative Care; Recurrence; Survival Rate; Taxoids; Time Factors | 2002 |
Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Ifosfamide; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure | 2003 |
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Drug Synergism; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2003 |
Docetaxel as neoadjuvant chemotherapy in patients with advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Taxoids; Uterine Cervical Neoplasms | 2003 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Taxoids | 2003 |
Radiotherapy with concomitant weekly docetaxel for Stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Survival Analysis; Taxoids | 2004 |
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; California; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mass Screening; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab | 2004 |
Docetaxel and carboplatin as first-line chemotherapy in patients with advanced gynecological tumors. A phase I/II trial of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO-OVAR) Ovarian Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Humans; Middle Aged; Ovarian Neoplasms; Taxoids | 2004 |
Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2004 |
Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Topics: Adult; Aged; Anemia; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Radiotherapy Dosage; Stomatitis; Taxoids; Thrombocytopenia | 2004 |
A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Humans; Male; Middle Aged; Otorhinolaryngologic Neoplasms; Taxoids | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mouth Neoplasms; Organoplatinum Compounds; Remission Induction; Taxoids; Treatment Outcome | 2004 |
Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Taxoids | 2004 |
Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Head; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intra-Arterial; Male; Middle Aged; Neck; Neck Dissection; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Thiosulfates; Time Factors; Treatment Outcome | 2005 |
Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids | 2005 |
Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Taxoids | 2005 |
Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Induction chemotherapy with cisplatin/docetaxel versus cisplatin/5-fluorouracil for locally advanced squamous cell carcinoma of the head and neck: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Feasibility Studies; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
[A Phase I study of docetaxel and cisplatin for advanced squamous cell carcinoma of the head and neck].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Stomach Neoplasms; Taxoids | 2005 |
Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose Fractionation, Radiation; Esophageal Stenosis; Female; Fluorouracil; Follow-Up Studies; Humans; Laryngeal Neoplasms; Laryngectomy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Salvage Therapy; Survival Rate; Taxoids | 2005 |
Lack of survival advantage in patients with advanced, resectable squamous cell carcinoma of the oral cavity receiving induction chemotherapy with cisplatin (CDDP), docetaxel (TXT) and 5-fluorouracil (5FU).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Prognosis; Survival Rate; Taxoids | 2004 |
[Evaluation of a combination chemotherapy with docetaxel and nedaplatin for patients with oral squamous cell carcinomas].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Taxoids | 2005 |
Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids | 2005 |
Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Radiation Injuries; Radiotherapy; Remission Induction; Sex Distribution; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Second-line chemotherapy with a modified schedule of docetaxel in elderly patients with advanced-stage non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Health Services for the Aged; Humans; Italy; Lung Neoplasms; Male; Neoplasm Staging; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Hyperselective intra-arterial preoperative chemotherapy in patients with squamous cell carcinoma of the oral cavity: preliminary results.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Magnetic Resonance Imaging; Male; Middle Aged; Mouth Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2006 |
Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2007 |
[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Quality of Life; Taxoids | 2007 |
[Evaluation of docetaxel, CDDP and 5-FU combined therapy as second-line chemotherapy for esophagus cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Taxoids | 2007 |
Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2007 |
Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prospective Studies; Taxoids | 2007 |
A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Taxoids; Treatment Outcome | 2007 |
Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Comorbidity; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagitis; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Radiation Pneumonitis; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Confidence Intervals; Docetaxel; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Laryngeal Neoplasms; Larynx; Male; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Pharyngeal Neoplasms; Pharynx; Radiotherapy; Radiotherapy Dosage; Taxoids; Time Factors; Treatment Outcome | 2007 |
Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Pharyngeal Neoplasms; Recurrence; Taxoids; Treatment Outcome | 2007 |
Prognostic significance of cyclin D1 and p16 in patients with intermediate-risk head and neck squamous cell carcinoma treated with docetaxel and concurrent radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Taxoids | 2007 |
A phase II study of weekly docetaxel for patients with advanced or recurrent cancer of the cervix.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Oklahoma; Survival Analysis; Taxoids; Treatment Outcome; Uterine Cervical Neoplasms | 2007 |
[Comparison of efficacy of docetaxel combined cisplatin (TP regimen) and cisplatin combined 5-fluorouracil (PF regimen) on locally advanced nasopharyngeal carcinoma].
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Particle Accelerators; Radiotherapy, High-Energy; Stomatitis; Taxoids | 2007 |
Phase I trial of motexafin gadolinium in combination with docetaxel and cisplatin for the treatment of non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Metalloporphyrins; Middle Aged; Prognosis; Survival Rate; Taxoids | 2007 |
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Rate; Taxoids; Uterine Cervical Neoplasms | 2007 |
A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mouth Neoplasms; Neutropenia; Organoplatinum Compounds; Remission Induction; Taxoids | 2008 |
A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis; Taxoids | 2007 |
Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Sulindac; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2007 |
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Survival Analysis; Taxoids | 2007 |
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiotherapy; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Prospective pilot study of consolidation chemotherapy with docetaxel and cisplatin after concurrent chemoradiotherapy for advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Radiotherapy Dosage; Remission Induction; Taxoids | 2008 |
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Salvage Therapy; Survival Analysis; Taxoids | 2008 |
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-CD8 Ratio; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Immunotherapy; Killer Cells, Natural; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; T-Lymphocytes; Taxoids | 2008 |
A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Taxoids | 2008 |
p53 expression in concurrent chemoradiotherapy with docetaxel for head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Phosphorylation; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Taxoids; Tumor Suppressor Protein p53 | 2009 |
[Late phase II trial of RP56976 (Docetaxel) in patients with non-small-cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Taxoids; Vomiting | 1995 |
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Asthenia; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Europe; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1994 |
[Phase II clinical study of RP56976 (docetaxel) in patients with carcinoma ovarii or carcinoma colli uteri].
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Paclitaxel; Taxoids; Thrombocytopenia; Uterine Cervical Neoplasms | 1994 |
Docetaxel: an active drug for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Treatment Outcome | 1996 |
Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix.
Topics: Adult; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Uterine Cervical Neoplasms | 1996 |
Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Middle Aged; Paclitaxel; Taxoids | 1998 |
First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Patient Compliance; Recombinant Proteins; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
[Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Remission Induction; Taxoids | 1999 |
Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
[Evaluation of chemotherapy with docetaxel and cisplatin in advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Evaluation; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1999 |
A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Life Tables; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Tomography, X-Ray Computed | 1999 |
[Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diosmin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Prednisolone; Premedication; Taxoids; Time Factors | 2000 |
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Recurrence; Taxoids | 2000 |
A phase II trial of palliative docetaxel plus 5-fluorouracil for squamous-cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Taxoids; Treatment Outcome | 2000 |
Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypocalcemia; Magnesium; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 2001 |
A phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2000 |
Docetaxel and cisplatin in locally advanced or metastatic squamous-cell carcinoma of the head and neck: a phase II study of the Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Head and Neck Neoplasms; Humans; Italy; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Phase II Trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2002 |
Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Leucovorin; Male; Middle Aged; Paclitaxel; Taxoids | 2002 |
Phase I study of carboplatin, irinotecan and docetaxel on a divided schedule with recombinant human granulocyte colony stimulating factor support in patients with stage IIIB or IV non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Recombinant Proteins; Taxoids | 2002 |
Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Cranial Irradiation; Docetaxel; Dose Fractionation, Radiation; Drug Tolerance; Feasibility Studies; Female; Humans; Injections, Intra-Arterial; Lymph Node Excision; Male; Middle Aged; Mouth Neoplasms; Neck; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Paclitaxel; Patient Compliance; Pilot Projects; Prognosis; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Survival Analysis; Taxoids | 2002 |
396 other study(ies) available for docetaxel anhydrous and Carcinoma, Squamous Cell
| Article | Year |
|---|---|
Clinico-epidemiological profile and treatment outcomes in patients with squamous cell carcinoma of the esophagus following docetaxel-based neoadjuvant chemotherapy: experience from a cancer care center in Northeast India.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome | 2021 |
ITGA5 is an independent prognostic biomarker and potential therapeutic target for laryngeal squamous cell carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Integrins; Laryngeal Neoplasms; Male; Middle Aged; Nomograms; Prognosis; Proportional Hazards Models; Survival Analysis | 2022 |
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Epitopes; Fluorouracil; Humans; Paclitaxel; Prospective Studies | 2022 |
Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Epithelial Cells; Humans; Lung Neoplasms; Ramucirumab; Retrospective Studies; Treatment Outcome | 2022 |
Neoadjuvant PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy in Locally Advanced Anal Canal Squamous Cell Carcinoma Patients: Antitumor Efficacy, Safety and Biomarker Analysis.
Topics: Adult; Aged; Anal Canal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Dermatitis; Docetaxel; Female; Humans; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Programmed Cell Death 1 Receptor; Radioimmunotherapy; Treatment Outcome | 2021 |
Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans | 2022 |
New approaches in palliative systemic therapy of anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Humans; Immunotherapy; Neoplasm Recurrence, Local; Palliative Care | 2022 |
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Immune Checkpoint Inhibitors; Ipilimumab; Lung Neoplasms; Nivolumab; Paclitaxel; Pemetrexed | 2022 |
Recurrence Pattern Comparing Preoperative Chemoradiotherapy and Preoperative Chemotherapy with Docetaxel plus 5-Fluorouracil and Cisplatin for Advanced Esophageal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2022 |
A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2022 |
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S-1 (DCS) induction chemotherapy followed by chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Neoplasm Recurrence, Local; Taxoids | 2023 |
Involvement of AMPKα and MAPK-ERK/-JNK Signals in Docetaxel-Induced Human Tongue Squamous Cell Carcinoma Cell Apoptosis.
Topics: AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Docetaxel; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Humans; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tongue; Tongue Neoplasms | 2022 |
Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Neoadjuvant Therapy; Retrospective Studies; Taxoids | 2023 |
Docetaxel-based CRT improves survival in cisplatin-ineligible patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Humans; Treatment Outcome | 2023 |
Evaluation of a docetaxel-cisplatin-fluorouracil-Au complex in human oral carcinoma cell line.
Topics: Carcinoma, Squamous Cell; Cell Line; Cisplatin; Docetaxel; Fluorouracil; Gold; Humans; Metal Nanoparticles; Mouth Neoplasms; Taxoids | 2023 |
Biomimetic Nanoparticle with Glutathione Depletion and Amplified ROS Generation Capabilities for Synergistic Chemo-Sonodynamic Therapy in Squamous Cell Carcinomas.
Topics: Biomimetics; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Glutathione; Humans; Nanoparticles; Neoplasms; Reactive Oxygen Species; Ultrasonic Therapy | 2023 |
Efficacy of concurrent chemoradiotherapy with retrograde super selective intra-arterial infusion combined with cetuximab for synchronous multifocal oral squamous cell carcinomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Taxoids; Tongue Neoplasms | 2023 |
[A Case of Breast Carcinoma That Changed Subtype to Squamous Cell Carcinoma after Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Cyclophosphamide; Docetaxel; Female; Humans; Liver Neoplasms; Mastectomy; Quality of Life | 2023 |
Oncological outcomes of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced squamous cell carcinoma of the external auditory canal: A single-center study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Ear Canal; Fluorouracil; Head and Neck Neoplasms; Humans; Retrospective Studies; Taxoids | 2023 |
Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells.
Topics: Carcinoma, Squamous Cell; Docetaxel; Head and Neck Neoplasms; HMGB1 Protein; Humans; Papillomavirus Infections; Phenotype; Squamous Cell Carcinoma of Head and Neck | 2023 |
USP9X mRNA expression predicts clinical outcome for esophageal squamous cell carcinoma treated with cisplatin-based therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Prognosis; Radiotherapy, Adjuvant; RNA, Messenger; Ubiquitin Thiolesterase | 2020 |
Preoperative intra-arterial chemotherapy with docetaxel, cisplatin, and peplomycin combined with intravenous chemotherapy using 5-fluorouracil for oral squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Humans; Mouth Neoplasms; Neoplasm Recurrence, Local; Peplomycin; Taxoids | 2020 |
Clinical impact of baseline renal function on the safety of radiotherapy with concurrent docetaxel for esophageal cancer in elderly patients.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Case-Control Studies; Combined Modality Therapy; Creatinine; Docetaxel; Esophageal Neoplasms; Female; Humans; Incidence; Kidney Function Tests; Male; Neoplasm Staging; Radiotherapy; Retrospective Studies; Safety; Survival Rate | 2020 |
The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Safety; Prognosis; Ramucirumab; Retrospective Studies; Survival Rate | 2020 |
Open label, Non-randomized, Interventional Study to Evaluate Response Rate After Induction Therapy with Docetaxel and Cisplatin in Locally Advanced Squamous Cell Carcinoma of Oral Cavity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Remission Induction | 2020 |
Gastric squamous cell carcinoma presenting in ascites: Negative to P63 and P40 after one course of chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Gastroscopy; Gene Expression; Humans; Keratins; Lymphatic Metastasis; Membrane Proteins; Middle Aged; NF-KappaB Inhibitor alpha; Stomach; Stomach Neoplasms; Tomography, X-Ray Computed | 2020 |
RAD51 Expression as a Biomarker to Predict Efficacy of Preoperative Therapy and Survival for Esophageal Squamous Cell Carcinoma: A Large-cohort Observational Study (KSCC1307).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Prognosis; Rad51 Recombinase; Treatment Outcome | 2022 |
MiR-92b as a marker for TPF induced chemotherapy response prediction and prognosis evaluation in with advanced oral squamous cell carcinoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Down-Regulation; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Logistic Models; Male; MicroRNAs; Mouth Neoplasms; Multivariate Analysis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Up-Regulation | 2020 |
Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Proliferation; Cisplatin; Disease-Free Survival; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Precision Medicine; Prognosis; Vascular Endothelial Growth Factor Receptor-2; Vesicular Transport Proteins | 2020 |
[Docetaxel and Ramucirumab Combination Chemotherapy after Nivolumab Treatment for Pretreated Pulmonary Squamous Cell Carcinoma-A Successful Case].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab; Ramucirumab | 2021 |
ZFX promotes tumorigenesis and confers chemotherapy resistance in esophageal squamous cell carcinoma.
Topics: Carcinogenesis; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gene Expression Regulation, Neoplastic; Humans | 2021 |
Induction Chemotherapy Followed by either Chemoradiotherapy or Bioradiotherapy in Laryngeal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Laryngeal Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2021 |
Decreased Annexin A1 expression enhances sensitivity to docetaxel, cisplatin and 5-fluorouracil combination induction chemotherapy in oral squamous cell carcinoma.
Topics: Annexin A1; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2021 |
Effects of miR-224-5p-enhanced downregulation of pannexin-1 on docetaxel-induced apoptosis in amoeboid-like CD44
Topics: Amoeba; Apoptosis; Carcinoma, Squamous Cell; Connexins; Docetaxel; Down-Regulation; Humans; Hyaluronan Receptors; MicroRNAs; Mouth Neoplasms; Nerve Tissue Proteins | 2021 |
MCL1 inhibition enhances the efficacy of docetaxel against airway-derived squamous cell carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Prognosis; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inhibitor of Apoptosis Proteins; Neoplasm Proteins; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2017 |
Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Survival Rate; Taxoids | 2017 |
Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Doxorubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Sarcopenia; Taxoids | 2017 |
A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Pilot Projects; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids | 2018 |
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cetuximab; DNA Mutational Analysis; Docetaxel; ErbB Receptors; Everolimus; Fluorouracil; Gene Expression; Head and Neck Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Mice; Mice, Inbred NOD; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Xenograft Model Antitumor Assays | 2017 |
Squamous cell carcinoma of neck metastasized to the lung and cervical lymph nodes, successfully treated with systemic docetaxel and local radiation therapy to the neck in a renal transplant patient.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male | 2017 |
Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Docetaxel; Fibroblasts; Fibrosis; Humans; Indoles; Lung Neoplasms; Neoplasm Invasiveness; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Transforming Growth Factor beta1 | 2017 |
[Cancers associated with systemic sclerosis involving anti-RNA polymerase III antibodies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Autoantigens; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Radiotherapy, Adjuvant; Raynaud Disease; Remission Induction; RNA Polymerase III; Scleroderma, Systemic; Taxoids; Tonsillectomy; Young Adult | 2018 |
Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Penile Neoplasms; Penis; Taxoids; Tomography, X-Ray Computed | 2017 |
Influence of a dosing-time on toxicities induced by docetaxel, cisplatin and 5-fluorouracil in patients with oral squamous cell carcinoma; a cross-over pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Circadian Rhythm; Cisplatin; Cross-Over Studies; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Mouth Neoplasms; Pilot Projects; Time Factors; Treatment Outcome; Young Adult | 2018 |
Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagoscopy; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Propensity Score; Taxoids; Treatment Outcome | 2018 |
[Atypical Hemolitic Uremic Syndrome after administration of Docetaxel].
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atypical Hemolytic Uremic Syndrome; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Humans; Lymph Node Excision; Male; Middle Aged; Penile Neoplasms; Plasma; Postoperative Complications; Renal Dialysis; Taxoids | 2018 |
Pre-treatment tumour perfusion parameters and initial RECIST response do not predict long-term survival outcomes for patients with head and neck squamous cell carcinoma treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Prognosis; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate; Taxoids | 2018 |
An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Canada; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cost-Benefit Analysis; Docetaxel; Humans; Lung Neoplasms; Nivolumab; Organizational Case Studies; Quality-Adjusted Life Years; Taxoids | 2018 |
Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Male; Prognosis; Retrospective Studies; Treatment Outcome | 2018 |
Lung Cancer with a Small Cell Carcinoma Component Diagnosed from Pleural Effusion and a Squamous Cell Carcinoma Component Diagnosed from the Tumor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Humans; Immunohistochemistry; Lung Neoplasms; Male; Pleural Effusion, Malignant; Small Cell Lung Carcinoma | 2018 |
Building evidence-based treatment recommendations for advanced anal cancer: the time is now.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Epitopes; Fluorouracil; Humans; Neoplasm Recurrence, Local | 2018 |
A highly integrated precision nanomedicine strategy to target esophageal squamous cell cancer molecularly and physically.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Proliferation; Chromones; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Drug Delivery Systems; Drug Therapy, Combination; Esophageal Neoplasms; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Nanomedicine; Neoplasm Invasiveness; Prognosis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Correlation between high FBXW7 expression in pretreatment biopsy specimens and good response to chemoradiation therapy in patients with locally advanced esophageal cancer: A retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Nucleus; Chemoradiotherapy, Adjuvant; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; F-Box-WD Repeat-Containing Protein 7; Female; Fluorouracil; Humans; Immunohistochemistry; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoadjuvant Therapy; Organoplatinum Compounds; Retrospective Studies; Taxoids | 2018 |
Genetic Variants in the Wingless Antagonist Genes (
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axin Protein; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Epistasis, Genetic; Female; Gemcitabine; Genetic Variation; Genotype; Humans; India; Intercellular Signaling Peptides and Proteins; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pemetrexed; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Smoking; Wnt Proteins | 2018 |
[A Case of Advanced Esophageal Cancer Successfully Treated with Neoadjuvant Chemotherapy Containing 5-FU, Docetaxel. and Nedaplatin Combination Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Positron Emission Tomography Computed Tomography; Taxoids | 2018 |
Dynamic changes in chemosensitivity immune predictors in patients with hypopharyngeal cancer treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cisplatin; Docetaxel; Female; Flow Cytometry; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Induction Chemotherapy; Male; Middle Aged; Prospective Studies; T-Lymphocytes, Regulatory | 2019 |
Thermochemoradiotherapy Using Superselective Intra-arterial Infusion for Patients With Oral Cancer With Cervical Lymph Node Metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Female; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Mouth Neoplasms; Neck; Neoplasm Staging | 2019 |
[Effect of silencing LASP1 on biological behaviors of oral squamous cell carcinoma cells and IC50 of three anti-tumor drugs].
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Docetaxel; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; LIM Domain Proteins; Mice; Mice, Nude; Mouth Neoplasms; Neoplasm Invasiveness | 2019 |
Successful Stenting Followed by Surgery for Perforated Esophageal Cancer Due to Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Contrast Media; Deglutition Disorders; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Perforation; Esophageal Stenosis; Esophagectomy; Fluorouracil; Follow-Up Studies; Humans; Male; Neoadjuvant Therapy; Risk Assessment; Stents; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Humans; Ifosfamide; Inguinal Canal; Kaplan-Meier Estimate; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Penile Neoplasms; Penis; Taxoids | 2019 |
Presurgical induction chemotherapy for squamous cell carcinoma of the tonsil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Neck Dissection; Papillomavirus Infections; Preoperative Period; Retrospective Studies; Tonsillar Neoplasms | 2020 |
Predictive Factors for Completion of TPF Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis | 2019 |
[A case of far advanced-esophageal squamous cell carcinoma successfully treated with docetaxel].
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Male; Taxoids | 2013 |
Epidermal growth factor receptor targeting in head and neck cancer: have we been just skimming the surface?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Taxoids | 2013 |
VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Survival Rate; Taxoids; Vascular Endothelial Growth Factor A | 2013 |
Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2013 |
Elevated cyclin D1 expression is predictive for a benefit from TPF induction chemotherapy in oral squamous cell carcinoma patients with advanced nodal disease.
Topics: Aged; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclin D1; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Prognosis; Taxoids | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Increasing the therapeutic efficacy of docetaxel for cutaneous squamous cell carcinoma through the combined inhibition of phosphatidylinositol 3-kinase/AKT signalling and autophagy.
Topics: Analysis of Variance; Antimalarials; Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Chloroquine; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction; Skin Neoplasms; Taxoids; Tumor Cells, Cultured | 2013 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Mouth Neoplasms; Neck Dissection; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Rate; Taxoids; Young Adult | 2013 |
Chemotherapeutic alteration of VEGF, PDGF and PDGFRα/β expression under 5-FU vs. docetaxel in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Cell Transformation, Viral; Docetaxel; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Immunoenzyme Techniques; In Vitro Techniques; Papillomavirus Infections; Platelet-Derived Growth Factor; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Taxoids; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Efficacy and safety of concomitant chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced squamous cell head and neck cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Hedgehog targeting by cyclopamine suppresses head and neck squamous cell carcinoma and enhances chemotherapeutic effects.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Hedgehog Proteins; Humans; KB Cells; Keratins; Male; Molecular Targeted Therapy; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay; Veratrum Alkaloids | 2013 |
Unexpected alteration of β-catenin and c-KIT expression by 5-FU and docetaxel in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Topics: Antimetabolites; Antineoplastic Agents; beta Catenin; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Immunohistochemistry; Papillomavirus Infections; Proto-Oncogene Proteins c-kit; Signal Transduction; Taxoids; Wnt Signaling Pathway | 2013 |
Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Docetaxel; Doxorubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Male; MicroRNAs; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids | 2013 |
Acetylated tubulin (AT) as a prognostic marker in squamous cell carcinoma of the head and neck.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Squamous Cell Carcinoma of Head and Neck; Taxoids; Tubulin | 2014 |
ABO blood groups are not associated with treatment response and prognosis in patients with local advanced non- small cell lung cancer.
Topics: ABO Blood-Group System; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Taxoids | 2013 |
Locally advanced squamous cell carcinoma of the head and neck: CT texture and histogram analysis allow independent prediction of overall survival in patients treated with induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Contrast Media; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Risk Factors; Software; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Matched-Pair Analysis; Middle Aged; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Basic T1 Perfusion magnetic resonance imaging evaluation of the therapeutic effect of neoadjuvant chemotherapy in locally advanced cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Magnetic Resonance Angiography; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Taxoids; Uterine Cervical Neoplasms | 2013 |
[A case with double primary cancers in both lung and nasal cavity].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Fatal Outcome; Humans; Lung Neoplasms; Male; Nasal Cavity; Neoplasms, Multiple Primary; Nose Neoplasms; Taxoids | 2013 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Survival Analysis; Taxoids | 2013 |
The effectiveness of chemoradiation therapy and salvage surgery for hypopharyngeal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Induction Chemotherapy; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Retrospective Studies; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Taxoids; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2013 |
Effects of fusaric acid treatment on HEp2 and docetaxel-resistant HEp2 laryngeal squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Caspase 7; Caspase 9; Cell Line, Tumor; Cell Survival; Cytokines; Docetaxel; Drug Resistance, Neoplasm; Fusaric Acid; Humans; Laryngeal Neoplasms; Poly(ADP-ribose) Polymerases; Taxoids; Time Factors | 2013 |
Strategies for non-resectable head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deglutition Disorders; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Patient Care Team; Patient Selection; Practice Patterns, Physicians'; Radiotherapy, Intensity-Modulated; Speech Disorders; Survival Analysis; Taxoids; Treatment Outcome | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Ifosfamide; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
TPF induction chemotherapy and concomitant irradiation with cisplatin and cetuximab in unresectable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunotherapy; Induction Chemotherapy; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Prognosis; Squamous Cell Carcinoma of Head and Neck; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Culture Techniques; Cell Nucleus; Cetuximab; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2014 |
Radiation therapy with concurrent retrograde superselective intra-arterial chemotherapy for gingival carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Female; Gingival Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Staging; Organ Sparing Treatments; Survival Rate; Taxoids | 2014 |
Effects of chemotherapy on the parotid and submandibular glands in head and neck cancer patients treated with chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbon Radioisotopes; Carcinoma, Squamous Cell; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Humans; Induction Chemotherapy; Neoplasm Staging; Otorhinolaryngologic Neoplasms; Parotid Gland; Positron-Emission Tomography; Radiotherapy, Intensity-Modulated; Retrospective Studies; Submandibular Gland; Taxoids; Xerostomia | 2014 |
A case of NUT midline carcinoma with complete response to gemcitabine following cisplatin and docetaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Child; Cisplatin; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Humans; Nuclear Proteins; Oncogene Proteins, Fusion; Remission Induction; Taxoids; Thoracic Neoplasms | 2014 |
Sequential therapy of advanced buccal mucosa squamous cell carcinoma: three-year outcome.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Neck Dissection; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Retrospective Studies; Sex Factors; Taxoids | 2014 |
Simultaneous thrombosis of superior mesenteric artery and superior mesenteric vein following chemotherapy: MDCT findings.
Topics: Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Laryngeal Neoplasms; Mesenteric Artery, Superior; Mesenteric Veins; Multidetector Computed Tomography; Taxoids; Thrombosis; Venous Thrombosis | 2014 |
[A case of small-sized lung cancer complicated by sarcoidosis].
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Lung Diseases; Lung Neoplasms; Sarcoidosis; Taxoids | 2013 |
Concomitant chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy as definitive, first line treatment of squamous cell carcinoma of the head and neck. A retrospective single center analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Feasibility Studies; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Otorhinolaryngologic Neoplasms; Retrospective Studies; Taxoids | 2014 |
PI3K/PTEN/AKT/mTOR polymorphisms: association with clinical outcome in patients with head and neck squamous cell carcinoma receiving cetuximab-docetaxel.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cetuximab; Class I Phosphatidylinositol 3-Kinases; Docetaxel; Female; Genotype; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Squamous Cell Carcinoma of Head and Neck; Taxoids; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Proportional Hazards Models; Retrospective Studies; Taxoids | 2016 |
Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cisplatin; Docetaxel; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Eukaryotic Translation Initiation Factor 5A; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Peptide Initiation Factors; Proportional Hazards Models; Protein Binding; RNA Interference; RNA-Binding Proteins; RNA, Messenger; Signal Transduction; Taxoids; Time Factors; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics.
Topics: Anticholesteremic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Female; Head and Neck Neoplasms; Humans; KB Cells; Male; Neoplasm Staging; Risk Factors; Simvastatin; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2014 |
Concurrent chemoradiotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Remission Induction; Survival Rate; Taxoids | 2014 |
Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA Glycosylases; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2014 |
Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: analysis of therapeutic results in 112 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Mouth Neoplasms; Organ Sparing Treatments; Remission Induction; Survival Rate; Taxoids | 2014 |
Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Transport System ASC; Amino Acid Transport System y+; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Fusion Regulatory Protein 1, Heavy Chain; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Large Neutral Amino Acid-Transporter 1; Lymphatic Metastasis; Male; Middle Aged; Minor Histocompatibility Antigens; Neoplasm Proteins; Neoplasm Staging; Oxonic Acid; Prognosis; Taxoids; Tegafur; Tongue Neoplasms; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Complications; Prognosis; Survival Rate; Taxoids | 2014 |
A pyriform sinus cancer organ preservation strategy comprising induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil, followed by potentiated radiotherapy: a multicenter, retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Paranasal Sinus Neoplasms; Pyriform Sinus; Retrospective Studies; Taxoids | 2014 |
Effect of HIFU treatment on tumor targeting efficacy of docetaxel-loaded Pluronic nanoparticles.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Survival; Docetaxel; Drug Delivery Systems; High-Intensity Focused Ultrasound Ablation; Male; Mice; Neoplasm Transplantation; Poloxamer; Polysorbates; Soybean Oil; Taxoids; Treatment Outcome; Tumor Burden | 2014 |
Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Thoracic Neoplasms | 2014 |
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by surgery and concurrent chemoradiotherapy improves outcome of recurrent advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2014 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids | 2015 |
Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Endothelium, Vascular; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; ROC Curve; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2015 |
Risk and predictors for early radiation pneumonitis in patients with stage III non-small cell lung cancer treated with concurrent or sequential chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiation Pneumonitis; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Risk Factors; Taxoids; Vinblastine; Vinorelbine | 2014 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Effects of D-allose in combination with docetaxel in human head and neck cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Docetaxel; Glucose; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Taxoids | 2014 |
Antitumor Efficacy of Docetaxel-loaded Nanocarrier against Esophageal Cancer Cell Bearing Mice Model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Chitosan; Docetaxel; Drug Carriers; Drug Delivery Systems; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Male; Mice; Mice, Nude; Nanoparticles; Taxoids | 2015 |
Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Docetaxel; Fluorouracil; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2014 |
Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Doxorubicin; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck; Neoadjuvant Therapy; Neoplasm Staging; Shoulder; Survival Rate; Taxoids | 2015 |
PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carrier Proteins; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2014 |
Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Feasibility Studies; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Platinum; Prognosis; Pyrimidines; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Cell Count; Cell Line, Tumor; Cell Proliferation; Dipeptides; Docetaxel; Drug Therapy, Combination; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Mice; Mitochondrial Proteins; Neoplasms, Experimental; Squamous Cell Carcinoma of Head and Neck; Taxoids; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2015 |
Salvage surgery after local recurrence in patients with head and neck carcinoma treated with chemoradiotherapy or bioradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cohort Studies; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Pharyngeal Neoplasms; Retrospective Studies; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2015 |
Role of induction chemotherapy for N3 head and neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Pharyngeal Neoplasms; Radiotherapy; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2015 |
[Recurrence sites following definitive intensity-modulated conformational radiotherapy of squamous-cell carcinomas of the upper aerodigestive tract].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids | 2015 |
RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Retinoblastoma Protein; Survival Rate; Taxoids; Young Adult | 2015 |
EGR1 regulates radiation-induced apoptosis in head and neck squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Docetaxel; Early Growth Response Protein 1; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Immediate-Early; Humans; Hypopharyngeal Neoplasms; Kaplan-Meier Estimate; Laryngeal Neoplasms; Larynx; Male; Middle Aged; Neoplasm Proteins; Organ Sparing Treatments; Photons; Radiation Tolerance; RNA Interference; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Taxoids; Transfection | 2015 |
Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids | 2015 |
Management for squamous cell carcinoma of the nasal cavity and ethmoid sinus: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Endoscopy; Ethmoid Sinus; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Nasal Cavity; Neoplasm Staging; Nose Neoplasms; Organoplatinum Compounds; Otorhinolaryngologic Surgical Procedures; Paranasal Sinus Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2015 |
[Safe treatment of lung squamous cell carcinoma with nanoparticle albumin-bound Paclitaxel in a patient with a previous hypersensitivity reaction after docetaxel administration].
Topics: Albumins; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Hypersensitivity; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2015 |
Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Body Weight; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Carriers; Emulsions; Humans; Hyaluronic Acid; Lactams, Macrocyclic; Lactic Acid; Mice; Mice, Nude; Microscopy, Confocal; Nanoparticles; Oils; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Taxoids; Transplantation, Heterologous; Water | 2015 |
Age most significant predictor of requiring enteral feeding in head-and-neck cancer patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Enteral Nutrition; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids | 2015 |
Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Mice, Nude; Middle Aged; Taxoids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Effects of JWA, XRCC1 and BRCA1 mRNA expression on molecular staging for personalized therapy in patients with advanced esophageal squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Docetaxel; Esophageal Neoplasms; Female; Gene Expression; Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Transport Proteins; Middle Aged; Precision Medicine; Prognosis; Response Evaluation Criteria in Solid Tumors; RNA, Messenger; ROC Curve; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2015 |
Establishment and characterization of triple drug resistant head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Head and Neck Neoplasms; Humans; Multidrug Resistance-Associated Proteins; RNA, Messenger; Taxoids | 2015 |
Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma.
Topics: Aged; Apoptosis; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Energy Metabolism; Female; Fluorouracil; G2 Phase Cell Cycle Checkpoints; Gene Deletion; Gene Expression; Humans; Isoenzymes; L-Lactate Dehydrogenase; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Prognosis; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Head and Neck Neoplasms; Humans; Imidazoles; In Situ Nick-End Labeling; Inhibitor of Apoptosis Proteins; Lysosomal-Associated Membrane Protein 2; Membrane Proteins; Mice; Mice, Knockout; Mice, Nude; Microtubule-Associated Proteins; Mitochondria; Naphthoquinones; Phosphorylation; Retinoblastoma Protein; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Survivin; Tamoxifen; Taxoids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2015 |
Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Disease-Free Survival; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Quality of Life; Remission Induction; Taxoids; Time Factors; Tonsillar Neoplasms; Treatment Outcome | 2016 |
Squamous Cell Carcinoma of the Head and Neck: Comparison of Diffusion-weighted MRI at b-values of 1,000 and 2,000 s/mm(2) to Predict Response to Induction Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Diffusion Magnetic Resonance Imaging; Docetaxel; Female; Fluorouracil; Forecasting; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Induction Chemotherapy; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Pharyngeal Neoplasms; Remission Induction; Retrospective Studies; Sensitivity and Specificity; Taxoids; Tumor Burden | 2015 |
Comparative study of phosphorylated histone H2AX expressions in the cervical cancer patients of pre- and post-neoadjuvant chemotherapy. .
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Histones; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2015 |
Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2016 |
Olfaction in chemotherapy for head and neck malignancies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Controlled Before-After Studies; Differential Threshold; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Olfaction Disorders; Pharyngeal Neoplasms; Prospective Studies; Sensory Thresholds; Smoking; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2016 |
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; In Vitro Techniques; Inhibitor of Apoptosis Proteins; Male; MAP Kinase Kinase Kinases; Middle Aged; Neoplasm Proteins; Radiation Tolerance; RNA, Messenger; ROC Curve; Taxoids; Ubiquitin-Protein Ligases; Zearalenone | 2015 |
Stemness and chemotherapeutic drug resistance induced by EIF5A2 overexpression in esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Eukaryotic Translation Initiation Factor 5A; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Stem Cells; Paclitaxel; Peptide Initiation Factors; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Taxoids | 2015 |
Rebamipide does not interfere with the antitumor effect of radiotherapy or chemotherapy in human oral tumor-bearing nude mice.
Topics: Alanine; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Disease Models, Animal; Docetaxel; Drug Interactions; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinolones; Radiotherapy; Stomatitis; Taxoids | 2015 |
Nutritional status and feeding-tube placement in patients with locally advanced hypopharyngeal cancer included in an induction chemotherapy-based larynx preservation program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Enteral Nutrition; Female; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Induction Chemotherapy; Intubation, Gastrointestinal; Male; Middle Aged; Nutritional Status; Organ Sparing Treatments; Retrospective Studies; Taxoids | 2016 |
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Taxoids; Treatment Outcome | 2015 |
Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Intensity-Modulated; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Time Factors | 2015 |
Nedaplatin: a new platinum for squamous lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2015 |
STAT3 blockade enhances the efficacy of conventional chemotherapeutic agents by eradicating head neck stemloid cancer cell.
Topics: Aminosalicylic Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Self Renewal; Cell Survival; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Fluorouracil; Head and Neck Neoplasms; Humans; Mice, Knockout; Mice, Nude; Neoplastic Stem Cells; Phenotype; Phosphorylation; Side-Population Cells; Squamous Cell Carcinoma of Head and Neck; STAT3 Transcription Factor; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
High expression of stathmin 1 is a strong prognostic marker in oral squamous cell carcinoma patients treated by docetaxel-containing regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Gene Expression; Humans; Immunohistochemistry; Male; Middle Aged; Mouth Neoplasms; Multivariate Analysis; Neoplasm Staging; Prognosis; Stathmin; Survival Analysis; Taxoids; Treatment Outcome | 2017 |
Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Image Interpretation, Computer-Assisted; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Concentration-dependent radiosensitizing effect of docetaxel in esophageal squamous cell carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Checkpoints; Cell Division; Cell Line, Tumor; DNA Breaks, Double-Stranded; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Taxoids | 2016 |
Induction docetaxel and S-1 followed by concomitant radiotherapy with low-dose daily cisplatin in locally advanced head and neck carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Oxonic Acid; Taxoids; Tegafur; Young Adult | 2016 |
Planned Esophagectomy after Neoadjuvant Hyperthermo-Chemoradiotherapy using Weekly Low-Dose Docetaxel and Hyperthermia for Advanced Esophageal Carcinomas.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagitis; Female; Humans; Hyperthermia, Induced; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cohort Studies; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Esophagus; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Retrospective Studies; Taxoids; Treatment Outcome | 2015 |
Comparison of Definitive Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Drug Combinations; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Male; Oxonic Acid; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Tegafur | 2016 |
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Humans; Immunosuppressive Agents; Immunotherapy; Lung Neoplasms; Nivolumab; Practice Guidelines as Topic; Survival Rate; Taxoids | 2016 |
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Docetaxel; Eye; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Medical Records; Middle Aged; Nasal Cavity; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Nose Neoplasms; Organ Sparing Treatments; Paranasal Sinus Neoplasms; Proportional Hazards Models; Retrospective Studies; Risk Factors; Squamous Cell Carcinoma of Head and Neck; Survival Rate; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2016 |
Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Early Detection of Cancer; Endoscopy, Digestive System; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Retrospective Studies; Taxoids; Treatment Outcome | 2017 |
Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Areca; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Smoking; Survival Rate; Taxoids | 2016 |
Retrograde intra-arterial chemotherapy and daily concurrent proton beam therapy for recurrent oral cavity squamous cell carcinoma: Analysis of therapeutic results in 46 cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Cohort Studies; Computed Tomography Angiography; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Imaging, Three-Dimensional; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Prognosis; Proton Therapy; Retrospective Studies; Risk Assessment; Squamous Cell Carcinoma of Head and Neck; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Outcome | 2016 |
Efficacy and Safety Assessment of Paclitaxel in Patients with Docetaxel-Resistant Esophageal Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Combined microwave ablation and systemic chemotherapy for liver metastases from oesophageal cancer: Preliminary results and literature review.
Topics: Ablation Techniques; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Microwaves; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome; Ultrasonography | 2016 |
[Maxillary Cancer with Metastasis to the Rouviere Nodes -- Complete Response to Chemoradiotherapy Using a Selective Intra-Arterial Infusion Technique].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Male; Maxillary Neoplasms; Organoplatinum Compounds; Remission Induction; Taxoids | 2016 |
Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Prognosis; Retrospective Studies; Survival Analysis; Taxoids | 2016 |
NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Self Renewal; Cisplatin; Diamines; Docetaxel; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Receptor, Notch1; RNA, Small Interfering; Taxoids; Thiazoles; Xenograft Model Antitumor Assays | 2016 |
Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Frail Elderly; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Taxoids | 2016 |
Expression of BRCA1, a factor closely associated with relapse-free survival, in patients who underwent neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil for squamous cell carcinoma of the esophagus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Gene Expression; Genetic Association Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids | 2017 |
Optimizing particle size of docetaxel-loaded micelles for enhanced treatment of oral epidermoid carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Delivery Systems; Humans; Mice; Micelles; Mouth Neoplasms; Particle Size; Polyethylene Glycols; Taxoids | 2016 |
Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Pneumonia; Propensity Score; Taxoids; Thrombocytopenia | 2016 |
Dynamic changes in immune cell profile in head and neck squamous cell carcinoma: Immunomodulatory effects of chemotherapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; CD8-Positive T-Lymphocytes; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunologic Memory; Lymphocyte Activation; Male; Middle Aged; Squamous Cell Carcinoma of Head and Neck; T-Lymphocytes, Regulatory; Taxoids | 2016 |
[Primary Squamous Cell Carcinoma of the Prostate in which Docetaxel Therapy was Effective : A Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Prostatic Neoplasms; Taxoids | 2016 |
The Expression of Checkpoint and DNA Repair Genes in Head and Neck Cancer as Possible Predictive Factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; DNA Damage; DNA Repair; Docetaxel; Down-Regulation; Female; Fluorodeoxyglucose F18; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Radiotherapy Dosage; Squamous Cell Carcinoma of Head and Neck; Taxoids; Up-Regulation | 2017 |
Fibronectin protects lung cancer cells against docetaxel-induced apoptosis by promoting Src and caspase-8 phosphorylation.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Caspase 8; Cell Proliferation; Docetaxel; Female; Fibronectins; Flow Cytometry; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; Neoplasm Staging; Phosphorylation; Prognosis; Proto-Oncogene Proteins pp60(c-src); Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
[Clinical analysis of multimodal treatment for orbital organ preservation in T4b squamous cell carcinoma of nasal cavity and paranasal sinuses].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; ErbB Receptors; Female; Fluorouracil; Humans; Induction Chemotherapy; Male; Middle Aged; Nasal Cavity; Nose Neoplasms; Organ Sparing Treatments; Paranasal Sinus Neoplasms; Quality of Life; Radiation Injuries; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2016 |
ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Taxoids | 2016 |
Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-sma
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Staging; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pemetrexed; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; Young Adult | 2016 |
The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Retrospective Studies; Taxoids; Tumor Suppressor Protein p53 | 2017 |
Clinical and Histologic Predictive Factors of Response to Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Cyclin-Dependent Kinase Inhibitor p16; Docetaxel; Female; Fluorouracil; France; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Lymphocytes; Male; Middle Aged; Neutrophils; Predictive Value of Tests; Prognosis; Taxoids; Tumor Suppressor Protein p53 | 2016 |
Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cytokines; Docetaxel; Dose Fractionation, Radiation; Fluorouracil; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Interleukin-1beta; Interleukin-6; Laryngeal Neoplasms; Mouth Neoplasms; Nasopharyngeal Neoplasms; Oropharyngeal Neoplasms; Prospective Studies; Radiotherapy, Intensity-Modulated; Saliva; Severity of Illness Index; Stomatitis; Taxoids; Time Factors; Tumor Necrosis Factor-alpha | 2016 |
[A Case of Synchronous Esophageal and Gastric Cancer Successfully Treated Using Multimodal Therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Drug Combinations; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrectomy; Humans; Male; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2016 |
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Immunoenzyme Techniques; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Taxoids; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2017 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Docetaxel; Fluorouracil; Humans; Induction Chemotherapy; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Male; Mediastinum; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Oropharyngeal Neoplasms; Positron Emission Tomography Computed Tomography; Precision Medicine; Radiotherapy, Intensity-Modulated; Receptor, ErbB-2; Taxoids; Tomography, X-Ray Computed; Trastuzumab | 2017 |
Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
Topics: Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Resistance, Neoplasm; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Polyethylene Glycols; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2017 |
Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Period; Preoperative Care; Prognosis; Prospective Studies; Taxoids; Treatment Outcome | 2017 |
[CR of All Target Lesions in a Patient with Metastatic Esophageal Cancer and Generalized Weakness Treated with Systemic Chemotherapy after Nutritional Support].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoplasm Metastasis; Parenteral Nutrition; Taxoids | 2016 |
A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cyclooctanes; Docetaxel; Dose-Response Relationship, Drug; Drug Combinations; Drug Compounding; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Emulsions; Esophageal Neoplasms; Humans; Inhibitory Concentration 50; Lignans; Mice, Inbred BALB C; Mice, Nude; Particle Size; Polycyclic Compounds; Solubility; Surface Properties; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
[Long-Term Complete Response in Postoperative Multiple Lung and Mediastinal Lymph Node Metastases of Esophageal Cancer Using Systemic Chemotherapy with DCF Treatment - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Recurrence; Taxoids; Time Factors; Treatment Outcome | 2017 |
Different functions of DEPTOR in modulating sensitivity to chemotherapy for esophageal squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Survivin; Taxoids | 2017 |
Development of taxane resistance in a panel of human lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bridged-Ring Compounds; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Survival; Docetaxel; Drug Combinations; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Taxoids | 2008 |
Pre-treatment haemoglobin level predicts response and survival after TPF induction polychemotherapy in advanced head and neck cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Hemoglobins; Humans; Male; Middle Aged; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Treatment for lung metastasis from head and neck squamous cell carcinoma: a preliminary study of docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Tolerance; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pilot Projects; Prognosis; Retrospective Studies; Taxoids | 2008 |
Effect of docetaxel on the surgical tumor microenvironment of head and neck cancer in murine models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Injections, Intralesional; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Transplantation; Otorhinolaryngologic Neoplasms; Pilot Projects; Salivary Gland Neoplasms; Taxoids; Tumor Burden; Wound Healing | 2008 |
[Combination chemotherapy with carboplatin and docetaxel for elderly patients with non-small-cell lung cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Humans; Lung Neoplasms; Male; Retrospective Studies; Taxoids | 2008 |
In vitro effect of radiation, antibody to epidermal growth factor receptor and Docetaxel in human head and neck squamous carcinoma cells with mutant P53 and over-expressed EGFR.
Topics: Antibodies, Monoclonal; Carcinoma, Squamous Cell; Cell Cycle; Cell Death; Cell Line, Tumor; Combined Modality Therapy; DNA, Complementary; Docetaxel; ErbB Receptors; Gene Expression Profiling; Gene Expression Regulation; Head and Neck Neoplasms; Humans; Oligonucleotide Array Sequence Analysis; Taxoids; Tumor Suppressor Protein p53 | 2009 |
Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Docetaxel; Endothelial Cells; Female; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Piperidines; Quinazolines; Taxoids; Xenograft Model Antitumor Assays | 2008 |
MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Gene Frequency; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Taxoids | 2009 |
Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Probability; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Targeting beta1 integrin restores sensitivity to docetaxel of esophageal squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Integrin beta1; Models, Biological; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Taxoids | 2008 |
Local control and survival following concomitant chemoradiotherapy in inoperable stage I non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Dose Fractionation, Radiation; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Conformal; Regression Analysis; Retrospective Studies; Survival Rate; Taxoids | 2009 |
Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Gene Amplification; Genes, erbB-2; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Remission Induction; Taxoids | 2009 |
Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cause of Death; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Male; Middle Aged; Mucositis; Neoadjuvant Therapy; Neoplasm Staging; Oropharyngeal Neoplasms; Radiotherapy Dosage; Retrospective Studies; Taxoids | 2010 |
Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunohistochemistry; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Tubulin; Tumor Suppressor Protein p53 | 2009 |
Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2009 |
[A case of the oldest old patient with advanced esophageal cancer responding completely to the combination chemotherapy of docetaxel/5-fluorouracil/nedaplatin with radiation].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Organoplatinum Compounds; Taxoids | 2009 |
[A squamous cell lung cancer patient who developed immune hemolytic anemia after gemcitabine and docetaxel administration].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Prednisone; Taxoids | 2009 |
Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Taxoids; Tumor Burden | 2010 |
Ubiquitin-conjugating enzyme UBE2Q2 suppresses cell proliferation and is down-regulated in recurrent head and neck cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; Chlorocebus aethiops; Cisplatin; COS Cells; Cytoskeletal Proteins; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; HeLa Cells; Humans; Immunohistochemistry; Mice; NIH 3T3 Cells; Signal Transduction; src-Family Kinases; Taxoids; Ubiquitin-Conjugating Enzymes | 2009 |
Radiotherapy and concomitant intra-arterial docetaxel combined with systemic 5-fluorouracil and cisplatin for oropharyngeal cancer: a preliminary report--improvement of locoregional control of oropharyngeal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Leukopenia; Male; Middle Aged; Mucositis; Oropharyngeal Neoplasms; Radiodermatitis; Radiotherapy Dosage; Remission Induction; Taxoids | 2009 |
Heterogeneity of epithelial and stromal cells of head and neck squamous cell carcinomas in ex vivo chemoresponse.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epithelial Cells; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Stromal Cells; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2010 |
A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Clinical Protocols; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; France; Head and Neck Neoplasms; Hospitalization; Humans; Male; Middle Aged; Radiodermatitis; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Stomatitis; Taxoids; Weight Loss | 2010 |
Successful treatment of syncope with chemotherapy irresponsive to cardiac pacemaker in head and neck cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pacemaker, Artificial; Radiography; Syncope; Taxoids; Tonsillar Neoplasms | 2009 |
Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Disease-Free Survival; Docetaxel; Exanthema; Female; Genes, erbB-1; Head and Neck Neoplasms; Humans; Male; Middle Aged; Polymorphism, Genetic; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Flow Cytometry; Humans; KB Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Taxoids; Vincristine; Xenograft Model Antitumor Assays | 2009 |
Does dexamethasone inhibit the antineoplastic effect of cisplatin and docetaxel in head and neck cancer cells?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Dexamethasone; Docetaxel; Drug Interactions; Head and Neck Neoplasms; Humans; Taxoids | 2010 |
A case of esophageal cancer with multiple lymph node metastases which responded to neoadjuvant chemotherapy (DCF therapy).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Taxoids | 2010 |
[Histological complete response in a case of primary squamous cell carcinoma of the stomach treated by chemotherapy with docetaxel and cisplatin plus 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Endoscopy, Gastrointestinal; Fluorouracil; Humans; Male; Stomach Neoplasms; Taxoids | 2010 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
Adjuvant cisplatin and docetaxel for non-small cell lung cancer: the Hospital of the University of Pennsylvania experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Pre-radiation enhances the cytotoxicity of docetaxel in head and neck squamous cell carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Head and Neck Neoplasms; Humans; Mutation; Radiotherapy, Adjuvant; Taxoids; Time Factors; Tumor Suppressor Protein p53 | 2010 |
Reirradiation with alternating docetaxel-based chemotherapy for recurrent head and neck squamous cell carcinoma: update of a single-center prospective phase II protocol.
Topics: Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage; Survival Analysis; Taxoids | 2010 |
A docetaxel-induced rash on a radiotherapy port.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Male; Middle Aged; Radiodermatitis; Taxoids; Tonsillar Neoplasms | 2010 |
XRP6258-induced gene expression patterns in head and neck cancer carcinoma.
Topics: Annexin A5; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cyclin A; Cyclin B1; Docetaxel; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Phosphorylation; Taxoids; Tumor Cells, Cultured | 2010 |
Organ preservation with daily concurrent chemoradiotherapy using superselective intra-arterial infusion via a superficial temporal artery for T3 and T4 head and neck cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Temporal Arteries; Treatment Outcome | 2011 |
Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Taxoids | 2010 |
Superselective intra-arterial chemoradiotherapy with docetaxel-nedaplatin for advanced oral cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Leukopenia; Male; Middle Aged; Mouth Neoplasms; Mucositis; Organoplatinum Compounds; Prognosis; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Docetaxel as a component in the combined therapy of locally advanced squamous cell carcinoma of the glottis and oral cavity].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Glottis; Humans; Kaplan-Meier Estimate; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Platinum Compounds; Radiotherapy, Adjuvant; Taxoids; Treatment Outcome | 2010 |
Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Persistent Krüppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Adhesion; Cell Movement; Cell Proliferation; Cisplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
[Early prediction of treatment response by serum CRP levels in patients with advanced esophageal cancer who underwent definitive chemoradiotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; C-Reactive Protein; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Retrospective Studies; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2010 |
[Successful treatment of advanced esophageal cancer with lymph node metastases by docetaxel, cisplatin and 5-FU followed by salvage lymphadenectomy--a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Salvage Therapy; Taxoids | 2010 |
Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. Early r
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Docetaxel; Feasibility Studies; Female; Follow-Up Studies; Humans; Hypopharyngeal Neoplasms; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Kaplan-Meier Estimate; Laryngeal Neoplasms; Leukopenia; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging; Opportunistic Infections; Paclitaxel; Positron-Emission Tomography; Radiodermatitis; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Salvage Therapy; Taxoids; Thrombocytopenia; Tomography, X-Ray Computed; Tongue Neoplasms; Treatment Outcome | 2011 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Docetaxel; Drug Administration Schedule; Fluorouracil; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasms, Squamous Cell; Neutropenia; Oropharyngeal Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome; Vomiting | 2010 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Randomized Controlled Trials as Topic; Taxoids; Time Factors | 2011 |
How does TPF improve survival over PF?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Disease-Free Survival; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Lost to Follow-Up; Randomized Controlled Trials as Topic; Research Design; Taxoids | 2011 |
Second-line chemotherapy in patients with primary unknown cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Failure; Treatment Outcome | 2011 |
MicroRNA expression profiles of head and neck squamous cell carcinoma with docetaxel-induced multidrug resistance.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; MicroRNAs; Neoplasms, Squamous Cell; Pharmacogenetics; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2011 |
[Evaluation of combination chemotherapy with oral S-1 administration followed by docetaxel by superselective intra-arterial infusion for patients with oral squamous cell carcinomas].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cerebral Infarction; Docetaxel; Drug Combinations; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Neutropenia; Oxonic Acid; Taxoids; Tegafur | 2011 |
Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Remission Induction; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2011 |
Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: characteristics of long-term survivors after concurrent chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neck; Neoplasm Staging; Prognosis; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Taxoids | 2011 |
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Enteral Nutrition; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Radiation-Sensitizing Agents; Taxoids; Weight Loss | 2011 |
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2011 |
Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis.
Topics: Amputation, Surgical; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fluorouracil; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Panitumumab; Penile Neoplasms; Positron-Emission Tomography; Sentinel Lymph Node Biopsy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Repair; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Polymorphism, Single Nucleotide; Proportional Hazards Models; Regression Analysis; Survival Rate; Taxoids | 2012 |
Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2011 |
Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report.
Topics: Antineoplastic Agents; Beverages; Carcinoma, Squamous Cell; Citrus paradisi; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Esophageal Neoplasms; Female; Food-Drug Interactions; Humans; Middle Aged; Taxoids | 2011 |
Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; DNA Repair; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Polymorphism, Genetic; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2011 |
Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calcium-Binding Proteins; Carcinoma, Squamous Cell; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Dasatinib; Docetaxel; Drug Synergism; Esophageal Neoplasms; Female; Humans; Mad2 Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Repressor Proteins; src-Family Kinases; Taxoids; Thiazoles; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Combined chemotherapy with cisplatin, docetaxel and capecitabine for metastatic nasopharyngeal carcinoma: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Retrospective Studies; Taxoids | 2011 |
[Complete response in a patient with liver metastasis of esophageal squamous cell carcinoma treated with docetaxel].
Topics: Aged; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Liver Neoplasms; Male; Taxoids; Tomography, X-Ray Computed | 2011 |
Optimizing treatments of locally advanced squamous cell carcinoma: where to go from here?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2011 |
mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Poly-ADP-Ribose Binding Proteins; Protein Inhibitors of Activated STAT; Retrospective Studies; RNA, Messenger; Small Ubiquitin-Related Modifier Proteins; Stomach Neoplasms; Taxoids | 2011 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome | 2012 |
Lung cyst caused by centrally located bronchogenic carcinoma.
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cough; Cysts; Docetaxel; Fatal Outcome; Hemoptysis; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Smoking; Taxoids; Tomography, X-Ray Computed | 2012 |
Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cohort Studies; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Middle Aged; Radioimmunotherapy; Radiotherapy; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Taxoids; Treatment Outcome | 2011 |
Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Docetaxel; ErbB Receptors; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Receptor, ErbB-2; Receptor, ErbB-3; Survival Rate; Taxoids; Tumor Suppressor Protein p53 | 2012 |
Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Monitoring; Fever; Fluorouracil; Head and Neck Neoplasms; Humans; Incidence; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Neutropenia; Severity of Illness Index; Survival Analysis; Taiwan; Taxoids | 2012 |
Neoadjuvant chemotherapy prior to surgery in head and neck cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids | 2012 |
Epidermal growth factor receptor mutations in small cell lung cancer patients who received surgical resection in China.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; China; Combined Modality Therapy; Cranial Irradiation; Docetaxel; Endostatins; Exons; Female; Genes, erbB-1; Humans; Incidental Findings; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Pneumonectomy; Recombinant Proteins; Smoking; Taxoids; Young Adult | 2012 |
Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cost-Benefit Analysis; Decision Support Techniques; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Induction Chemotherapy; Markov Chains; Monte Carlo Method; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Survival Analysis; Taxoids | 2012 |
Hand and foot syndrome associated with docetaxel treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Foot Dermatoses; Hand Dermatoses; Humans; Taxoids; Treatment Outcome | 2012 |
Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cells, Cultured; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gossypol; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Neovascularization, Physiologic; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
[A case of docetaxel-induced acute lung injury refractory to treatment].
Topics: Acute Lung Injury; Carcinoma, Squamous Cell; Critical Care; Docetaxel; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Tomography, X-Ray Computed | 2012 |
Treatment of oropharyngeal squamous cell carcinoma with IMRT: patterns of failure after concurrent chemoradiotherapy and sequential therapy.
Topics: Aged; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oropharyngeal Neoplasms; Paclitaxel; Panitumumab; Papillomavirus Infections; Proportional Hazards Models; Radiation Tolerance; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids; Treatment Failure | 2012 |
Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; ErbB Receptors; Fatal Outcome; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index; Smoking; Taxoids; Tomography, X-Ray Computed | 2012 |
[Refractory thrombotic thrombocytopenic purpura revealing an epiglotis neoplasia].
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Epiglottis; Fluorouracil; Humans; Laryngeal Neoplasms; Male; Middle Aged; Plasma Exchange; Plasmapheresis; Platelet Count; Purpura, Thrombotic Thrombocytopenic; Rituximab; Taxoids; Vitamin B 12; Vitamins | 2012 |
Combination of docetaxel and cetuximab for penile cancer: a case report and literature review.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Docetaxel; Drug Administration Schedule; Fluorodeoxyglucose F18; Humans; Male; Penile Neoplasms; Positron-Emission Tomography; Taxoids; Treatment Outcome | 2012 |
[A successful resected case of advanced esophageal cancer with early gastric cancer responding to neoadjuvant chemotherapy of docetaxel, CDDP and 5-FU].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Multiple Primary; Stomach Neoplasms; Taxoids | 2012 |
Thermochemoradiation therapy using superselective intra-arterial infusion via superficial temporal and occipital arteries for oral cancer with N3 cervical lymph node metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheter Ablation; Cerebral Arteries; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Mouth Neoplasms; Neck; Neck Dissection; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Taxoids; Temporal Arteries | 2012 |
Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Synergism; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Quinolones; ras Proteins; Signal Transduction; Taxoids | 2013 |
The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Organoplatinum Compounds; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Case involving long-term survival after esophageal cancer with liver and lung metastases treated by multidisciplinary therapy: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Catheter Ablation; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Taxoids; Time Factors | 2013 |
Platinum-based combination chemotherapy for the treatment of advanced-stage squamous cell carcinoma of the vulva.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; HIV; HIV Infections; Humans; Middle Aged; Paclitaxel; Remission Induction; Taxoids; Vulvar Neoplasms | 2012 |
Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma.
Topics: Aged; Aldehyde Dehydrogenase 1 Family; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Case-Control Studies; Chi-Square Distribution; Cisplatin; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Hyaluronan Receptors; Isoenzymes; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Proportional Hazards Models; Retinal Dehydrogenase; Retrospective Studies; Taxoids | 2013 |
Multi-institutional analysis of early glottic cancer from 2000 to 2005.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Glottis; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Tegafur; Time Factors; Uracil | 2012 |
Outcomes following chemoradiotherapy for N3 head and neck squamous cell carcinoma without a planned neck dissection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Lymph Nodes; Male; Middle Aged; Neck Dissection; Neoplasm Staging; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
Combined intra-arterial infusion and systemic chemoradiotherapy for stage IV squamous cell carcinoma of the mandibular gingiva.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Gingival Neoplasms; Humans; Infusions, Intra-Arterial; Male; Mandible; Middle Aged; Taxoids; Treatment Outcome | 2012 |
RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Female; Hexosyltransferases; Humans; Male; Neoadjuvant Therapy; Proteasome Endopeptidase Complex; Taxoids | 2012 |
Radiology quiz case 2. Docetaxel (Taxotere)-induced photosensitivity.
Topics: Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Follow-Up Studies; Glottis; Humans; Laryngeal Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Invasiveness; Neoplasm Staging; Parotid Neoplasms; Photosensitivity Disorders; Positron-Emission Tomography; Radiosurgery; Risk Assessment; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Efficacy of multidrug superselective intra-arterial chemotherapy (docetaxel, cisplatin, and 5-fluorouracil) using the Seldinger technique for tongue cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Radiotherapy, Adjuvant; Risk Assessment; Salvage Therapy; Survival Analysis; Taxoids; Tongue; Tongue Neoplasms; Treatment Outcome | 2012 |
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Goserelin; Humans; Lymph Node Excision; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2012 |
Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chromatography, Liquid; Cisplatin; Deoxycytidine; Docetaxel; Electrophoresis, Gel, Two-Dimensional; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Proteomics; Radiotherapy, Intensity-Modulated; Tandem Mass Spectrometry; Taxoids; Vinblastine; Vinorelbine | 2013 |
Laryngeal preservation in advanced piriform sinus squamous cell carcinomas using superselective intra-arterial chemoradiation therapy with three agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Infusions, Intra-Arterial; Larynx; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Pyriform Sinus; Survival Rate; Taxoids | 2013 |
[Efficacy of docetaxel and nedaplatin combined with concurrent intensity modulated radiation therapy in the treatment of esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagitis; Female; Fluorouracil; Follow-Up Studies; Humans; Male; Middle Aged; Organoplatinum Compounds; Radiotherapy, Intensity-Modulated; Remission Induction; Survival Rate; Taxoids; Vomiting | 2012 |
Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Hospitals, High-Volume; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2013 |
[A case of effective chemoradiotherapy using docetaxel and nedaplatin for recurrent anal canal squamous cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Docetaxel; Female; Humans; Organoplatinum Compounds; Recurrence; Taxoids | 2013 |
BRCA1 mRNA expression as a predictive and prognostic marker in advanced esophageal squamous cell carcinoma treated with cisplatin- or docetaxel-based chemotherapy/chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids | 2013 |
Larynx preservation for patients with locally advanced laryngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Cisplatin; Docetaxel; Fluorouracil; Hoarseness; Humans; Induction Chemotherapy; Laryngeal Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organ Sparing Treatments; Smoking; Smoking Cessation; Taxoids; Treatment Outcome; Vocal Cords; Xerostomia | 2013 |
Hypofractionated palliative radiotherapy for advanced head and neck cancer: the IHF2SQ regimen.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Docetaxel; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Palliative Care; Radiotherapy; Retrospective Studies; Sex Factors; Taxoids | 2013 |
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Endosonography; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Thoracic Neoplasms; Tomography, X-Ray Computed | 2013 |
The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasms; Paclitaxel; Taxoids | 2002 |
[Therapeutic strategy for a patient suffering from a peripheral pulmonary tumor in the right upper lobe and an endotracheal tumor in the carina].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Humans; Laser Therapy; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Pneumonectomy; Taxoids; Tracheal Neoplasms | 2002 |
Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Squamous Cell; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
[A case of hypopharyngeal carcinoma in which a complete response to chemotherapy was achieved with docetaxel, cisplatin, 5-FU and levofolinate].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Leucovorin; Male; Paclitaxel; Remission Induction; Taxoids | 2002 |
Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot.
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; DNA Primers; Docetaxel; Endothelial Growth Factors; fas Receptor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
A third-generation matrix metalloproteinase (MMP) inhibitor (ONO-4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP-expressing tumor cells in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Drug Therapy, Combination; Humans; In Vitro Techniques; Injections, Intravenous; Lung Neoplasms; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Paclitaxel; Phenyl Ethers; Survival Rate; Taxoids | 2003 |
Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Dose Fractionation, Radiation; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Leucovorin; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2003 |
[Two patients with distant metastases from head and neck squamous cell carcinomas successfully treated with docetaxel and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Paclitaxel; Remission Induction; Taxoids | 2003 |
Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids | 2003 |
Additive effects of radiation and docetaxel on murine SCCVII tumors in vivo: special reference to changes in the cell cycle.
Topics: Animals; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Ki-67 Antigen; Male; Mice; Mice, Inbred C3H; Mitosis; Paclitaxel; Taxoids | 2003 |
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Dacryocystorhinostomy; Docetaxel; Drainage; Esophageal Neoplasms; Female; Humans; Intubation; Lacrimal Duct Obstruction; Lung Neoplasms; Male; Middle Aged; Nasolacrimal Duct; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Taxoids; Texas | 2003 |
[A case of posterior wall cancer of the hypopharynx treated with docetaxel followed by radiation].
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Female; Humans; Hypopharyngeal Neoplasms; Paclitaxel; Taxoids | 2003 |
Antitumor effects of epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Coloring Agents; DNA-Binding Proteins; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotides, Antisense; Phosphotyrosine; Signal Transduction; STAT3 Transcription Factor; Taxoids; Tetrazolium Salts; Thiazoles; Time Factors; Trans-Activators; Vascular Endothelial Growth Factor A | 2003 |
[A case of a 91-year-old woman with maxillary sinus carcinoma who achieved a complete response to chemoradiotherapy with intra-arterial administration of docetaxel].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Maxillary Sinus Neoplasms; Remission Induction; Taxoids | 2003 |
Reply to "Radiation pneumonitis and docetaxel".
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lung Neoplasms; Radiation Pneumonitis; Radiotherapy; Survival Rate; Taxoids | 2004 |
[A clinical study of neoadjuvant radiochemotherapy with docetaxel and cisplatin for oral cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Neutropenia; Radiotherapy Dosage; Radiotherapy, Adjuvant; Stomatitis; Taxoids | 2003 |
[A case of pulmonary metastases from laryngeal cancer showing a complete response to chemotherapy with docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Laryngeal Neoplasms; Lung Neoplasms; Male; Middle Aged; Remission Induction; Taxoids | 2004 |
[Metastatic oropharyngeal cancer successfully treated with docetaxel, cisplatin, 5-FU and l-leucovorin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Oropharyngeal Neoplasms; Remission Induction; Taxoids | 2004 |
[Complete remission of locally advanced squamous cell lung cancer induced by chemotherapy with cisplatin and docetaxel].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Lymph Node Excision; Male; Mediastinum; Pneumonectomy; Remission Induction; Taxoids | 2004 |
A case of radiation recall mucositis associated with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Humans; Inflammation; Male; Middle Aged; Mucous Membrane; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy, Adjuvant; Taxoids; Tongue Neoplasms | 2004 |
Low dose fractionated radiation potentiates the effects of taxotere in nude mice xenografts of squamous cell carcinoma of head and neck.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Cytochromes c; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; G2 Phase; Head and Neck Neoplasms; Immunohistochemistry; In Situ Nick-End Labeling; Kinetics; Mice; Mice, Nude; Microscopy, Fluorescence; Mitosis; Neoplasm Transplantation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation-Sensitizing Agents; Taxoids; Time Factors; Up-Regulation | 2004 |
Use of LeVeen pleuroperitoneal shunt for refractory high-volume chylothorax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chylothorax; Cisplatin; Combined Modality Therapy; Docetaxel; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Fluorouracil; Humans; Ligation; Male; Middle Aged; Neoplasm Metastasis; Parenteral Nutrition, Total; Peritoneovenous Shunt; Pleural Effusion; Postoperative Complications; Respiration, Artificial; Taxoids; Thoracostomy; Thoracotomy; Tissue Adhesives | 2004 |
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for tongue cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Fluorouracil; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Remission Induction; Taxoids; Tongue Neoplasms | 2004 |
Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bridged-Ring Compounds; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Enterovirus; Genetic Therapy; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Protein Biosynthesis; Taxoids; Transduction, Genetic; Tumor Suppressor Protein p53 | 2004 |
Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cervical Vertebrae; Docetaxel; Female; Humans; Mediastinal Neoplasms; Mediastinum; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Spinal Neoplasms; Taxoids; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
[A case of oropharyngeal cancer with multiple bone metastases from prostate cancer that responded to docetaxel, ifosfamide and cisplatin combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Male; Oropharyngeal Neoplasms; Prostatic Neoplasms; Quality of Life; Taxoids | 2005 |
Involvement of NF-kappaB and mitochondrial pathways in docetaxel-induced apoptosis of human oral squamous cell carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Squamous Cell; Caspase 8; Caspases; Cytochromes c; Docetaxel; Humans; Membrane Potentials; Mitochondria; Mouth Neoplasms; NF-kappa B; Reactive Oxygen Species; Taxoids; Tumor Cells, Cultured | 2005 |
[Combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF), and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Head and Neck Neoplasms; Humans; Taxoids | 2005 |
Persistent serpentine supravenous hyperpigmented eruption associated with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Arm; Carcinoma, Squamous Cell; Docetaxel; Drug Eruptions; Humans; Hyperpigmentation; Lung Neoplasms; Male; Middle Aged; Taxoids; Veins | 2005 |
An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Chromatography, High Pressure Liquid; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Taxoids | 2005 |
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids | 2005 |
Combination docetaxel plus vitamin D(3) as an immune therapy in animals bearing squamous cell carcinomas.
Topics: Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Count; Cholecalciferol; Dendritic Cells; Disease Models, Animal; Docetaxel; Drug Therapy, Combination; Interferon-gamma; Lymph Nodes; Mice; Spleen; Stem Cells; T-Lymphocytes; Taxoids; Vitamins | 2005 |
[The docetaxel radiosensitization experience for the treatment of unresectable esophageal cancer].
Topics: Aged; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids | 2005 |
Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cisplatin; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; In Vitro Techniques; Pilot Projects; Signal Transduction; Taxoids; Thrombospondins | 2005 |
[Intra-arterial chemotherapy for head and neck cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Infusions, Intra-Arterial; Radiotherapy Dosage; Taxoids | 2005 |
[Combination therapy with TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2005 |
Radiation therapy for T2N0 laryngeal cancer: A retrospective analysis for the impact of concurrent chemotherapy on local control.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Female; Glottis; Humans; Laryngeal Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; Voice Quality | 2006 |
Ultrasonographic guidance for spinal extracranial radiosurgery: technique and application for metastatic spinal lesions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Feasibility Studies; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Phantoms, Imaging; Radiosurgery; Spinal Neoplasms; Taxoids; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2001 |
Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents, Phytogenic; Aspartic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Glutamic Acid; Humans; Mice; Mice, Nude; Microtubules; Paclitaxel; Point Mutation; Protein Conformation; Taxoids; Tubulin; Verapamil | 2006 |
Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation.
Topics: Animals; Antineoplastic Agents; Carbon; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Rats; Taxoids; Treatment Outcome; X-Rays; Xenograft Model Antitumor Assays | 2006 |
[Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Fluorouracil; Humans; In Vitro Techniques; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous | 2006 |
[Organ-preserving treatment in inoperable patients with primary oral and oropharyngeal carcinoma: chances and limitations].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Oropharyngeal Neoplasms; Palliative Care; Radiotherapy, Adjuvant; Retreatment; Survival Rate; Taxoids | 2006 |
[A case of recurrent esophageal cancer responding to second-line chemotherapy of TS-1/docetaxel combination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Esophagectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mediastinum; Oxonic Acid; Pyridines; Taxoids; Tegafur | 2006 |
Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2006 |
[Combination chemotherapy of TS-1, docetaxel and CDDP produces a remarkable response in a patient with advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Esophageal Neoplasms; Humans; Male; Oxonic Acid; Quality of Life; Remission Induction; Taxoids; Tegafur | 2006 |
[Superselective intra-arterial infusion therapy with docetaxel, cisplatin and 5-fluorouracil for head and neck cancer--for tongue cancer patients in comparison patients with other therapies].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Hydrocortisone; Infusions, Intra-Arterial; Male; Middle Aged; Remission Induction; Survival Rate; Taxoids; Tongue Neoplasms | 2006 |
Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Fluorouracil; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Molecular Sequence Data; RNA, Small Interfering; Taxoids; Xenograft Model Antitumor Assays | 2006 |
Combination chemotherapy with docetaxel and nedaplatin for recurrent esophageal cancer in an outpatient setting.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Esophagectomy; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2006 |
Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Endoscopy; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Prognosis; Remission Induction; Taxoids | 2007 |
NFV, an HIV-1 protease inhibitor, induces growth arrest, reduced Akt signalling, apoptosis and docetaxel sensitisation in NSCLC cell lines.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Down-Regulation; Drug Combinations; Glycogen Synthase Kinases; HIV Protease Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nelfinavir; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Signal Transduction; Taxoids; Tumor Suppressor Protein p53 | 2006 |
Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Remission Induction; Salvage Therapy; Taxoids | 2006 |
[A case of metastatic lung cancer responding well from tongue carcinoma using a combination of stereotactic radiation therapy and docetaxel/cisplatin/5-FU chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Radiotherapy Dosage; Remission Induction; Taxoids; Tongue Neoplasms | 2006 |
The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinases; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Esophageal Neoplasms; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Serine-Threonine Kinases; RNA, Small Interfering; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Thoracic; Bronchi; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pericardium; Taxoids; Trachea | 2007 |
[A feasible study of docetaxel/nedaplatin combined chemotherapy for relapsed or refractory esophageal cancer patients as a 2nd-line chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Feasibility Studies; Humans; Infusions, Intravenous; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Taxoids | 2007 |
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Docetaxel; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microtubules; Mitosis; Pyrazoles; Quinazolines; Sulfonamides; Taxoids | 2007 |
Enhancement of docetaxel efficacy in head and neck cancer treatment by G0 cell stimulation.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Docetaxel; Drug Synergism; Granulocyte Colony-Stimulating Factor; Head and Neck Neoplasms; Humans; Interleukin-6; Ki-67 Antigen; Resting Phase, Cell Cycle; Serotonin; Taxoids; Tumor Cells, Cultured | 2007 |
[A case of recurrent esophageal cancer successfully treated with concurrent radiochemotherapy with low-dose docetaxel plus 5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Remission Induction; Taxoids | 2007 |
[A case of acute respiratory distress syndrome (ARDS) induced by docetaxel administration for lung metastases from oral cancer].
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Dexamethasone; Docetaxel; Gingival Neoplasms; Humans; Lung Neoplasms; Male; Mandible; Neck Dissection; Respiratory Distress Syndrome; Taxoids | 2007 |
Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Head and Neck Neoplasms; Humans; Pyrazines; Taxoids | 2008 |
Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Drug Tolerance; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platinum; Retrospective Studies; Taxoids; Treatment Outcome | 2007 |
Neoadjuvant docetaxel and cisplatin chemotherapy followed by local irradiation is highly active on locoregionally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Feasibility Studies; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Head and Neck Neoplasms; Humans; Immunohistochemistry; Injections, Intraperitoneal; Mice; Mice, Nude; Models, Biological; Oligonucleotides, Antisense; Oncogene Protein v-akt; Random Allocation; Statistics as Topic; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2008 |
[Evaluation of combination chemotherapy with S-1 and docetaxel for patients with oral squamous cell carcinomas].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Mouth Neoplasms; Neoadjuvant Therapy; Oxonic Acid; Taxoids; Tegafur | 2007 |
Atrial flutter and myocardial infarction-like ECG changes as manifestations of left ventricle involvement from lung carcinoma.
Topics: Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Flutter; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Diabetes Mellitus; Docetaxel; Echocardiography; Electrocardiography; Enalapril; Fatal Outcome; Glyburide; Heart Neoplasms; Humans; Hypertension; Hypoglycemic Agents; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction; Radiotherapy; Taxoids; Tomography, X-Ray Computed | 2008 |
The effect of combined treatment on head and neck human cancer cell lines with novel analogs of calcitriol and cytostatics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Calcitriol; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cisplatin; Dihydroxycholecalciferols; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Ergocalciferols; G1 Phase; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Resting Phase, Cell Cycle; Taxoids | 2007 |
Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Quinazolines; Taxoids | 2008 |
A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Organoplatinum Compounds; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vindesine | 2008 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2008 |
Proteomic investigation of taxol and taxotere resistance and invasiveness in a squamous lung carcinoma cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Humans; Lung Neoplasms; Neoplasm Invasiveness; Neoplasm Proteins; Paclitaxel; Proteomics; Reactive Oxygen Species; Taxoids | 2008 |
The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Line; Cisplatin; Docetaxel; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Taxoids | 1994 |
Typhlitis associated with docetaxel treatment.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cecal Diseases; Docetaxel; Enterocolitis, Pseudomembranous; Fatal Outcome; Humans; Ileal Diseases; Lung Neoplasms; Male; Middle Aged; Necrosis; Paclitaxel; Taxoids | 1996 |
[Recurrent squamous-cell lung cancer treated with bronchial-arterial infusion of docetaxel--case report].
Topics: Aged; Antineoplastic Agents, Phytogenic; Bronchial Arteries; Carcinoma, Squamous Cell; Docetaxel; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Paclitaxel; Taxoids; Tracheal Neoplasms | 1998 |
[Inhibition of tumor neo-angiogenesis and induction of apoptosis as properties of docetaxel (taxotere)].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capillaries; Carcinoma, Squamous Cell; Docetaxel; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Skin Neoplasms; Taxoids; Tumor Cells, Cultured | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
[Experimental chemotherapy of xenotransplanted oral squamous epithelial carcinoma: effectiveness of docetaxel (taxotere) in the nude mouse model].
Topics: Aged; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Docetaxel; Humans; Male; Mice; Mice, Nude; Mouth Mucosa; Mouth Neoplasms; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Cytomegalovirus colitis after administration of docetaxel-5-fluorouracil-cisplatin chemotherapy for locally advanced hypopharyngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Colitis; Cytomegalovirus Infections; Docetaxel; Fatal Outcome; Fluorouracil; Ganciclovir; Humans; Hypopharyngeal Neoplasms; Immune Tolerance; Male; Middle Aged; Paclitaxel; Taxoids | 1999 |
Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Docetaxel; Dose Fractionation, Radiation; Growth Inhibitors; Intestinal Mucosa; Jejunum; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 1999 |
[A case of synchronous bilateral double primary lung cancer successfully treated by Nd-YAG laser therapy and chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Laser Therapy; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Taxoids | 1999 |
[A case of squamous cell lung cancer in a nonsmoking female, successfully treated with docetaxel and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Smoking; Taxoids | 2000 |
Integration of taxanes into primary chemotherapy for squamous cell carcinoma of the head and neck: promise fulfilled?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Trials as Topic; Docetaxel; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation-Sensitizing Agents; Taxoids | 2000 |
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
Topics: Acute Disease; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Docetaxel; Enterocolitis; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Taxoids; Tomography, X-Ray Computed | 2000 |
[Preoperative bronchial arterial infusion of docetaxel for squamous cell carcinoma of the lung--clinical evaluation and correlation between anti-tumor effect and apoptosis].
Topics: Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Bronchial Arteries; Carcinoma, Squamous Cell; Docetaxel; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Paclitaxel; Taxoids | 2000 |
[Refractory non-small-cell lung cancer responding to combination chemotherapy with docetaxel, gemcitabine and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
Combined effect of docetaxel and cisplatin for non-small cell lung cancer cell lines in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cisplatin; Docetaxel; Drug Interactions; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2000 |
Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki ).
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Female; Flow Cytometry; Head and Neck Neoplasms; Humans; Paclitaxel; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy; Taxoids; Time Factors; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2001 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Disease Models, Animal; Docetaxel; Female; Fluorouracil; Head and Neck Neoplasms; Humans; Ifosfamide; Methotrexate; Mice; Mice, Nude; Paclitaxel; Survival Rate; Taxoids | 2001 |
Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Squamous Cell; Disease Progression; Docetaxel; Doxorubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Sternum; Taxoids | 2001 |
A preliminary pharmacokinetic study of docetaxel, carboplatin and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Combined Modality Therapy; Docetaxel; Half-Life; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Paclitaxel; Taxoids | 2001 |
[Outpatient chemotherapy for advanced lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
[A case of advanced hypopharyngeal carcinoma successfully treated with superselective intra-arterial infusion of docetaxel].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Humans; Hypopharyngeal Neoplasms; Infusions, Intra-Arterial; Male; Paclitaxel; Taxoids | 2002 |
Neoadjuvant treatment with docetaxel and the effects of irradiation for human ovarian adenocarcinoma and cervical squamous cell carcinoma in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Combined Modality Therapy; DNA, Single-Stranded; Docetaxel; Female; Humans; In Vitro Techniques; Neoplastic Stem Cells; Ovarian Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Head and Neck Neoplasms; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Failure | 2002 |
Squamous syringometaplasia associated with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Docetaxel; Esophageal Neoplasms; Humans; Male; Metaplasia; Middle Aged; Necrosis; Paclitaxel; Sweat Gland Neoplasms; Sweat Glands; Taxoids | 2002 |